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 The discovery of penicillin and resounding success of β-lactam antibiotics changed 
the way humanity interacts with its microbiotic environment. Now, after more than 80 
years of being the leading class of antibiotics, β-Lactams continue to reappear in new 
research settings as the understanding of β-lactam biology expands.  As new biological 
activities are discovered, a reoccurring theme is that the specific mechanism of action is 
challenging to pinpoint. 
Following recent discoveries that cephalosporins are capable of killing 
Mycobacterium tuberculosis (Mtb), we designed a library of benzazetidines to be shape-
mimicking isosteres of cephalosporins. We used newly published C–H activation methods 
to synthesize benzazetidines that were subsequently modified to increase the 
resemblance to cephalosporins. In total 35 compounds were synthesized and tested for 
antibiotic activity against Mtb and ESKAPE pathogens. None of the compounds were 
active in these assays, but nonetheless this work represents early efforts to test biological 
activities of benzazetidines.  
 If β-lactams are engaging non-classical targets, then the rules of engagement are 
likely different from what is known for β-lactam antibiotics. Stereochemistry in the design 




appear in the natural products, since deviation from this configuration leads to the loss of 
antibiotic activity. However, this preference for the natural configuration might not hold 
true for non-classical targets. We used total synthesis to access the unnatural enantiomer 
of penicillin and then tested it, along with other unnatural stereoisomers of cephalosporin, 
in a variety of biological settings in order to gain a more comprehensive understanding of 
the biological activities for these stereoisomers. The unnatural stereoisomers failed to 
inhibit the growth of methicillin sensitive Staphylococcus aureus. However, in vitro 
screening against CNS receptors revealed that several unnatural stereoisomers were 
capable of binding. An ent-penicillin derivative showed the strongest activity in the assay 
toward the 5-HT2B receptor (Ki = 850 nM). We also conducted proteomic studies that 
confirmed that the enantiomers of penicillin have different binding profiles in different cell 
types. These proof of concept studies could serve as a starting point for further 
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CHAPTER 1.  INTRODUCTION OF b-LACTAM ANTIBIOTICS, THEIR SYNTHESIS, 
AND APPLICATIONS 
 
1.1 The discovery and importance of b-lactam antibiotics  
Early germ theory experiments dating back to 1871 noted that Penicillium molds 
often grew exclusively without the presence of microzymes (now known as bacteria),1 but 
it wasn’t until 1929 that Alexander Fleming recognized the value of this antibiotic 
phenomenon.2 Fleming performed a crude extraction of the active compound that he 
named penicillin, and showed that the extract could reliably inhibit the growth of bacteria 
in vitro. Later experiments by Howard Florey, Ernst Chain, Edward Abraham, and Norman 
Heatley, confirmed that the compound was both safe and effective as a therapeutic for 
infection.3, 4 However, initially the natural product was difficult to produce at scale. After 
finding optimal Penicillium strain and fermentation conditions, the molecule was finally 
able to be produced at scale with hundreds of billions of units being produced each month 
by the end of World War II. Today, the biosynthesis is well understood and penicillin can 
be produced by fermentation in 40-50 g/L yields and sold in bulk for less than $13 per 
kilogram.5  
By becoming the first natural antibiotic to be mass-produced, penicillin shifted how 
humanity interacts with its microbiotic environment. Widespread access to antibiotics has 
greatly reduced the burden of many deadly bacterial infections and enabled medical 
procedures, improved agriculture yields, and has become an integral part of biochemical 




bioactive chemicals from soils and other natural resources, which has provided many 
other antibiotics including the related b-lactam containing small molecules, 
cephalosporins and carbapenems, as well as other macromolecules such as 
erythromycin and vancomycin. Today amoxicillin remains the most widely used 
antibiotic.7  
 
1.2 Reactivity of the b-lactam 
Penicillin and cephalosporin antibiotics contain a privileged b-lactam scaffold that 
some fungi and bacteria evolved to produce as a weapon for inhibiting the growth of other 
nearby bacteria. The b-lactam found in the penam and cepham core has greater acylating 
potential than a typical amide. The resonance that typically gives amide bonds increased 
double bond character and stability compared to other carboxylic acid derivatives is 
partially disrupted in penams due to the geometry of the bicycle, which pyrimidalizes the 
nitrogen by 0.1–0.4 Å so that the nitrogen lone pair of electrons lies out of plane with the 
carbonyl pi orbitals (Figure 1.1).8 The decreased resonance is reflected in the distinct IR 
stretches for the b-lactam carbonyls, which occur at higher energies, 1750–1790 cm–1, 
rather than 1600–1680 cm–1 seen in typical amide bonds. Nucleophilic attack at the 
carbonyl of b-lactams is driven further by the release of strain in the opening of the 4-
membered ring. Together these stereoelectronic effects allow the b-lactam to act as an 







Figure 1.1. A 3-D model of phenoxymethylpenicillin highlighting the geometry that gives 
rise to the highly reactive nature of the b-lactam. 
 
The b-lactam warhead is essential for the classic mechanism of action of penicillin 
and cephalosporin wherein the drug disrupts the formation of the bacteria cell wall by 
covalently inhibiting transpeptidases that are necessary for crosslinking newly 
synthesized peptidoglycan strands. These transpeptidases, called penicillin-binding 
proteins (PBPs), come in a variety of sizes and are expressed differently across bacteria 
species. Each PBP includes a set of domains that are specialized for D,D-peptidase 
activities including D,D-transpeptidation, D,D-carboxypeptidation, and D,D-
endopeptidation. The D,D designation refers to the enzyme’s recognition of short peptide 
sequences that contain D-Ala-D-Ala. Transpeptidation and endopeptidation describe the 
forward and reverse reaction for the cross-linking of two adjacent strands, while 
carboxypeptidation describes the hydrolytic removal of the terminal dipeptide from a 
peptide strand.9  





For each of these roles, the specificity for binding the PBP substrate relies on the 
D,D configuration of the D-Ala-D-Ala substrate found on the terminus of the peptidoglycan 
strands (Figure 1.2a).  
 
 
Figure 1.2. (a) Two newly synthesized peptidoglycan strands with the terminal D-Ala-D-
Ala sequence highlighted in green. Penicillin G inhibits the binding of penicillin-binding 

















































































































In most cases, the amino acids that ribosomes use to build proteins are 
predominantly homochiral favoring the L configuration, but peptidoglycans in bacterial cell 
walls are one example where D-amino acids provide selectivity for specific peptidases 
and designate the site of peptidoglycan polymerization and crosslinking.10 Donald Tipper 
and Jack Strominger hypothesized that b-lactam antibiotics covalently inhibit PBP by 
mimicking the D-Ala-D-Ala sequence (Figure 1.2b) and binding to the active site, and this 
mechanism of action has since been supported by X-ray crystallography studies (Figure 
1.3).11, 12 If a sufficient number of PBPs become covalently inhibited by penicillin, then a 
dividing cell will not be able to carry out peptidoglycan crosslinking in the cell wall, which 






Figure 1.3. A view of protein data bank structure 1hvb published by Lee and Mobashery12 
showing the product of a modified cephalosporin (yellow) binding to serine 62 (green) 
within the active site of a penicillin-binding protein from Streptomyces species strain R61. 
 
1.3 Drug resistance  
Unfortunately, antibiotics that were initially touted as miracle cures are quickly 
losing effectiveness due to the evolution of drug-resistant bacteria. Over-prescription and 
misuse of antibiotics creates selective pressure in which populations of bacteria with drug 
resistant mutations are able to thrive. In fact, hospitals, where antibiotics are frequently 




Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii,  
Pseudomonas aeruginosa, and Enterobacter species, which together are called ESKAPE 
pathogens. In the USA, an estimated 1.7 million infections are acquired during hospital 
visits each year leading to ca. 98 thousand deaths.14 A multi-state survey of 183 hospitals 
showed that ESKAPE pathogens are responsible for up to 41% of hospital acquired 
infections.15 The ESKAPE pathogens and other drug resistant bacteria employ many 
strategies for avoiding, removing, or destroying drug molecules, but for b-lactams, the 
main modes of resistance are active site mutation of penicillin-binding proteins, increased 






Figure 1.4. Common drug resistance mechanisms in bacteria include increased efflux, 
mutation of the PBP active site, and b-lactamase hydrolysis of penicillin. 
 
b-Lactamases were first observed by Abraham and Chain, who noticed that 
enzymes isolated from Staphylococcus aureus were able to deactivate penicillin.18 As b-
lactams became popular drugs, b-lactamases became established as anti-targets for the 
development of new antibiotics. New generations of penicillins and cephalosporins were 
























































































example, methicillin was once a preferred treatment for S. aureus since the bulky 
dimethoxyphenyl group provided resistance to b-lactamases, which are prevalent in S. 
aureus.19 The effectiveness of methicillin in S. aureus proved to be short-lived, however, 
since methicillin resistant S. aureus (MRSA) evolved with a new PBP called PBP2a that 
has decreased affinity for b-lactam antibiotics.20   
An alternative solution to prolong the effectiveness of existing drugs is to combine 
the drug with adjuvants that specifically inhibit or reverse drug resistance mechanisms. 
To increase the effectiveness of b-lactam antibiotics, a variety of b-lactamase inhibitors 
are used, including tazobactam, clavulanic acid, and sulbactam (Figure 1.5). These three 
b-lactamase inhibitors contain b-lactams that selectively react with b-lactamases to 
covalently inhibit them and allow the penicillin or cephalosporin to reach their PBP target. 
Recently, new classes of b-lactamase inhibitors that do not contain a b-lactam ring have 
also been approved for combination therapies including diazabicyclooctanes (avibactam) 
and boronates (vaborbactam) (Figure 1.5).21  The continual rise in multi-drug resistant 
forms of bacteria provides impetus for discovering new antibiotic classes that overcome 
existing drug resistance mechanisms as well as finding new strategies for limiting the 



















































1.4 Non-classical therapeutic applications of b-lactams 
Recent discoveries in the field of b-lactams have shown that b-lactams have the 
potential to be repurposed into new therapies and tools (Figure 1.6). For many years it 
was taken for granted that b-lactams were ineffective against Mycobacterium tuberculosis 
(Mtb) due to the extra layer of mycolic acids that surround the cell and high b-lactamase 
activity coming from expression of the blaC gene. Hugonnet and Blanchard investigated 
the ability of sulbactam, tazobactam, and clavulanic acid to inhibit blaC b-lactamase 
activity in Mtb, and found that clavulanic acid was able to irreversibly inhibit the b-
lactamase.22 Later, the combination of clavulanic acid with meropenem was discovered 
to be a effective at killing Mtb (Figure 1.7).23 Then, a high throughput screening assay led 
to the discovery that cephalosporins bearing C2 esters or an oxadiazole were potent at 
inhibiting the growth of Mtb under growing conditions that model the mycobacteria’s 
dormant, non-replicating state (Figure 1.7).24 Although pulldown and other target 
identification experiments have shown that these cephalosporins are not targeting 
classical PBP or transpeptidase targets, their mechanism of action for killing the non-
replicating Mtb has yet to be pinpointed. The pulldown assay identified 30 targets 
including proteins for fatty acid metabolism, ribosomal/transcriptional function, universal 
stress proteins and chaperones, ATP synthesis, and intermediary metabolism enzymes, 
but when each protein was knocked down, none of them appeared to account for the 
potent bactericidal activity of the cephalosporins.25 Nonetheless, the data revealed that 
cephalosporins can bind a variety of non-canonical targets which could be contributing 








Figure 1.7. b-Lactam antibiotics that were discovered to have activity against Mtb.23, 24 
 
 Although penam and cepham based b-lactams have not been approved as 
treatments for any other indications besides treating or preventing bacterial infections, 
both are implicated in a variety of eukaryotic pathways (Figure 1.6).26 The first sign that 
pointed to penicillin having neurological interactions was the observation that intrathecal 
penicillin injections occasionally cause seizures.27 Upon closer investigation, it was 
revealed that penicillin directly modulates the excitability of synapses, which triggers 
epileptic neuron firing in the cerebral cortex.28 This phenomena was reproduced in a 
variety of in vivo and ex vivo animal models, and several mechanisms of action were 









MIC90 non-replicating Mtb: 1.05 µg/mL





















that was linked to a decrease in chlorine conductance and antagonism of the gamma 
aminobutyric acid (GABA) pathway.29 GABA is the major inhibitory neurotransmitter and 
GABA receptor activation typically reduces the excitability of neurons by opening ion 
channels resulting in an increase in chloride conductance. Thus, as penicillin reduces 
chloride conductance, it has the effect of reversing the GABA inhibitory pathway. Under 
physiological conditions penicillin carries a negative charge on the C2 carboxylate and it 
was proposed that the ionic charge draws the penicillin to the chloride ion channel where 
it blocks the flow of chloride ions. Interestingly, the penicillin b-lactam must be intact for 




Figure 1.8. Summary of neurological effects of penicillin G and cefoselis. 
 
There are conflicting reports about the binding site and mechanism of action for 









• Intrathecal injections cause seizures
• Decreases neuron chloride conductance
• Antagonizes the GABA pathway

















• Convulsant activity in mice




appeared to directly compete with GABA to inhibit the GABA response.29, 30 Thus, it was 
proposed that the antibiotics were likely binding to the GABA receptor. This hypothesis 
was reaffirmed when a panel of cephalosporins were delivered to mice by intracerebral 
injection, and the dose-dependent convulsant activity was strongly correlated with the 
measured binding affinity of the cephalosporin to the GABAA receptors.31 These 
cephalosporins also showed an ability to compete with radio-labeled muscimol (a highly 
selective agonist for GABAA receptors), which further supports the hypothesis that the b-
lactams are capable of directly blocking GABA receptor activation. However, other studies 
found evidence that penicillin does not compete with GABA.32, 33 Under closer inspection, 
it appeared that the identity of the b-lactam can dictate whether the GABA response is 
modulated competitively or non-competitively. For example, penicillin G and cefoselis 
diverged in their mechanism of inhibition, where penicillin appeared to inhibit the GABA 
receptors non-competitively, while cefoselis was a competitive inhibitor of GABA-induced 
currents.34 Although the specifics of the mechanism of action remain obscure, it is clear 
that b-lactam antibiotics have a reliable pathway for modulating the GABA inhibitory 
system of neurons. 
Further study of these off-label interactions could lead to the development of new 
therapies that redesign and repurpose the b-lactam to engage new targets through a non-
classical mechanism of action. For example, ceftriaxone, a cephalosporin designed to 
penetrate the blood brain barrier, has been linked to many positive neurological effects. 
In contrast to the convulsant interactions described above, ceftriaxone was able to 









Figure 1.9. Summary of neurological effects and other non-classical activities observed 
for ceftriaxone.  
 
The neuroprotective mechanism of ceftriaxone and other b-lactams was proposed 
to come from an increase in expression of glutamate transporter 1 (GLT1), which are 
responsible for transporting glutamate across neuronal membranes to regulate glutamate 
homeostasis.36, 37 Glutamate is the primary excitatory neurotransmitter that is released 
into the synaptic cleft when a neuron is excited, causing other nearby neurons to become 
excited too. A lack of glutamate transporters results in an overabundance of glutamate in 
















• Anticonvulsant activity in mice and other           
  neuroprotective effects
• Decreases pain sensation
• Increases GLT1 expression
• Inhibits growth of lung cancer in mice




neurotoxicity and seizures.38 The importance of GLT1 expression is demonstrated by the 
major genetic disorder associated with epileptic seizures, tuberous sclerosis complex 
(TSC), which is associated with a decrease in GLT1 expression and an increase in 
extracellular glutamate levels leading to neuronal death. Ceftriaxone was able to reverse 
the TSC pathology in Tsc1 knockout mice and led to an increase in GLT1 expression, 
decrease in extracellular glutamate levels, and an overall reduction in neuronal death, 
seizures, and mouse morbidity.39 Since glutamate is ubiquitously involved in neuronal 
signaling, it is complicated in a wide variety of pathologies. It is unsurprising then, that 
ceftriaxone has been shown to protect neurons from degradation associated with brain 
injury, ischemia, alcohol withdrawal, and Parkinson’s disease, as well as protection from 
alcohol, morphine, and amphetamine dependence.40-49 
Moreover, since glutamate levels are involved in the transmission of pain signaling, 
ceftriaxone, and other b-lactams have demonstrated potential to be developed into 
analgesics.50 In fact, a single dose of ceftriaxone administered pre-surgery produced a 
significant decrease in post-surgery pain sensation compared to treatment with saline or 
cefazolin, a b-lactam that does not activate GLT1 expression.51 Studies in rodent models 
have found that the analgesic effects of ceftriaxone can be synergistic with non-steroidal 
anti-inflammatory drugs.52 The hypothesis that GLT1 expression is a major contributing 
factor to the analgesia was supported when administration of GLT1 anti-sense 
oligonucleotides reversed the analgesic effects.50 Similar anti-glutamate neuroprotective 
effects have been observed for b-lactamase inhibitors, like clavulanic acid, which 




action.53-55 Thus, b-lactams have potential to be developed into new therapies that target 
the glutamate system.56  
A limited number of cephalosporins have also been demonstrated to have 
antitumor and anti-inflammatory properties. For example, ceftriaxone is able to inhibit the 
growth of lung cancer in mice by inhibiting Aurora-B kinase.57 Aurora-B is one of the many 
kinases that plays a role in mitosis and meiosis. Normally, it is necessary for connecting 
the mitotic spindle to the centromeres of sister chromatids during metaphase, which 
results in the sister chromatids being centered along the metaphase plate. When Aurora-
B is overexpressed, it leads to the improper connections that allow two sister chromatids 
to move to the same side of the replicating cell. The resulting daughter cells each develop 
an abnormal number of chromosomes, which is a driver for cancer. When ceftriaxone 
was screened against a panel of kinases, Aurora-B was inhibited with good selectivity. 
The kinase was also pulled-down from a cell extract using ceftriaxone-sepharose beads. 
In vitro studies using recombinant Aurora-B confirmed that ceftriaxone competes with 
ATP and inhibits the phosphorylation of histone H3 by Aurora-B. Mice transplanted with 
lung cancer cells were protected from lung tumor growth when the mice were injected 
three times per week with ceftriaxone.57 Similarly, ceftiofur is able to decrease kinase 
activity in both the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-
kB) and mitogen-activated protein kinase pathways (MAPKs)  that are responsible for 
inflammation.58 These results demonstrate the potential for b-lactams to be repurposed 






1.5 Recent developments of b-lactams into chemical biology probes 
The ability for the b-lactam warhead to covalently bind active site nucleophiles 
makes penicillins and cephalosporins amenable to being developed into chemical tools 
for labeling, visualizing, and pulling down targeted proteins, enzymes, and other biological 
entities (Figure 1.10). Historically, radioactive 3H-, 14C-, or 125I-labeled penicillin was used 
to detect and image PBPs using fluorography,59 but this strategy requires lengthy 
exposure times needed to visualize the results and has hazards associated with working 
with radioactive materials. More recently, b-lactam antibiotics have been combined with 
a wide array of fluorescent tags as well as azide/alkyne and biotin tags for the purpose of 




Figure 1.10. Penicillin can be equipped with an affinity or fluorescent tag and used for 
protein affinity purification and mass spec analysis or used for visualization of proteins 





Dargis and Malouin attached a biotin affinity tag to 6-aminopenicillanic acid (6-
APA), ampicillin, and 7-aminocephalosporonic acid (7-ACA) by reacting each precursor 
with an N-hydroxysuccinimide (NHS) ester of biotin.60 The biotin tag proved to be useful 
for protein affinity purification as well as visualization of penicillin-binding proteins by 
western blot. Similarly, penicillin and cephalosporin have been conjugated to fluorescent 
tags to produce PBP labeling probes named Bocillin FL and Ceph C-T that allow PBPs 
to be visualized using fluorescence microscopy.61, 62 In practice, these probes have 
mainly been used to measure the varying levels of engagement with PBPs and b-
lactamases in bacteria since these are historically the main targets of these drugs.63-65 
Each b-lactam antibiotic has different selectivity profiles for different subsets of PBPs, so 
researchers have some control for targeting specific PBPs.  But perhaps what is more 
exciting, is that some unexpected targets have appeared as unidentified binders in these 
assays, which suggests that the natural forms of penicillins and cephalosporins could 






























































































The classic mechanism of action for b-lactam antibiotics has also been leveraged 
to engineer drug delivery systems and bifunctional linkers. In one case, 6-APA was 
equipped with a side chain for anchoring covalently bound proteins to a gold-silver 
surface.66 In the case of cephalosporins, ring-opening the b-lactam can trigger the 
elimination of a C3 substituent. This phenomenon can be exploited to deliver drugs or 
release other payloads upon b-lactam opening.  
 
 
Figure 1.12. Enzymes or other nucleophiles can bind cephalosporins to release a drug 
or other leaving group attached to the C3 position. 
 
In Mtb, this strategy allowed pyrithione-equipped cephalosporins to kill the 
mycobacteria under replicating and non-replicating conditions.67 In anti-cancer therapy, a 
system was developed which uses a cephalosporin as a delivery system that allows the 
anti-cancer drug to be selectively released at the location of the tumor.68 The spatial 
selectivity is achieved by pretreating the tumor with an antibody-b-lactamase conjugate. 
Since b-lactamases are non-native to mammals, the cephalosporin-oncolytic prodrug is 
able to circulate through the body intact until it reaches the surface of the tumor where 
the b-lactamases are attached by the antibody. In the presence of the b-lactamase, the 

























Repurposing the b-lactam into new chemical biology technology could usher in a 
renewed future of innovation and interest in the field of b-lactams. So far, the proof of 
concept for labeling, linking, and drug delivery platforms was successful in using the 
acylating activity of the b-lactam to engage native targets like PBPs and b-lactamases, 
but the remaining challenge is to translate this success into other areas of biology and 
science. For typical b-lactam targets, these probes have provided additional resolution to 
the spatiotemporal relationships of specific PBP subtypes, and provided increased 
access to activity-based protein profiling of PBPs.25, 61-63, 69 This technology provides a 
deeper understanding of existing antibiotics and could guide the design of new and 
improved antibiotics. Moreover, as b-lactams continue to break through into new 
biological spaces, like they have in Mtb and neurobiology, the ability to identify and 
characterize other “off-target” binding events will become useful for developing b-lactams 
for new therapeutic purposes. 
 
1.6 The relationship between stereochemistry and activity of b-lactam antibiotics  
b-lactam antibiotics have traditionally maintained the same stereochemical 
configurations that are found in the active Penicillium natural products that they are 
derived from, since deviation from this natural configuration is thought to diminish the 
bactericidal activity. A  convenient semi-synthetic route (Figure 1.13) provides the natural 
stereoisomer for nearly all of the penicillins and cephalosporins described in the literature 





Figure 1.13. Industrial process that is used to produce a variety of semi-synthetic 
penicillin and cephalosporin antibiotics. 
 
The reliance on this semi-synthetic route, and overall neglect of the other 
stereoisomers, has left a gap in b-lactam research, leaving it unknown if the other 
stereoisomers have any therapeutic value, particularly against non-classical targets. So 
far, early racemic total syntheses of penicillins and cephalosporins yielded the enantiomer 




















































in antibiotic assays.71, 72 Similarly, epi-penicillins and cephalosporins have been 
synthesized as intermediates, or targeted in their own right, and each showed negligible 








Figure 1.14. Unnatural stereoisomers of penicillins and cephalosporins previously 
















































































While changing the configuration clearly has a negative impact on the ability to 
bind PBPs through the classical mechanism of action, there may be other useful changes 
in binding and affinity toward other proteins of interest. For example, C6 epimerization of 
a penicillin has been leveraged to create a b-lactamase inhibitor that resembles 
carbapenems (Figure 1.15).78 
 
 
Figure 1.15. A b-lactamase inhibitor that was designed to mimic the C6 stereochemistry 
and functional groups of meropenem.78 
 
In contrast, others have observed that epimeric b-lactam antibiotics have 
increased resistance to b-lactamases.73, 79 The contradicting evidence that some epimeric 
b-lactams can act as b-lactamase inhibitors while others are resistant to b-lactamases 
points to the fact that subtle changes to the configuration in combination with different 
decorations of the scaffold can be used to tune the affinity and activity towards targets or 
away from anti-targets. This strategy is particularly appealing in the context of non-
classical b-lactam targets for other human disease, wherein the ability to avoid b-
lactamases and transpeptidases would allow the drug to reach its desired target while 


























1.7 Synthesis of b-lactam antibiotics 
1.7.1 Synthesis of penicillin 
To date, only four major total syntheses have been completed for penicillin, likely 
because the pharmaceutical industry relies heavily on a semi-synthetic process to 
generate penicillin for medicinal and research purposes.71, 80-83 This semi-synthetic route, 
however, does not provide direct access to the unnatural enantiomer of penicillin since 
the Penicillium molds use amino acid precursors and enzymes to stereospecifically give 
the natural configuration during biosynthesis.84 The existing total syntheses on the other 
hand, can be modified to give the ent-b-lactam final product by separation of the racemic 
final product or by following an asymmetric route and starting from the enantiomeric 
starting materials. 
The four major total syntheses of penicillin use different strategies to form the 
thiazolidine and b-lactam rings. In the original total synthesis of penicillin71 published by 
John Sheehan, the b-lactam ring was formed near the end of the synthesis. Once the b-
lactam is installed, chemistry is limited by the susceptibility of the b-lactam to hydrolysis 
or attack by nucleophiles, so Sheehan’s strategy allowed the remainder of the molecule 
to be built without inadvertently opening the ring. The thiazolidine ring was constructed 
first from the condensation of penicillamine with tert-butyl phthalimidomalonaldehydate, 
which resulted in a mixture of diastereomers that were separated by crystallization 







Scheme 1.1. Condensation of penicillamine with tert-butyl phthalimidomalonaldehydate 





The phenoxyacetyl side chain was installed by hydrazinolysis of the phthalimide 
and coupling the resulting primary amine with the phenoxyacetyl chloride. Finally, the b-
lactam was formed in the last step using dicyclohexyl carbodiimide coupling chemistry 
























































The Sheehan route minimizes the number of number of steps by carrying the C2 
carboxylic acid, which originates from the penicillamine starting material, through the 
entire synthesis unprotected. However, the approach lacks stereocontrol and the 
formation of the thiazolidine results in a mixture of at least two diastereomers that required 
separation by recrystallization.  Altogether, the route is fairly concise with 7 steps in the 
longest linear sequence and an overall yield of 1.1% from penicillamine. It was an 
incredible feat to be the first chemists to successfully synthesize the delicate penicillin 
nucleus and even more impressive considering the limited technology available at the 
time. Sheehan’s synthesis also produced the first sample of ent-penicillin V from 
resolution of the racemic final product. Sheehan’s synthesis is remembered as a 



























































After a decade passed, Ajay Bose published a distinct route to 6-epi-penicillin 
which would ultimately lead to the first stereocontrolled approach to penicillin (Scheme 
1.3).80 The penam scaffold was formed rapidly using a Staudinger formal [2+2] 
cycloaddition, which brings an acid chloride and imine together to form a b-lactam. In the 
case of penicillin, the imine component is a thiazoline, which provides the thiazolidine ring 
to the penam. The acid chloride is azidoacetyl chloride, which after azide reduction, 
provides the amine at C6 to which the penicillin side chain is attached.  
 




The Staudinger formal [2+2] cycloaddition produces 2-azetidinones with two new 
stereocenters and the configuration of the substituents depends on the stereoelectronic 
effects of the substituents on the imine and reactive ketene intermediate.85 For 













































been observed and strategies have been designed to influence the preference.86, 87 
However, for bicyclic b-lactams like penicillins and cephalosporins, there has not been 
success in overcoming the products’ natural tendency to be cis or trans. In the case of 
penicillin, the product usually forms with the C6 substituent trans to the sulfide.  
The proposed mechanism for the Staudinger formal [2+2] cycloaddition begins 
with the imine attacking the ketene to form an enolate intermediate that is isoelectric with 
butadiene. Then, a 4p electrocyclization can occur in a conrotatory fashion. The trans 
configuration in the penicillin product is consistent with the lowest energy enolate 
intermediate that places the azide or another substituent furthest away from the thiazoline 
to avoid steric interactions. Many studies on the epimerization of the C6 position have 
shown that the trans product is more thermodynamically favored, so the natural 
configuration can readily be converted to C6-epi configuration while only under careful 













Figure 1.16. Proposed mechanism for the formation of penicillin by the Staudinger formal 
[2+2] cycloaddition. 
 
Kinetically controlled C6 and C7 epimerization of 6-epi-penicillin and 7-epi-
cephalosporin was first published by Firestone at Merck and this advancement led to the 
completion of the second total synthesis of penicillin (Scheme 1.4).81 The epimerization 
strategy begins by converting the 6-amino group to a p-nitrobenzaldehyde Schiff base 
which makes the proton at C6 more acidic. Then, under cold conditions (–78 °C) the 
proton is removed using phenyllithium. Dimethylformamide is added to coordinate the 
lithium and allow the anionic intermediate to persist, ablating the C6 stereocenter. The 
anionic intermediate can be reprotonated on either face of the sp2 hybridized carbon, and 
since the sulfide has more steric bulk than the proton at C5, the protonation occurs on the 


































the Schiff base is removed and the free amine is coupled with an acid chloride to attach 
the penicillin side chain. Finally, the C2 carboxylic acid is revealed by debenzylating the 
benzyl ester to give the desired penicillin in its natural configuration (Scheme 1.5).  
 
Scheme 1.4. Kinetically controlled epimerization strategy for epimerizing the C6 
stereocenter of penicillin.81 
 
 
Including three steps used to epimerize the C6 stereocenter, the total synthesis 


































































of this sequence are the stereocontrol and convergence provided by the Staudinger 
formal [2+2] cycloaddition. The down side to the approach is that the Staudinger 
cycloaddition reaction has particularly low yields for producing the penam core, ranging 
from 5–13% for azidoacetyl chloride to 30% for (2-benzyloxy)acetyl chloride.80, 81, 88 The 
yield for the transformation can be increased by using a selenium activated thiazoline 
derivative.89 This kinetic epimerization strategy has been used for many subsequent total 
























An alternative stereospecific route to penicillin starting from the amino acid D-
isodehydrovaline and a thiazolidine carboxylic acid derived from cysteine was described 








































































coupled together to form a dipeptide, and then the b-lactam is formed by nucleophilic 
displacement of the amide nitrogen on a chlorinated carbon located on the thiazolidine. 
The isopenam intermediate at this early stage in the synthesis resembles the intermediate 
used in Woodard’s total synthesis of cephalosporin C. The intermediate does not contain 
the thiazolidine ring that exists in the final product, instead, the isopenam is rearranged 
by a series of reactions that ring-opens the thiazolidine (Scheme 1.16a) and eliminates 
the excess carbons in the form of methacraldehyde to reveal an amide and sulfenic acid 
(Scheme 1.6b). The cascade continues with the sulfenic acid reacting with the 
































































































  Finally, the sulfoxide is deoxygenated to restore the thiazolidine to give a 6-amido 
penicillin methyl ester. The original communication published by the group did not 
describe the conversion of their final product into a natural penicillin, which would require 
a C2 carboxylic acid and an alternative amide side chain, but presumably a slightly 
modified route could be used to produce other penicillins. Overall, the route requires 13 





















Scheme 1.7. Total synthesis of a penicillin analog by Baldwin.82 
 
 
 The most recent total synthesis of penicillin was completed by Barrett and 
Sakadarat in 1990 and followed a distinct route.83 First, a penicillin-like monobactam is 

















2. hog acyclase 

















































































to give optically pure b-lactam using a previously established strategy from the total 
synthesis of thienamycin by Salzmann and coworkers at Merck (Scheme 1.8).92  
 
Scheme 1.8. Synthesis of the monobactam precursor for the Barrett and Sakadarat 




To convert the monobactam into 6-APA (Scheme 1.9), the b-lactam was first N-
silylated and equipped with a sulfide at “C5” that provided the carbon skeleton for the 
thiazolidine ring. In order to form the CN bond needed to complete the thiazolidine ring, 
the sulfide was preinstalled with an alkene that was converted to an aldehyde by 
ozonoylsis and then condensed with (benzyloxy)nitromethane, which served as a 
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into a bicyclic penam using a Michael addition of the b-lactam nitrogen into the nitro 
activated alkene. Then, a Nef reaction was performed to convert the nitro group into a 
carbonyl, resulting in a C2 benzyl ester. The C6 amino group was installed by 
deprotecting the alcohol, converting it to a triflate, and displacing the triflate with lithium 
azide. This displacement also served to invert the stereocenter at C5 to give a cis 
relationship between the C5 and C6 substituents. A reductive global deprotection of the 
azide and the benzyl ester gave 6-APA as the final product. This target is significant for 
penicillin research because the derivatization of 6-APA is used to make the semi-synthetic 
penicillins. In total, the synthesis of 6-APA by Barrett and Sakadarat was accomplished 
in 27 steps with an overall yield of 1.8%. While this sequence is significantly longer than 
the previous total syntheses, the overall yield is relatively high due to the robust, high 















Scheme 1.9. Synthesis of 6-APA by Barrett and Sakadarat.83 
 
 
In summary, there are four major total synthesis of penicillin that were published 
between 1957 and 1990. Each route follows a unique strategy for the assembly of the 
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lactam for the last step, while the Barrett and Baldwin syntheses formed the b-lactam first 
before adding on the thiazolidine. The Staudinger formal [2+2] cycloaddition continues to 
serve as a robust method for producing b-lactams and is a particularly concise route to 
bicyclic b-lactams like penicillins and cephalosporins, although the reaction itself is 
subject to low yields for these bicyclic systems. Each route showcases a variety of 
strategies for overcoming the synthetic challenges in working with the sensitive b-lactam 
nucleus. However, in terms of producing penicillin for commercial purposes, none of the 
existing total syntheses are able to compete with the semi-synthetic process for the bulk 
production of b-lactam antibiotics. Thus, while these feats of total synthesis added much 
to our knowledge and understanding of the synthesis of penicillins and cephalosporins, 
in practice, the impact has been limited to the synthesis of exotic b-lactam research 
entities. With over 30 years passed since the most recent total synthesis by Barrett, it 
remains to be seen if the synthesis of penicillin will be reinvented once again by modern 
synthetic methodology. 
 
1.7.2 Synthesis of cephalosporin 
 Cephalosporins consist of a b-lactam containing bicyclic cepham core that is 
chemically related to the penam except for replacement of the 5-membered thiazolidine 
ring with a 6-membered thiazine ring. In fact, penicillins can be converted into 
cephalosporins through a variety of simple transformations (Scheme 1.10).93-96 For years, 
this was the preferred method for producing cephalosporins since the natural product, 
cephalosporin C, was much more difficult isolate from fermentation than natural 




synthetic processes which produce cephalosporin C by fermenting Acremonium 
chrysogenum to extract cephalosporin C. The natural cephalosporin can then be 
deacylated to give the 7-ACA building block, which can be equipped with a variety of side 
chains to give popular drugs like cefalexin and cefadroxil, or further elaborated to give 





















































































































The first total synthesis of cephalosporin C1 and cephalothin was published by 
Robert Woodward and colleagues in 1966.98 As mentioned above, the strategy for the 
Baldwin synthesis of penicillin follows a very similar approach to the Woodward synthesis. 
Generally speaking, the routes are similar in that they first construct an iso-penam, which 
temporarily ties up the sulfur while the remaining skeleton of the thiazine system is 
attached to the b-lactam nitrogen, and then finally the thiazolidine ring is opened to 
release the sulfur and allow it to cyclize to form the dihydrothiazine. To begin, optically 
pure L-cysteine was condensed with acetone to afford the dimethylthiazolidine (Scheme 
1.11). After esterification of the carboxylic acid, the b-carbon was selectively 
functionalized with dimethyl azodicarboxylate (DMAD) and the resulting hydrazine was 
converted into an alcohol and then mesylated. The mesylate was displaced with sodium 



















The displacement also inverts the stereochemistry to allow the azide and ester to 
be cis, and after azide reduction, the cis relationship allows the b-lactam to form between 
the free amine and the ester. With the b-lactam intact, and the sulfur temporarily protected 
in the thiazolidine, the amide is coupled to a dialdehyde which serves as an electrophilic 
precursor to the dihydrothiazine ring. The resulting adduct was then ready for a cascade 
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conditions, followed by condensation of the sulfur with the nearby aldehyde, to give an 
aminoaldehyde with an isocepham framework (Scheme 1.12).  
 
Scheme 1.12. Synthesis of the di-aldehyde, coupling with the isopenam intermediate, 









































































2. ring opening, then 
    sulfur condenses 

















The free amine was coupled with the desired cephalosporin side chain, and then 
the C4 aldehyde was transformed into an acetoxy group (Scheme 1.13). In order to 
isomerize the double bond to the correct position, the molecule was stirred in anhydrous 
pyridine to re-equilibrate the iso-cepham into a mixture (1:3 or 1:4 still favoring the 
isocepham) which was then separated by chromatography to give the final product as the 
b,b,b-trichloroethyl ester. Reduction with Zn dust and acetic acid reveals the C2 carboxylic 
acid, which is essential for activity, and completes the synthesis of cephalosporin C and 
cephalothin. The total synthesis of cephalothin required 16 linear steps from cysteine, 
with an additional 3 steps to make the electrophilic dialdehyde, while the total synthesis 
of cephalosporin C used additional protection steps to avoid potential cross-reactivity of 
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 The Staudinger formal [2+2] cycloaddition followed by kinetic epimerization route 
developed at Merck for the total synthesis of penicillin proved to be equally valuable for 
the total synthesis for cephalosporins. While the Bose/Firestone synthesis of penicillin 
uses a thiazoline as the imine component for the [2+2] cycloaddition, the total synthesis 
of cephalosporins requires a thiazine to produce the 6-membered dihydrothiazine in the 
cepham system. Starting from 1,3,5-tribenzylhexahydro-1,3,5-triazine, a-thio-formamido-
diethylphosphonoacetate was prepared by reaction with diethylphosphite, followed by 
debenzylation, condensation with benzaldehyde, acylation of the a-carbon with a 
chloroformate, removal of the benzylidene group by p-TsOH, and thioformylation with 
ethyl thioformate (Scheme 1.15).99 The a-thio-formamido-diethylphosphonoacetate 
intermediate possesses two nucleophilic groups, the sulfur on the thioformamide, and 
after deprotonation, the a  anion. In one step, this intermediate can react with a-
chloroacetone derivatives to displace the chloride with the thioformamide and 
intramolecularly cyclize by a Horner-Wadsworth-Emmons condensation of the a center 











Scheme 1.15. Synthesis of the thiazine intermediate for cephalosporin synthesis by the 





For the synthesis of cephalothin, the resulting thiazine was immediately reacted 
with azidoacetyl chloride to give the racemic 7a-azido cephalosporin, which contains the 
trans configuration at the C6-C7 junction (Scheme 1.16).72 After reducing the azide to an 
amine, the stereochemistry was corrected using the p-nitrobenaldehyde Schiff base 


































































racemic 7b-amino cephalosporin was acylated with 2-thienylacetyl chloride and finally the 
C2 carboxylic acid was revealed by removing the p-methoxylbenzyl (PMB) ester using 
TFA-anisole. The synthetically generated racemate was reported to have only 50% of the 
antibiotic activity of naturally derived cephalothin, due to the presence of the non-active 
enantiomer. In a follow-up paper, the researchers at Merck demonstrated that a modified 
strategy could be used to generate cefoxitin, which differs from cephalothin by having a 
7a methoxy substituent geminal to the C7-amido side chain.91  
Cephalosporins lack the C2 stereocenter found in penicillin, and thus the thiazine 
provides an achiral imine component to the Staudinger formal [2+2] cycloaddition and 
ultimately results in a racemic product. The formation of a racemic product provides a 
convenient route to quickly access all four diastereomers of cephalosporin, and in 1996 
Thomas Oberhauser at Hoffmann-La Roche used this strategy to access all 4 
diastereomers of 7-ACA and then isolated each isomer using chiral HPLC.90 By 
comparing naturally derived 7-ACA to the synthetic isolates, the enantiomeric excess and 












Scheme 1.16. The total synthesis of racemic cephalothin by Ratcliffe et al.72 
 





























































































To summarize, cephalosporins can be derived from penicillin, and their total 
synthesis has been achieved using the routes described above. The Staudinger formal 
[2+2] cycloaddition that was used to synthesize penicillin is also convenient for making 
cephalosporins and this strategy was used by Ratcliffe and Oberhauser, while Woodward 
provided a distinct route to produce cephalosporin C and cephalothin. So far, these 
syntheses are the only published total syntheses of cephalosporins, but other groups 
have used alternative approaches to access cephalosporin derivatives. For example, 
Stocksdale, Ramurthy, and Miller published a total synthesis of a 3-
(hydroxymethyl)carbacephalosporin that starts from a monobactam and then forms the 
second ring through an Horner-Wadsworth-Emmons reaction.100  
The step counts and overall yields for the total syntheses of b-lactams leave much 
to desire. However, these pioneering syntheses were critical for providing the foundation 
for b-lactam synthesis and have allowed researchers to explore novel b-lactam 
derivatives that would be difficult to produce from the semi-synthetic route. For our 
purposes, these total synthesis methods were crucial for accessing the unnatural 
enantiomers of penicillin and cephalosporin for biological studies.  
 
1.7.3 Epimerization strategies for penicillins and cephalosporins 
 Another strategy for accessing unnatural stereoisomers of b-lactam antibiotics is 
to epimerize the stereocenters of intact penicillins and cephalosporins. The kinetically 
controlled epimerization of C6 and C7 described in Section 1.7.1 and 1.7.2 that was used 
for the Firestone, Ratcliffe, and Oberhauser total syntheses is just one example of the 




stereocenters (cis to trans) is thermodynamically favorable because the trans relationship 
of the C5 and C6 substituents reduces steric interactions. The first method of 
epimerization of penicillin was reported by Johnson and coworkers at Bristol-Myers 
company and used aqueous sodium hydroxide to deprotonate the C6 proton of hetacillin 
(a prodrug of ampicillin), followed by reprotonation with HCl to give epi-hetacillin (Scheme 
1.17a).101 Soon afterward, 6-phthalimidopenillinate was shown to be susceptible to the 
same epimerization using a variety of bases including sodium hydride, potassium tert-
butoxide, and triethylamine (Scheme 1.17b).102 Epimerization of penicillin sulfoxides with 
standard amide side chains was the next advancement that was published by Gutowski 
at Eli Lilly (Scheme 1.17c).75 Gutowski’s method is base-free and instead uses 
bis(trimethylsilyl)acetamide (BSA) to equilibrate the penicillin sulfoxide into a mixture of 
starting material and C6 epimer. It was proposed that silylation converts the b-lactam 
carbonyl into a silyl enol ether, which ablates the C6 stereocenter, and then the enol is 
subsequently reprotonated on either face to give a mixture of epimers favoring the 6-epi-
penicillin sulfoxide. This strategy was further developed by Vlietinck, who showed that 
silylation with BSA followed by treatment with base was effective at epimerizing the C6 
stereocenter of penicillins with secondary amide side chains without the need to oxidize 
the penicillin to the sulfoxide (Scheme 1.17d).76 Finally, a direct C6 epimerization of 
penicillin V methyl ester using 2 equivalents of lithium diisopropylamide (LDA) followed 
by reprotonation was reported by Koppel at Eli Lilly (Scheme 1.17e).103 The epimerization 
uses one equivalent of LDA to deprotonate the amide side chain, and the second 
equivalent to remove the C6 proton to give a di-anion species that produces a mixture of 




















































































































up to 50% isolated
3:1 trans/cis for CO2Bn




80% (trans + cis)
70% isolated for CO2H




 Epimerization of the C5 stereocenter can achieved by a sequence of reactions that 
breaks the carbon-sulfur bond to open the thiazolidine ring and then reforms the carbon-
sulfur bond. This transformation was first reported by Kukolja at Eli Lilly for the C5 
epimerization of a 6-phthalimidopenicillinate (Scheme 1.18).104, 105 The Kukolja protocol 
breaks the carbon-sulfur bond through a chlorinolysis reaction using either chlorine or 
sulfuryl chloride. The reaction gives a mixture of dichloride diastereomers (4:1 trans/cis) 
that are treated with stannous chloride to re-cyclize the penicillin resulting in a 5:1 mixture 
of C5 epimers, favoring the C5-epi-penicillin product. The initial stereochemical 
relationship between the phthalimide and chloride groups after chlorinolysis is 
inconsequential to the final stereochemistry after re-cyclization, since the cyclization goes 
through the acyl iminium ion, which eliminates the stereocenter. The thiol attacks the 




















 A combination of C6 and C5 penicillin epimerization techniques has been used 
successfully by multiple groups for the synthesis of ent-cephalosporins. After epimerizing 
the C6 and C5 stereocenters, the epimerized penicillin can be converted to a 
cephalosporin via a Morin rearrangement (Scheme 1.10). Since cephalosporins lack a 
C2 stereocenter, epimerization of these two stereocenters is sufficient to reach the ent-
cephalosporin. This sequence was first published by Fekner et al. and used to convert 6-
APA into (6S, 7S) and (6S, 7R) cephalosporins.106, 107 Recently the sequence was 
adapted by Adaligil et al. in order to produce an ent-cephalosporin for phage display of a 









































to ent-penicillin derivatives, which would require further epimerization of the C2 
stereocenter, or starting from ent-6-APA.  
 Finally, Baldwin showed that the C2 stereocenter of penicillin can be epimerized 
through a sequence of reactions that eliminates the C2 carboxylic acid and then re-installs 
a tert-butyl amide at the C2 position through an Ugi-like rearrangement.109 The penicillin 
C2 carboxylic acid was first converted into an isocyanate. Then, the b-lactam was 
hydrolyzed, which resulted in elimination of the isocyanate. The resulting imine was 
treated with tert-butyl isocyanide, which attacks the imine and triggers an Ugi 
rearrangement. The Ugi rearrangement reforms the b-lactam and results in a C2 amide 
with epimerized stereocenter. The reaction stereospecifically gives the C2 epimerized 




















Overall, these epimerization strategies are convenient for the preparation of 
unnatural stereoisomers of penicillin and cephalosporins since intact penicillins and 























































Crauste et al for the synthesis of penicillin-based inhibitors of bacterial signal peptidase I 
inhibitors.110 A combination of C5 and C6 epimerization techniques were used to 
synthesize unnatural diastereomers of penicillin, which were linked to a lipopeptide. 
Importantly, their work demonstrated that the penicillin core could be used as an 
electrophilic warhead for targeting other types of enzymes, and their efforts to identify the 
best stereoisomer of penicillin paid off since an unnatural stereoisomer of penicillin 
provided the strongest activity against their target. One limitation to epimerizing penicillins 
and cephalosporins is that the epimerization techniques often require specific 
substituents, like a bulky phthalimido group, in order to favor formation of the desired 
epimer. Thus, additional reaction steps are needed to remove these groups and replace 
them with the substituents of the final target penicillin or cephalosporin. Also, these 















CHAPTER 2. SYNTHESIS AND BIOLOGICAL EVALUATION OF THE UNNATURAL 
ENANTIOMER OF PENICILLIN 
 
2.1 Introduction  
 As previously discussed in Chapter 1, b-lactam antibiotics are one of the most 
impactful classes of drugs and they continue to reappear in new research settings as the 
understanding of b-lactam biology continues to expand. As new activities are uncovered, 
b-lactams have the prospect to be repurposed to solve new problems. The biological 
activities of the natural configurations of penicillin and cephalosporin have been well-
studied for over 80 years, while study of the unnatural stereoisomers of penicillin and 
cephalosporins has been limited, since deviation from this natural configuration has been 
shown in some cases to diminish the bactericidal activity (Section 1.6 for details).11, 111 
The enantiomers in particular have only appeared in a limited number of publications, 
usually as a biproduct of a b-lactam total synthesis. The forthcoming section describes 
the total synthesis of penicillin and ent-penicillin for further biological investigation. 
Existing total synthesis strategies (Section 1.7) were evaluated and modified in order to 
develop a route to the unnatural enantiomer.  
Our synthetic route employs the Staudinger formal [2+2] cycloaddition, previously 
used by Bose and Firestone, as a key reaction for forming the penam (section 1.7). Our 
synthesis diverges from the previous routes by using an SN2 reaction to invert the C6 
stereocenter and install a progenitor of the C6 amine. The sequence leading to the SN2 




combining these strategies was to identify an appropriate acid chloride for the Staudinger 
formal [2+2] reaction that would install a protected alcohol at the C6 position, which could 
subsequently be deprotected to give a C6 hydroxyl group. After activating the hydroxyl 
group and displacing it with azide, only a few steps would remain to install the C6 amide 
side chain and reveal the C2 carboxylic acid. This asymmetric route to penicillin produces 
natural penicillin from D-penicillamine, and ent-penicillin from L-penicillamine (Figure 2.1). 
We used D-penicillamine to work out the synthesis since D-penicillamine ($200/100 g) 
was more available and less costly than L-penicillamine ($1000–1600/100 g). 
 
 
Figure 2.1. Configurations of D- and L-penicillamine leading to (+) and (–) penicillin V. 
 
Once the synthesis of penicillin V and ent-penicillin V was achieved, a variety of 
biological studies were conducted in order to compare the biological activities of the two 
enantiomers. The enantiomers were tested in growth inhibition assays against bacteria 































receptors. In addition, the enantiomers of penicillin were further developed into pull-down 
probes to conduct chemical proteomic experiments to compare and identify the cellular 
targets for each enantiomer. 
 
2.2 Results and discussion 
2.2.1 Synthesis of (+) and (–) penicillin V 
 Each of the total syntheses described in the introduction (Section 1.7) could 
conceivably be used to produce the enantiomer of penicillin by starting from the opposite 
enantiomeric starting materials in the asymmetric routes, or by separating the 
enantiomers produced by a racemic route. In the interest of expediting the attainment of 
proof of concept biological data, we adapted strategies that were pioneered by Bose, 
Firestone, and Christensen that employ the Staudinger formal [2+2] cycloaddition for 
constructing the b-lactam. The major advantages to this strategy are its stereospecificity 
and conciseness. Previously, it allowed (+)-penicillin G to be produced in nine steps. With 
some modifications the strategy was adopted here to produce (+) and (–) penicillin V and 
a related biotin probes. 
 Forming a penam by the Staudinger formal [2+2] cycloaddition first requires the 
synthesis of an appropriate thiazoline and acid chloride precursors. The thiazoline was 
generated in two steps from penicillamine (Scheme 2.1). First, penicillamine was 
esterified by a Fischer esterification. Initially, a methyl ester was installed to give (+)-2.2b 
by reacting the amino acid in methanol with sulfuric acid. The methyl ester (+)-2.2b was 
convenient for piloting the initial explorations of the synthetic route, but ultimately a better 




synthesis (since hydrolysis of the methyl ester would likely hydrolyze the b-lactam as 
well). Thus, benzyl esterification of penicillamine was used instead to give 2.1, which 
allowed the C2 carboxylic acid to be revealed at the last step by a catalytic 
hydrogenolysis. The benzyl ester protecting group was implemented successfully for 
penicillin syntheses by Firestone, Barrett, and Baldwin.81, 83, 106 In order to form thiazoline 
2.2, 2.1 was condensed with triethyl orthoformate following a modified procedure 
published by Emtenäs that uses molecular sieves to drive the condensation to 
completion.112  
 




In our case, p-toluenesulfonic acid was not necessary for catalyzing the reaction, 
perhaps due to the geminal methyl groups on penicillamine, which would be expected to 
accelerate the cyclization via the Thorpe–Ingold effect.113  After chromatography, 
thiazoline 2.2 was isolated as either an amorphous white solid, or crystals. While the 
amorphous solid form of 2.2 tends to decompose rapidly over 2-3 days, crystals of 2.2 
remain stable at room temperature for >10 months. By serendipity, it was found that 
amorphous 2.2 can be sublimated under high vacuum with 55-65 °C temperatures to give 






























Figure 2.2. Thiazoline 2.2 crystal growth in a sublimation apparatus. 
 
Traditionally, penicillin and cephalosporin total syntheses that use the Staudinger 
formal [2+2] cycloaddition rely on azidoacetyl chloride to produce a C6-azido penicillin or 
C7-azido cephalosporin intermediate, which is subsequently inverted by a kinetically 
controlled epimerization procedure first discovered by Firestone (Section 1.7, Scheme 
1.4). Instead, our synthesis of penicillin used the Staudinger formal [2+2] to reach a C6-
hydroxy intermediate that could be inverted by SN2 displacement with nucleophilic azide. 
The ketene to provide such an intermediate required a protected alcohol that could be 




reaction was successfully employed at the C6 position using a silyl ether as the protected 
alcohol, which was deprotected, triflated, and then displaced by lithium azide.83 For this 
work, a variety of silyl ether protecting groups were briefly examined. A limited number of 
publications show that 2-silyl ether acid chlorides or silyl enol esters can be used in 
Staudinger formal [2+2] reactions to prepare monobactams.114-118 However, it has not 
been shown whether or not these 2-silyl ether acid chlorides can be combined with 
thiazolines or thiazines to prepare bicyclic b-lactams. We prepared 2-O-TBDMS and 2-
O-TBDPS acetyl chloride, but when they reacted with the thiazoline in the presence of 
triethylamine, they produced a complex mixture with only trace amounts of the desired 
product detected by LCMS. Manhas and Bose previously explored the feasibility of using 
an acid chloride with a benzyl ether to produce alpha hydroxy b-lactams and the scope 
included one example of an alpha benzyloxy penicillin, (+)-2.3b, made by this 
methodology.88 The publication shows many examples where the benzyl ether was 
removed to give the alpha hydroxy b-lactam. However, the debenzylation of (+)-2.3b was 
not included in the paper, nor was there any discussion surrounding the debenzylation of 
this compound. Our attempts to produce (+)-2.4b using 2-O-benzylacetyl chloride were 
consistent in yield with the original study (up to 30%), but ultimately we were unable to 
debenzylate (+)-2.4b using standard hydrogenolysis conditions, TMS-iodide, or 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). Thus, we abandoned the benzyl ether 
protecting group and decided to install a PMB protecting group, which is typically cleaved 





Scheme 2.2. Staudinger formal [2+2] cycloaddition using thiazoline (+)-2.2b and 
deprotection to (+)-2.4b. 
 
 
The desired 2-O-PMB-acetyl chloride was prepared by reacting bromoacetic acid 
with 4-methoxybenzylalcohol to give 2-O-PMB-acetic acid, which was subsequently 
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reacted with triethylamine to give the desired penam (+)-2.4b with the C6 PMB ether trans 
to the C5 sulfide. The selective formation of the trans C5-C6 diastereomer is consistent 
with previous reports of penams constructed by the Staudinger formal [2+2] 
cycloadditions (introduced in Figure 1.16). The yields for making penam structures by the 
Staudinger formal [2+2] reaction are usually low (literature shows up to 12.7% for C6 
azide81 and up to 30% for the C6 benzyl ether88), and the yields for the PMB analogs here 
were consistent with this trend (up to 22% yield). 
As the reaction was optimized, it was found that the 2-O-PMB-acetyl chloride tends 
to form an unknown biproduct which causes the Staudinger formal [2+2] cycloaddition to 
fail. The 1H NMR spectrum of the biproduct is similar to the desired acid chloride, except 
the integration for the protons alpha to the carbonyl is reduced by ½ compared to the 
desired acid chloride, which is consistent with either the formation of a ketene or ketene 
dimer. When the crude mixture of acid chloride and biproduct was vacuum distilled (bp 
85–90 °C) in an attempt to purify the acid chloride, only the pure biproduct was found in 
the receiving flask. After varying the temperature and order of addition, it was found that 
adding the carboxylic acid last to the stirring mixture of DCM, oxalyl chloride, and catalytic 
DMF at room temperature gave the desired acid chloride while suppressing the formation 
of the biproduct. As planned, the PMB group was conveniently removed by reaction with 
DDQ to finally give the C6-hydroxy penicillin 2.4 in 79% yield. After purification by reverse-













Figure 2.3. Recrystallization of 2.4. 
 
The next objective was to invert the C6 stereocenter by displacement with a 
nitrogen-containing progenitor of the penicillin C6 amine. Displacement of the alcohol with 

































Scheme 2.4 and Table 2.1. Trial of Mitsunobu conditions for the displacement of the C6 
alcohol. 
 
 R TPP equiv azodicarboxylate nucleophile solvent temp time observation 




(0.1 M) RT overnight decomp 






reflux overnight decomp 




(0.1 M) RT overnight decomp 














(0.1 M) RT overnight 
unreacted 
SM 




(0.1 M) RT overnight 
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SM 
















         
9 benzyl – DBU (1.1 equiv) DPPA (1.5 equiv) 
THF 
(0.2 M) RT overnight decomp 
 
 
Inspiration was drawn from a paper that surveyed displacement chemistry at C6 
of penicillin and C7 of cephalosporin published by Kemp and coworkers at Pfizer.121 Their 
results show that the C6-trifloxy group is viable for substitution reactions, particularly with 
soft nucleophiles. One entry showed that reaction of the triflate with lithium azide could 
achieve the desired transformation in 42% yield. Encouraged by this report, a variety of 






















azide, and sodium azide. None of these azides were successful until sodium azide was 
combined with 15-crown-5 ether. This combination of sodium azide and 15-crown-5 was 
optimized to give the desired 2.6 with an average yield of 74%.   
 
Scheme 2.5 and Table 2.2. Optimization for transforming 2.4 to 2.6 through a two step 
displacement sequence. 
 
Entry Nucleophile Additive Temp Time (h) Molarity Yield % 
1 sodium azide (1.3 equiv) none RT overnight 0.10 
Unreacted 
SM 
2 TBAA (1.0 equiv) none RT overnight 0.10 Decomp 
3 TMS-N3 (1.9 equiv) none RT overnight 0.10 
Unreacted 
SM 
4 sodium azide (2.6 equiv) 
15-crown-5 
ether (1.2 equiv) RT overnight 0.05 22 
5 sodium azide (2.8 equiv) 
15-crown-5 
ether (1.2 equiv) RT overnight 0.09 33 
6 sodium azide (2.7 equiv) 
15-crown-5 
ether (1.2 equiv) RT overnight 0.15 29 
7 sodium azide (2.7 equiv) 
15-crown-5 
ether (1.2 equiv) RT overnight 0.22 24 
8 sodium azide (2.7 equiv) 
15-crown-5 
ether (0.9 equiv) RT 3.0 0.14 51 
9 sodium azide (2.3 equiv) 
15-crown-5 
ether (0.8 equiv) RT 1.0 0.14 29 
10 sodium azide (1.8 equiv) 
15-crown-5 
ether (0.5 equiv) 
0 °C 1 h 
then RT 2.5 h 3.5 0.14 49 
11 sodium azide (1.9 equiv) 
15-crown-5 
ether (0.5 equiv) 
0 °C 1 h 
then RT 2.5 h 3.5 0.14 62 
12 sodium azide (2.0 equiv) 
15-crown-5 
ether (0.5 equiv) 
0 °C 15 min 
then RT 2 h 2.25 0.14 68 
13 sodium azide (2.0 equiv) 
15-crown-5 
ether (0.5 equiv) 
0 °C 35 min 





























The stereochemistry at C6 is inverted during the transformation, which was 
indicated by the increase in the coupling constants for the C5 and C6 hydrogen atoms (J 
= 1 hz for 2.4 to J = 4 hz for 2.6). 
 
 
Figure 2.4. Snapshot of the NMR spectra of 2.4 and 2.6 showing the change in J value 
for the coupled b-lactam protons. 
 
The dihedral angle between the C5 and C6 protons is 90° for the trans isomer and 
0° for the cis. The observed increase in J value is consistent with the Karplus equation, 
which states that the J value oscillates as the dihedral angle between the coupled protons 
changes according to: 






















J = 4.0 Hz  




where ø is the dihedral angle. The J value reaches a maximum when cosø is at a 
maximum at a dihedral angle of 0° (corresponding to the cis relationship for the b-lactam 
substituents). With the azide installed and the stereocenter corrected, only a few 
remaining functional group interconversions remained to reach penicillin.  
 The next objective was to install the penicillin side chain. Initially we targeted the 
phenylacetyl side chain due to its simplicity and its occurrence in the natural product, 
penicillin G. If the hypothesis is true that the ent-penicillin mimics L-Ala-L-Ala, then 
perhaps a phenylacetyl side chain would mimic a phenylalanine residue and be consistent 
with the overall peptidomimetic property of the molecule. A Staudinger reduction allowed 
the C6 azide of 2.6 to be selectively reduced while preserving the C2 benzyl ester. Then, 
2.7 was acylated with phenylacetyl chloride using pyridine as base according to 
conditions from the Firestone total synthesis.81 The reaction proceeds nearly 
instantaneously according to TLC analysis and was quenched rapidly after 30–60 
seconds to prevent decomposition. If the reaction is allowed to stir longer (15–30 min), 












Scheme 2.6 and Table 2.3. Transformation of 2.6 into 2.8 and optimization of the 
acylation for installing the amide side chain. 
 
 
Entry Acid chloride Temperature °C Time (min) Yield % Yield Amt (g) 
1 phenylacetyl 25 30 31 0.0026 
2 phenylacetyl 25 20 22 0.0066 
3 phenylacetyl 25 6 55 0.0139 
4 phenylacetyl 0 6 62 0.0112 
5 phenoxyacetyl 0 6 33 0.0093 
6 phenoxyacetyl 0 6 53 0.0296 
7 phenoxyacetyl 0 3 77 0.0444 
8 phenoxyacetyl 0 1 84 0.0635 
9 phenoxyacetyl 0 1 64 0.0368 
10 phenoxyacetyl 0 1 73 0.0440 
 
 
After work-up and normal phase chromatography (0–40% EtOAc/hexanes), the 
penicillin G benzyl ester 2.8 was isolated in yields up to 62%. However, the penicillin G 
side chain became problematic when the proceeding debenzylation was attempted on 



































consistent by NMR with the penicillin G free acid, which was unstable and decomposed 
rapidly over 2–3 days (Figure 2.5b). Adding 1 equivalent of sodium bicarbonate (inspired 
by Firestone et al.)81 gave a mixture of products that were inseparable by extraction or 
chromatography (Figure 2.5a). Attempts to purify the free acid by chromatography or form 
the sodium salt by addition of sodium bicarbonate all caused degradation of the product 





























Figure 2.5. (a) UPLC trace when 1 equivalent of NaHCO3 is added to the debenzylation 







under neutral conditions. (c) UPLC trace when commercial penicillin G was subjected to 
acidic conditions.  
 
 
Figure 2.6. NMR spectra of material isolated from attempts to form the sodium salt after 
debenzylation of 2.8a. 
 
Degradation of penicillin G has been previously studied and is thought to occur 
mainly by rearrangement to an oxazalone under acidic conditions or by hydrolysis of the 
b-lactam under basic conditions.122-124 The NMR spectrum of the degradation product of 
2.8a isolated after chromatography was indeed consistent with oxazalone formation. 
Alternative side chains that are more electron withdrawing can be used to decrease the 
Authentic penicillin G sodium salt 
Salt formation with excess NaHCO3 












nucleophilicity of the amide and suppress oxazalone formation. This increase in stability 
is exemplified in comparing penicillin G to penicillin V. Penicillin G is acid labile and cannot 
be administered orally due to the acidity of the stomach, while penicillin V has a more 
electron withdrawing side chain and is much more stable under acidic conditions and 
orally bioavailable.125  
 




Thus, we abandoned the phenylacetyl side chain and the amino penicillin 
intermediate was acylated with phenoxyacetyl chloride instead to give 2.8b. Analog 2.8b 
proved to be much more stable and allowed the debenzylation reaction to occur, giving 
2.9 without formation of biproduct. The debenzylation was accomplished with a palladium 
on carbon hydrogenation procedure published by Fekner using a 1:1 mixture of 
THF/water with 1 equivalent of sodium bicarbonate to give 2.9 as a sodium salt, which 
conveniently increases the stability of the penicillin and allows the material to be stored 


















































Scheme 2.8. Transformation of 2.7 into 2.9. 
 
 
As mentioned above, D-penicillamine was used to develop the total synthesis since 
it was less costly than L-penicillamine (200$/100 g vs 1600$/100 g). Thus, the initial total 
synthesis gave (+)-2.9, the natural enantiomer of penicillin V. Once the total synthesis 
route was established, L-penicillamine was used to produce (–)-2.9, the unnatural 
enantiomer of penicillin V. For each intermediate, the (+) and (–) enantiomers were 
produced and analyzed by chiral HPLC to assess enantiopurity. After screening a variety 
of chiral chromatography conditions, it was found that the use of a CHIRAL PACK IC 
preparatory column (DAICEL Corporation) with isopropanol/hexane eluent was best 
suited for separating the various penicillin intermediates. A small amount of the minor 
enantiomer (1–5%) could be detected in intermediates proceeding the thiazoline forming 
reaction. After comparing the retention time differences between each pair of 
enantiomers, it was found that the C6-amino, and PMB ether intermediates 2.3 and 2.7 
would be easiest to separate on preparative scale. Thus, 2.3 and 2.7 were purified by 
preparative chiral chromatography and used to produce enantiomerically pure 2.8 and (+) 








































Figure 2.7. Chiral chromatography retention times for each intermediate plotted against 



























Retention time t1 (min)



















































up to 10 g
39% 


























































































2.2.2 Synthesis of biotinylated (+) and (–) penicillin probes 
The total syntheses of (+) and (–) penicillin V provided the ability to compare the 
biological activity of the enantiomers in a variety of in vitro binding assays and cell growth 
inhibition assays. Next, we wanted to produce biotin-linked penicillin probes, which would 
allow us to conduct proteomic experiments to directly compare the binding of each 
enantiomer to cellular proteins. Our total synthesis route provided a convenient 
intermediate 2.7 with a C6 amine that could function as a reactive handle for attaching a 
biotin tag (Scheme 2.10). Biotin has previously been linked to penicillin through a variety 
of linkers (see Section 1.5 for details). We used a linker that was previously published by 
Dargis since it had precedence for binding penicillin binding proteins in bacteria.60 That 
way, we could compare our results in bacteria for the naturally configured penicillin probe, 
(+)-2.14, with published results to help validate our assay before we began experiments 
with the novel ent-penicillin–biotin probe. 
The carbon chain of D-biotin was extended and then activated as the NHS ester 
using a series of amide coupling reactions. We targeted the NHS ester because it is 
commonly used to bind affinity and fluorescent tags to free amines, which would make it 
suitable for binding both penicillins and cephalosporins with C6 or C7 primary amines. 
Biotin was reacted with DCC and NHS to give the biotin NHS ester 2.10. Then, 2.10 was 
reacted with aminocaproic acid to extend the carbon chain by six carbons to give 2.11. 
The terminal carboxylic acid was activated once again with NHS and EDCI to give the 
desired long-chain biotin NHS ester 2.12. As we hoped, 2.12 reacted with our amino-
penicillin intermediate to give biotinylated penicillin 2.13. Finally, the benzyl ester was 




sodium bicarbonate to give the penicillin–biotin probe (+)-2.14 as the sodium salt. 
Enantiomerically pure (>99% er) amino-penicillins were used to produce both the 





































NaHCO3, H2O/DMF, RT (85%)



























2. Pd/C, H2, 1 equiv NaHCO3

















































Since chiral D-biotin was linked to each enantiomer, the resulting biotinylated 
probes (+)-2.14 and (–)-2.14b are not enantiomers of one another, but rather 
diastereomers. This feature of the probes could perceivably introduce some uncertainty 
as to whether the results of the experiments could be viewed as a perfect head to head 
comparison for assessing the binding activities of the (+) and (–) penicillin enantiomers. 
However, if the linker length is sufficiently long, then the stereochemistry at the biotin-end 
of the molecule should theoretically have minimal influence on the ability for each 
penicillin stereoisomer to bind their target proteins (unless it produced significant changes 
in the conformation of the molecule, which is unlikely). L-Biotin is not found in nature, and 
not commercially available, since it must be accessed by total synthesis. Furthermore, 
since L-biotin has rarely been studied, it is unknown whether streptavidin would have 
strong affinity for this unnatural enantiomer, which is essential for our proteomics 
experiments. Thus, we determined that attaching the D-biotin linker to both enantiomers 
of penicillin was the best strategy for our proof of concept experiments.  
 
2.2.3 In vitro binding assays for (+)- and (–)-penicillin V 
 Samples of (+)- and (–)-penicillin V (2.9) were submitted to Eurofins for screening 
in the BioPrint® panel, which assesses a compound’s binding or uptake for 133 different 
proteins or enzymes. The panel includes G protein-coupled receptors (GPCRs), ion 
channels, transporters, phosphodiesterases, kinases, enzymes involved in steroid, 
neurotransmitter, nitrogen, and lipid metabolism, proteases, and other miscellaneous cell 
surface and cytosolic proteins. The compounds were screened against each target 




pre-determined ligand or substrate that was radiolabeled and could be detected by 
scintillation counting. The test compounds, (+)- or (–)-2.9 (named JDC-01 and JDC-02 in 
the study), were administered to the target at a 10 µM concentration, followed by the 
appropriate radioligand. Compound binding was calculated as a percent inhibition of the 
binding of the radioactively labeled ligand specific for each target. Compound enzyme 
inhibition effect was calculated as a percent inhibition of control enzyme activity. The 
experiment was repeated in duplicate and then the percent inhibition results were 
averaged. A percent inhibition greater than zero indicated that the compound reduced 
binding of the radioligand, while a percent inhibition less than zero could be interpreted 
as increasing binding of the radioligand (possibly through an allosteric effect). However 
the results interpretation guide provided by Eurofins explains that in most cases a 
negative value is due to variability of signal at the control level. A percent inhibition greater 
than 50% was considered a hit that would be worthy of follow-up assessment, while 
results showing an inhibition (or stimulation) between 25% and 50% was indicative of 
weak to moderate effects (in most assays, they should be confirmed by further testing as 
they are within a range where more inter-experimental variability can occur). Results 
showing an inhibition (or stimulation) lower than 25% were not considered significant and 
mostly attributable to variability of the signal around the control level.  
Neither (+)- nor (–)-2.9 produced a percent inhibition greater than 50% for any of 
the targets. A few targets saw weak competition of the radio ligand, for example JDC-01, 
(+)-2.9, had a 29.6% inhibition of Abl kinase and a 24.5% inhibition of CDK2, while JDC-
02, ent-penicillin V, showed its highest inhibition of 23.6% against Abl kinase. However, 




panel is not a comprehensive assessment of all possible binding activities, these data 
suggest that ent-penicillin V does not have widespread, non-specific activity, like what 
might be expected for an L-Ala-L-Ala mimic. It remains possible that the unnatural ent-
penicillin V could have specific binding activity for proteins that were not included in the 
panel. Natural penicillin V is an effective drug due to its overall good specificity for 
bacterial penicillin-binding proteins, which is thought to arise from its mimicking the 
configuration of D-Ala-D-Ala. One limitation to this study is that we only examined the 
activity of a single penicillin chemotype with the phenoxyacetyl side chain and C2 
carboxylic acid. These functional groups are effective for binding PBPs, but might not be 
optimal for binding other types of proteins that were included in the panel. For example, 
changing the canonical C2 carboxylic acid of cephalosporins to a non-ionic ester or 
oxadiazole gave cephalosporins newly discovered activity against Mtb under non-
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Following previous reports that showed b-lactams having biological activity against 
neurological targets (see section 1.4 for details), we screened a set of 8 penicillin and 
cephalosporin analogs against a collection of GPCRs within in the UNC National Institute 
of Mental Health (NIMH) Psychoactive Drug Screening Program (PDSP). The penicillin 
derivatives included the (+) and (–) enantiomers of penicillin V (2.9), along with their 
related benzyl ester analogs (2.8). The cephalosporins included each of the 4 
diastereomers of cephalosporin V ((+) or (–) CN1 and CN2), which were synthesized in 
our lab by Dr. Chip Norwood. The targets of the assay included serotonin transporters, 
norepinephrine transporters, serotonin receptors, adrenergic receptors, muscarinic 
receptors, dopamine receptors, opioid receptors, and sigma receptor chaperone proteins. 
The receptor targets were overexpressed in an appropriate cell line and then the cell 
membrane fractions were pelleted. For each receptor preparation, a saturation binding 
experiment is performed with the designated radioligand in order to determine the 
receptor expression level and the binding affinity (KD) for the ligand. Then, each 
compound was screened at 10 µM in the radioligand inhibition assay for four replicates. 
The drugs were incubated with cell membrane pellet and then the radioligand was added. 
After washing away the unbound radioligand, the percent inhibition was determined by 
counting the scintillation of the bound radioligands and dividing the observed scintillation 
count by the scintillation count in the absence of test compound. The four replicates were 
averaged to give a mean percent inhibition for the compound and receptor.  
A percent inhibition greater than 50% or less than –20% was considered a hit in 
the assay and warranted further screening in a secondary binding assay. The secondary 




compound was dosed at 12 concentrations. The inhibition of radioligand binding was then 
measured at each concentration and the data were plotted and fitted to a curve using a 
linear regression algorithm, which is then used to calculate an inhibition constant (Ki) for 
the compound. The Ki value can be interpreted as the concentration of test compound 
that causes a 50% reduction in scintillation count, or a concentration that inhibits 50% of 
the radioligand from binding the receptor. Thus, lower Ki values indicate stronger binding 
between the test compound and the receptor. 
So far, the compounds have been screened against 41 different targets (Tables 
2.7–2.10), and 25 hits have been identified (Table 2.11). Each compound has produced 
at least two hits in the primary screen. For example the ent-penicillin benzyl ester (–)-2.8 
showed binding activity for serotonin transporter (SERT) (Ki = 1.3 µM), 5-HT2B (Ki = 0.85 
µM), D5, Alpha2C, and Sigma 1 (Ki = 2.5 µM). Some of the targets showed binding affinity 
for multiple compounds, such as the 5-HT2B receptor, which showed binding for both 
enantiomers of  2.8, but had increased affinity for the unnatural (–) configuration (Ki = 2.5 
µM for (+) and Ki = 0.85 µM for (–)). The D5 receptor favored the (–) enantiomers of 
penicillin 2.8 (57% inhibition for (–) vs 38% inhibition for (+)) and cephalosporin CN2 (77% 
inhibition for (–) vs 9% inhibition for (+)). Some of the hits that were identified in the 
primary screen failed to produce activity in the secondary screen. For example, (–)-CN1 
produced 87% inhibition of 5-HT1D in the primary screen, but failed to inhibit 5-HT1D in 
the secondary assay even at 10 µM. The same compound also failed to inhibit the 
Alpha1A receptor in the secondary assay.  This discrepancy between the primary and 
secondary assay results could come from the compound degrading during storage 




accuracy of the Ki values from the secondary screen are limited by the fact that the 
compounds are all screened at the same pre-determined concentrations ranging from 10-
11 to 10-5 M. The resulting inhibition curves (Figure 2.14) do not have a full “S” shape, 
which means that the receptors did not reach the maximum inhibition. More accurate Ki 
values could be determined by adding data points at higher concentrations until the % 
inhibition stops increasing. Nonetheless, these data show that the various stereoisomers 

















































Table 2.11. Percent inhibition values for (+)-2.8b (left) and (–)-2.8b (right) against PDSP 
targets. 
























Table 2.12. Percent inhibition values for (+)-CN1 (left) and (–)-CN1 (right) against PDSP 
targets. 
               
  
 
Receptor Inhibition 1 Inhibition 2 Inhibition 3 Inhibition 4 Mean %
5-HT1A 12.16 17.01 19.75 -0.11 12.2
5-HT1B -7.56 -2.19 -0.35 -9.39 -4.87
5-HT1D 19.81 12.14 17.69 6.32 13.99
5-HT1E 2.79 -1.19 1.99 -4.22 -0.16
5-HT2A -4.26 -3.58 -3.92 -17.64 -7.35
5-HT2B 8.42 -1.39 -11.34 -17.23 -5.39
5-HT2C 12.94 -13.16 12.59 18.24 7.65
5-HT3 32.26 17.22 5.71 24.8 20
5-HT5A 39.26 -22.02 -14.67 -21.1 -4.63
5-HT6 0.66 -10.2 -9.52 -19.7 -9.69
5-HT7A -12.1 -17.75 1.57 -19.76 -12.01
Alpha1A -11.22 -51.27 -35.93 -28.84 -31.82
Alpha1B -18.92 5.73 -16.86 37.11 1.77
Alpha1D -25.57 -18.24 -12.81 14.89 -10.43
Alpha2A 4.48 11.13 11.13 18.38 11.28
Alpha2B 7.61 -8.75 1.04 7.74 1.91
Alpha2C -12.08 19.09 0.3 -7.99 -0.17
Beta1 -6.06 0.02 7.87 12.02 3.46
Beta3 -1.19 -5.06 7.83 39.03 10.15
BZP Rat Brain 
Site 45.4 22.95 15.64 18.75 25.69
D1 15.48 4.1 -46.59 28.73 0.43
D2 -3.9 -9.1 -19.95 -7.11 -10.02
D3 2.47 -13.94 -3.58 -13.94 -7.25
D4 3.31 -14.81 -30.71 28.21 -3.5
D5 21.34 3.9 11.53 -3.72 8.26
DAT
DOR -41.58 -4.68 -13.07 -30.71 -22.51
H1
H2
H3 -5.67 5.83 -1.66 25.1 5.9
H4 31.42 18.96 27.88 53.35 32.9
KOR 11.31 -6 18.86 30.48 13.66
M1 -14.1 -4.78 3.75 13.58 -0.39
M2 6.65 15.98 15.34 12.07 12.51
M3 -4.92 -7.74 48.34 18.71 13.6
M4 -21.09 -24.56 9.09 31.8 -1.19
MOR -3.38 -14.67 -3.87 -11.23 -8.29
NET
PBR
SERT -17.42 -14.32 -39.92 -23.32 -23.75
Sigma 1 -7.4 6.45 -5.86 -25.25 -8.02
Sigma 2
Receptor Inhibition 1 Inhibition 2 Inhibition 3 Inhibition 4 Mean %
5-HT1A 7.74 6.86 21.43 -1.35 8.67
5-HT1B -15.19 -13.91 -25.78 -22.81 -19.42
5-HT1D 95.73 84.62 77.74 88.59 86.67
5-HT1E -18.88 -12.66 -2.15 24.61 -2.27
5-HT2A 13.19 4.21 -0.53 -2.56 3.58
5-HT2B 22.69 10.52 17.72 5.41 14.09
5-HT2C 11.8 -7.34 -9.2 1.65 -0.77
5-HT3 8.37 19.36 0.27 -7.09 5.23
5-HT5A -3.34 -3.83 0.12 11.5 1.11
5-HT6 3.38 -9.52 -10.6 -23.09 -9.96
5-HT7A 1.57 -8.09 25.64 -21.22 -0.52
Alpha1A -19.37 -33.94 -42.01 -29.16 -31.12
Alpha1B 0.67 -5.62 1.61 31.15 6.95
Alpha1D -19.41 -1.67 -5.66 2.67 -6.02
Alpha2A 43.45 24.89 15.61 22.85 26.7
Alpha2B 25.31 9.23 32.7 -8.83 14.6
Alpha2C -1.98 30.74 -3.07 2.58 7.07
Beta1 23.99 -2.24 3.03 13.58 9.59
Beta3 44.98 23.76 11.86 7.72 22.08
BZP Rat Brain 
Site 56.76 40.67 39.85 30.79 42.02
D1 48.32 44.28 38.38 30.03 40.25
D2 5.78 -10.6 -7.61 -22.6 -8.76
D3 6.78 0.96 -8.94 3.41 0.55
D4 1.08 -3.59 10.08 0.27 1.96
D5 22.43 14.44 9.35 11.35 14.39
DAT
DOR 30.39 48.03 28.13 20.17 31.68
H1
H2
H3 -3.48 17.6 -9.55 42.69 11.82
H4 -2.84 29.06 26.05 31.79 21.02
KOR -4.39 -11.01 -5.32 91.47 17.69
M1 -32.72 -22.63 -18.23 1.42 -18.04
M2 18.77 -1.8 14.86 7.13 9.74
M3 -10.82 -6.68 43.32 2.05 6.97
M4 -17.55 -3.59 2.85 16.87 -0.36
MOR -6.32 -15.81 -3.38 -4.19 -7.43
NET
PBR
SERT -28.46 -51.38 -21.28 -27.75 -32.22





Table 2.13. Percent inhibition values for (–)-CN2 (left) and (+)-CN2 (right). 




Receptor Inhibition 1 Inhibition 2 Inhibition 3 Inhibition 4 Mean %
5-HT1A 8.19 -0.99 11.72 -47.68 -7.19
5-HT1B -22.53 -5.3 -26.63 -23.8 -19.57
5-HT1D -4.79 23.51 -5.32 20.6 8.5
5-HT1E -9 -36.72 -11.23 10.43 -11.63
5-HT2A -1.55 0.15 -1.21 4.55 0.49
5-HT2B 11.3 0.18 -13.95 6.59 1.03
5-HT2C 8.89 1.83 -10.61 23.53 5.91
5-HT3 -6.99 -1.87 -20 -0.48 -7.34
5-HT5A 15.46 -0.87 -3.34 -8.78 0.62
5-HT6 4.73 -6.53 11.93 -19.16 -2.26
5-HT7A 13.73 23.14 10.11 11.26 14.56
Alpha1A -20.92 -54.57 -43.19 -34.79 -38.37
Alpha1B -11.02 -20.31 17.13 36.05 5.46
Alpha1D -12.26 -4.48 -19.23 -0.14 -9.03
Alpha2A 31.9 33.15 3.51 13.35 20.48
Alpha2B 15.6 20.61 2.8 9.49 12.13
Alpha2C -4.15 7.55 1.23 -2.86 0.44
Beta1 -2.37 -2.24 20.17 1.98 4.39
Beta3 47.22 17.03 33.07 14.96 28.07
BZP Rat Brain 
Site 47.43 10.37 13.34 21.73 23.22
D1 3.96 15.91 8.28 17.5 11.41
D2 12.09 7.5 2.19 -4.45 4.33
D3 53.1 33.38 34.75 25.58 36.7
D4 1.29 -22.8 -2.03 -1.42 -6.24
D5 85.63 72.92 76.91 71.83 76.82
DAT
DOR -25.12 -3.98 -10.49 -21.51 -15.28
H1
H2
H3 -0.76 -5.54 -19.77 30.66 1.15
H4 -3.13 17.42 40.13 33.52 21.99
KOR 7.46 8.36 6.78 22.1 11.18
M1 -22.89 -20.56 3.75 34.01 -1.42
M2 9.28 5.29 -3.4 -6.99 1.05
M3 -0.33 -1.3 37.23 -0.6 8.75
M4 -19.48 -4.36 1.69 34.31 3.04
MOR -5.01 -4.36 -4.68 -7.79 -5.46
NET
PBR
SERT 4.5 -1.89 -5.01 6.32 0.98
Sigma 1 14.72 -12.59 -5.3 -21.87 -6.26
Sigma 2
Receptor Inhibition 1 Inhibition 2 Inhibition 3 Inhibition 4 Mean %
5-HT1A 22.04 8.89 7.13 5.45 10.88
5-HT1B -12.64 -26.21 -32.99 -14.76 -21.65
5-HT1D 16.1 37 12.93 16.37 20.6
5-HT1E 4.54 9.48 -3.9 6.29 4.1
5-HT2A 9.81 -17.3 -12.73 -0.87 -5.27
5-HT2B 17.85 2.93 -1.91 -3.09 3.95
5-HT2C -7.95 -12.85 -5.04 -12.77 -9.65
5-HT3 -28.1 -39.09 -13.81 3.57 -19.36
5-HT5A 12.49 -1.86 0.62 -13.73 -0.62
5-HT6 -3 -0.7 0.66 12.61 2.39
5-HT7A 11.26 -2.93 19.67 3.67 7.92
Alpha1A -0.61 -27.9 -35.49 -39.73 -25.93
Alpha1B -27.09 -17.08 12.07 31.71 -0.1
Alpha1D -8.64 -0.95 4.66 3.58 -0.34
Alpha2A 15.84 8.15 3.28 8.94 9.05
Alpha2B -1.25 6.47 14.51 34.12 13.46
Alpha2C 9.05 24.22 12.72 -0.79 11.3
Beta1 7.51 3.03 12 19.25 10.45
Beta3 37.39 26.18 22.21 28.59 28.59
BZP Rat Brain 
Site 64.2 39.18 40.13 58.79 50.58
D1 14.76 5.98 11.45 9.86 10.51
D2 7.94 3.73 -3.24 -7.11 0.33
D3 4.91 -1.66 34.89 -0.98 9.29
D4 -0.81 -18.67 -7.37 4.94 -5.48
D5 19.52 6.99 10.99 -1.54 8.99
DAT
DOR 5.97 -7.8 -7.31 -29.26 -9.6
H1
H2
H3 2.34 3.51 -9.55 40.36 9.17
H4 1.9 14.41 34.24 20.44 17.75
KOR 26.63 12.02 12.15 28.65 19.86
M1 -6.81 3.94 24.49 -2.75 4.72
M2 2.5 4.97 5.93 6.01 4.85
M3 26.21 1.1 -13.96 0.67 3.51
M4 -6.42 22.15 24.02 48.92 22.17
MOR -6.65 -4.19 -13.69 -10.9 -8.86
NET
PBR
SERT -10.6 -26.93 -10.89 -7.55 -13.99





Table 2.14. Top hits from the PDSP primary screening binding assay along with Ki 








(–)-CN1 5-HT1D 86.67 >10,000
(–)-2.8 SERT 80.09 1335
(+)-2.8 SERT 77.15 1888
(–)-CN2 D5 76.82
(–)-2.8 5-HT2B 59.83 850
(+)-2.8 5-HT2B 58.33 2542
(–)-2.8 D5 57.25
(–)-2.8 Alpha2C 56.47
(–)-2.8 Sigma 1 52.57 2498
(+)-2.8 DOR 52.26 6896
(+)-CN2








(+)-2.9 Sigma 2 -24.44
(+)-CN2 Alpha1A -25.93
(–)-CN1 Alpha1A -31.12 >10,000
(+)-CN1 Alpha1A -31.82 >10,000
(–)-2.9 Sigma 2 -32.22
(–)-CN1 SERT -32.22
(–)-CN2 Alpha1A -38.37 1739
(–)-2.9





















2.2.4 Cell growth inhibition assays  
 The (+) and (–) enantiomers of several penicillin and cephalosporin analogs were 
screened against methicillin sensitive Staphylococcus aureus (MSSA) in growth inhibition 
assays. A total of 12 compounds were screened and an effort was made to include 
intermediates from the total synthesis that had a variety of C6 functional groups for the 
penicillin series. Each compound was purified to ≥99% er and >99% purity (measured by 
HPLC). As expected the natural (+) enantiomers of penicillin V and cephalosporin V (Entry 
1 and 5) were potent inhibitors of the growth of the bacteria (MIC 0.125 µg/mL and 8 
µg/mL respectively). In addition, the benzyl ester of (+) penicillin V (Entry 7) was active 
(MIC 4 µg/mL), while all other (+) analogs were inactive. All (–) enantiomers were inactive 
in the assay, which is consistent with the limited available data in previous reports71-76, 79, 



















































































































































































































2.2.5 Proteomic experiments for biotinylated (+) and (–) penicillin probes 
 Dargis and Malouin previously showed that biotinylated b-lactams could be used 
to visualize and isolate penicillin-binding proteins in a variety of bacteria.60 The b-lactam 
allows the probe to covalently bind nucleophilic residues on target proteins, while the high 
affinity biotin-streptavidin interaction allows the probe to be visualized by streptavidin 
horseradish peroxidase (HRP) or isolated from mixtures using streptavidin-agarose 
beads. We adapted these assays in order to conduct proteomic profiling of the (+)-2.14 
and (–)-2.14b penicillin–biotin probes. Our goal was to identify cellular binding 
interactions for each probe in bacteria and human cells. We hypothesized that that (+)-
2.14 and (–)-2.14b would show different binding profiles, and in addition, we hoped that 
novel binding interactions would be identified, particularly for the ent-penicillin derived 
probe  (–)-2.14b. In bacteria, we expected (+)-2.14 to bind the penicillin binding proteins 
of the cell wall, while the (–)-2.14b probe was expected to have little, if any, interaction 
with penicillin binding proteins, since ent-penicillin has previously been reported to be 
inactive against bacteria. 
 A western blot assay was developed for visualizing the binding of each probe to 
proteins in cell lysates. Cell lysates were incubated with (+)-2.14 or (–)-2.14b and then 
the lysates were separated by gel electrophoresis and subsequently transferred to a 
nitrocellulose membrane. Proteins that bound the probes were visualized by streptavidin-
HRP using an enhanced chemiluminescence (ECL) kit. The ECL kit includes substrates 
for HRP that produce chemiluminescence upon binding HRP. This assay compliments 
the pull-down assay, since pull-down experiments only reveal protein-probe interactions 




blot allows broader visualization of protein-probe interactions in the total cell lysate. Thus, 
the western blot can allow highly sensitive visualization of protein-probe interactions that 
the pull-down affinity purification fails to enrich. This feature was helpful because the 
western blot could be used as a primary screen to see if the probes visualized any 
proteins from the cell lysate, and then the pull-down assay could be optimized to isolate 






























once with PBS 
pH=7.0 resuspend in phosphate buffered saline pH=7.0
aliquot cell 
suspension
incubate 30 min RT
aliquot sample into 
Laemmli buffer, boil 5 min










gel electrophoresis 4-20% SDS polyacrylamide gel,
then transfer to nitrocellulose membrane,
block membrane with 5% milk,
incubate membrane with streptavidin-HRP,



















 Initial optimization of the western blot assay was performed in E. coli cells using 
(+)-2.14. The first batch of experiments varied the amount of cells that were aliquoted for 
the experiment. In addition, the eluent from a batch of pull-down experiments was 
analyzed to compare with the total lysate labeling experiments, and the order of the pull-
down experiment was varied by either adding the probe before, after, or before and after 
cell lysis. These initial results demonstrated that (+)-2.14 was capable of labeling proteins 
in the E. coli lysate and that the probe could be visualized by western blot. The ideal 
amount of cells to be aliquoted for the experiment was found to be approximately 3 mL of 
cell suspension with OD600 = 0.4. The western blot also visualized a subset of proteins in 
the eluent of the pull-down experiments.  
 
 
Figure 2.14. Initial results for the western blot using probe (+)-2.14 and E. coli cells from 
1 mL, 3 mL, or 10 mL of suspension grown to OD600 = 0.4. The probe was administered 
before lysis, after lysis, or before and after lysis and visualized by streptavidin-HRP. 
Streptavidin beads were used to conduct a pull-down experiment and the eluent was 




 Next, (–)-2.14b was introduced to the E. coli cell lysate labeling experiments and 
analyzed by western blot. For the first time, the binding profiles of the (+)-2.14 and         
(–)-2.14b probe were compared side by side, and showed what was expected; (+)-2.14 
labeled several proteins in the E. coli cell lysate (presumably penicillin binding proteins), 
while (–)-2.14b did not show any noticeable labeling of the lysate. The control lane 
showed that a strong band near the bottom of the membrane was visualized in a non-
specific manner, meaning that it was not dependent on a probe-streptavidin-HRP 
interaction. This band appeared in many of the E. coli experiments and is consistent in 
size with lysozyme, which was used to lyse the cells. Adding the probe to whole cells 
before lysis or after lysis both led to visualization of proteins. A subsequent batch of 
experiments varied the concentration of probe added to the cell lysate by orders of 
magnitude and showed that concentrations of 0.98 µM or less were not sufficient for 
visualizing probe-protein interactions. The 2.11 control was added to the experiments to 






Figure 2.15. Western blot visualized by streptavidin-HRP for experiments comparing D 





Probe concentration (µM): 
















D = (+) D-penicillin–biotin 
L  = (–) L-penicillin–biotin 
N = none 
B = before lysis 





Figure 2.16. Western blot visualized by streptavidin-HRP for experiments varying the 
concentration of D or L probe ((+)-2.14 and (–)-2.14b, respectively). 
 
 After determining a working set of conditions for the assay, the next goal was to 
move into other cell types. Xiaokang Yan provided HEK293T cell lysate for the 
experiments. The human cells were treated with probe in a similar manner to the E. coli 
experiments. The first batch of experiments compared cell labeling of E. coli cells and 
human cells with (+)-2.14 vs (–)-2.14b. Consistent with previous experiments, (+)-2.14 
interacted with proteins in the E. coli cells while (–)-2.14b showed no significant 
interactions in E. coli. In human cells, (+)-2.14 and (–)-2.14 both showed a smear of bands 
at the top of the membrane at high concentrations. Importantly, (–)-2.14b also labeled a 
protein near the bottom of the membrane (highlighted in red in lane 7 and 8). This protein 
showed specific binding to the (–)-2.14b penicillin probe, which suggests that it could be 





Figure 2.17. Western blot visualized by streptavidin-HRP for labeling of E. coli and 
HEK293t cell lysates with D and L probes ((+)-2.14 and (–)-2.14b respectively). 
 
In an effort to validate this result, we conducted a competition experiment to 
determine whether ent-penicillin V, (–)-2.9, would compete with (–)-2.14b and reduce the 
intensity of the bands visualized by the western blot. However, the results of the 
experiments showed little to no competition. The lack of competition could indicate that 
the phenoxyacetyl side chain of (–)-2.9 is not suitable for binding the specific proteins 




could have failed due to experimental errors such as using a concentration of (–)-2.14b 





Figure 2.18. Western blot visualized by streptavidin-HRP for a competition assay 
between the L-penicillin probe (–)-2.14b and ent-penicillin V (–)-2.9. Compound 2.9 was 
pre-administered to the cell lysate before treatment with (–)-2.14b. 
 
 In order to identify the proteins that are binding the penicillin–biotin probes by mass 
spectrometry, the proteins must first be isolated by affinity purification. The high affinity 
biotin-streptavidin interaction is ideal for affinity purification. However, developing an 




more difficult than developing the cell labeling assay. Magnetic streptavidin beads and 
streptavidin-agarose beads were used in attempts to isolate the target proteins. In the 
initial design of the experiment, E. coli cells were incubated with penicillin–biotin probe, 
washed to remove excess unreacted probe, and then lysed. Next, the lysate was 
incubated with streptavidin beads and during that time the proteins that covalently bound 
the penicillin–biotin probe would be expected to form a high affinity complex with the 
streptavidin beads. Several washes would remove the remaining proteins that did not 
bind the streptavidin beads. Finally, the bound proteins would be eluted by boiling the 
beads in Laemmli buffer. The eluent from the beads would then be subjected to 
electrophoresis and then visualized on the gel using a general stain for proteins such as 
Coomassie blue or silver stain. Ideally the stain would reveal that only a subset of proteins 















Scheme 2.12. Overview of the pull-down assay protocol. 
 





wash with PBS 
pH=7.0




incubate 30 min RT
incubate lysate with 
streptavidin beads for 
1 h with rotation
Remove flowthrough, wash 
beads several times to 
remove non-bound proteins
Elute bound proteins:
Add Laemmli buffer 
and boil 10 min
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 The initial experiments using pierce streptavidin magnetic beads showed the 
enrichment of two bands on the gel (Figure 2.19). However, these bands also appeared 
in the lanes of control experiments that omitted (+)-2.14, meaning that they come from 
non-specific interactions with the streptavidin beads. The smallest protein had a mass of 
~15 kDa, which is consistent with lysozyme, while the remaining protein had a mass of 
~30 kDa. Switching to silver stain (Figure 2.20) provided increased sensitivity to reveal 
additional bands on the gel, but again the control experiment showed that the proteins 
that were pulled down could be attributed to non-specific binding. The results also 
appeared to be nearly identical when the experiment included (–)-2.14b. 
 
 
Figure 2.19. Initial results for the pull-down assay using (+)-2.14 as the probe and 





Figure 2.20. Pull-down assay results using D and L probes ((+)-2.14 and (–)-2.14b 
respectively) visualized by silver stain. 
 
 A variety of conditions were tried in an effort to troubleshoot the pull-down assay. 
Seeing exclusively non-specific binding in the pull-down assay could come from the probe 
failing to bind proteins in the cell; however, the successful appearance of bands in the 
whole-lysate western blot assay (Figures 2.14–2.17) suggested that this was not the 
source of error. The probe bound proteins might fail to bind the beads, especially if the 
beads were overwhelmed with non-specific binding proteins. We tried increasing the 
incubation of the lysate with the streptavidin beads overnight, hoping that additional time 
would allow the biotinylated-proteins (probe-bound proteins) to compete for the 
streptavidin active sites. In addition, the order of the experiment was varied to allow the 
probes to bind the streptavidin beads first, followed by incubation of cell lysate with the 
probe-bound beads. Theoretically, occupying the streptavidin sites with the penicillin–




still allow the proteins to be captured by the penicillin hanging off the pre-activated beads. 
Another possible source of error is that the probe-bound proteins could be inadvertently 
washed off the beads during the wash steps, so the wash steps were modified to include 
different buffers, and different numbers of wash steps. The probe bound proteins might 
also fail to elute off the beads during the elution step. To that end, we tried increasing the 
concentration of SDS in the elution buffer, and also tried increasing the time spent boiling 
during the wash step from 3–15 min. Each attempt produced similar results showing only 
non-specific binding when compared to the control experiment that did not include a 
penicillin–biotin probe. 
 To further diagnose the error in the pull-down experiments, a set of pull-down 
experiments was run and visualized by gel staining and then by western blot (Figure 2.21 
and 2.21). Consistent with previous results, the gel stain revealed the same pattern of 
bands in the pull-down experiments with the penicillin–biotin probe as without the probe, 






Figure 2.21. Pull-down assay results using D probe (+)-2.14 and various assay conditions 
visualized by Biorad stain-free gel analysis. The lysates were fractionated by 
centrifugation at either 14,000 x G or 21,000 x G and the resulting supernatants and 
pellets were subjected to the pull-down assay using either pre-bound probe-streptavidin-
beads or treatment with probe followed by streptavidin beads. 
 
 However, when the eluents from the same batch of experiments were analyzed by 
western blot, the western blot visualized additional bands in the pull-down lanes 
compared to control lanes. Since the ECL western blot has increased sensitivity for 
visualizing the penicillin–biotin probe, these results could be interpreted as there being a 
slight enrichment of probe-bound proteins in the pull-down experiment, but still not 
enough enrichment to be observed by staining the gel. The non-specifically bound 




bound proteins. A potential solution to this problem would be to increase the concentration 
of lysate that is incubated with the probe, which would increase the amount of probe-
bound proteins that can compete with the non-specific binding proteins. Ideally, the total 
number of probe-bound proteins in the lysate should be sufficiently high to occupy all of 










 The initial pull-down experiment attempted with HEK293T also failed to enrich for 
probe-bound proteins (Figure 2.23). Ideally, we hoped to enrich the band that appeared 
in the western blot for (–)-2.14b (highlighted in red in Figure 2.17), so that the protein 
target could be isolated and analyzed by mass spectrometry. Instead, one band ~18 kDA 
was prominent in all experiments where the streptavidin beads were used, irrespective of 
whether a penicillin–biotin probe was present. The absence of probe-specific bands could 
indicate that the wash steps were too aggressive and removed the probe-bound proteins 









Figure 2.23. Initial pull-down experiments using HEK293T lysate with D and L probes 
((+)-2.14 and (–)-2.14b respectively) visualized by Biorad stain-free gel analysis. 
 
 
2.3 Conclusions and future directions 
 b-Lactams are such successful antibiotics that the vast majority of b-lactam 
research has been narrowly focused on trying improve the bactericidal activity of the 
compounds. In other words, b-lactams that weren’t effective at killing bacteria tended to 
be abandoned and as a consequence it has remained relatively unknown how these b-




limits of b-lactam research beyond this canonical setting in order to better understand 
how stereochemistry influences the biological activities of b-lactam antibiotics. It is well-
accepted that b-lactam antibiotics mimic D-Ala-D-Ala to bind penicillin binding proteins, 
which implies that ent-b-lactams resemble L-Ala-L-Ala. If the enantiomers mimic L-Ala-L-
Ala then they might be suitable for binding other biological entities that are not typically 
considered to be targets of b-lactams.  
Both enantiomers of penicillin were produced via an asymmetric total synthesis in 
order to assess and compare their biological activities in a variety of settings. Our total 
synthesis route was inspired by previous total syntheses, but included new reactions that 
avoided some of the pitfalls of the existing routes. Notably, for the Staudinger formal [2+2] 
cycloaddition we replaced azidoacetyl chloride with a more benign alternative that gave 
higher yields for the reaction, and by going through an alcohol displacement at C6, we 
obtained full inversion of the stereocenter and avoided the challenge of separating 
mixtures of diastereomers. Overall the synthesis took 9 steps (same step-count as the 
Firestone synthesis) and had slightly better yields than the Firestone synthesis (overall 
2.1% vs 1.3%).  
We collected new biological data for uncommon stereoisomers of penicillin and 
cephalosporin that have not previously been studied aside from being briefly reported to 
lack antibiotic activity. Our compounds also did not show antibiotic activity against MSSA, 
which is consistent with what has been reported for unnatural stereoisomers of penicillin 
and cephalosporin. Our primary objective goal was to investigate activity against non-
classical targets. Both enantiomers of penicillin V failed to produce significant binding to 




penicillin V likely does not have wide-reaching non-specific activity. However, this study 
does not represent all ent-penicillins and ent-cephalosporins, and follow up studies could 
investigate the biological activities of ent-b-lactams with different side chains or other 
structural modifications. As we expanded our investigation to include additional b-lactam 
analogs and other CNS targets in the PDSP, we found evidence that unnatural 
stereoisomers of penicillin and cephalosporin are capable of binding a variety of biological 
targets in vitro. For many targets including 5-HT2B, Alpha1A, benzylpiperazine (BZP) rat 
brain site, SERT, and Sigma 2, both enantiomers of a given b-lactam showed binding 
activity at the receptor. This lack of selectivity is in stark contrast to the classic targets of 
b-lactams, PBPs, which so far have only showed binding activity for the natural 
configuration of penicillin and cephalosporin. These CNS targets still appeared to have 
some preference for binding one enantiomer over the other. For example, the 5-HT2B 
receptor showed more binding to (–)-2.8 (Ki = 0.85 µM) than (+)-2.8 (Ki = 2.5 µM); and 
similarly, SERT showed more binding to (–)-2.8 (Ki = 1.3 µM) than (+)-2.8 (Ki = 1.8 µM). 
These results provide evidence that the stereochemistry of b-lactams can be modified to 
optimize binding to non-classical targets (a strategy that was already successfully used 
to design b-lactam inhibitors of signal peptidase I).110 
These are the first binding interactions identified for the unnatural enantiomers of 
penicillin and cephalosporin and they could provide a starting point for further 
development of b-lactams into inhibitors for the CNS targets. So far, none of the 
compounds performed better than the reference ligands for the receptors, and the lowest 
Ki value was for (–)-2.8 binding to 5-HT2B (Ki = 0.85 µM). However, synthesis strategies 




design semi-synthetic b-lactam antibiotics, so analogs could readily be generated for 
future SAR campaigns. Additional biochemical studies could also determine the mode of 
binding (covalent vs non-covalent) and the site of binding (orthosteric vs allosteric) in 
order to inform the rational design of better inhibitors. 
The western blot and pull down assays provided initial evidence that the various 
stereoisomers of penicillin could be equipped with an affinity tag in order to conduct 
proteomic analysis to compare the binding profiles for each stereoisomer. This strategy 
could provide a more comprehensive view of how stereochemistry influences the binding 
of penicillins or other b-lactams to various enzymes and proteins across different cell 
types. The western blot revealed that the naturally configured penicillin–biotin probe was 
able to bind and visualize several proteins in E. coli cells that the ent-penicillin–biotin 
probe did not. This is consistent with the fact that ent-penicillin shows no antibacterial 
activity while the natural penicillin is potent and known to bind many PBPs. In HEK293T 
cells, the western blot revealed that the ent-penicillin-probe had an additional band that 
was not present for the naturally configured penicillin-probe. The remaining challenge is 
to isolate and verify the identity of the proteins that were visualized by the western blot. 
Overall, these studies provide additional evidence that b-lactams are not solely 
selective for binding PBPs, and instead are capable of binding other non-classical 
biological targets. Furthermore, while previous studies have shown that naturally 
configured b-lactams can engage non-PBP targets, we have shown that the unnatural 
stereoisomers have activity against biological targets too. Thus, as b-lactams are 
repurposed for new applications, researchers should consider evaluating the unnatural 




the stereochemistry could be a useful strategy for enhancing affinity or tuning the 
selectivity for b-lactams as they are designed for new biological applications.  
 
2.4 Experimentals 
General Information  
Reactions were performed under an argon atmosphere in flame-dried glass vials 
or round-bottom flasks sealed with a rubber sleeve type septa and argon balloon. All 
chemicals were used as received from a commercial source without further purification, 
unless otherwise noted. Thin-layer chromatography (TLC) was preformed using 
commercial silica gel 60 F254 coated aluminum-backed sheets. Visualization was 
accomplished with UV light (254 nm), iodine vapor chamber or ninhydrin stain by heating. 
Purification was carried out on an automated flash chromatography/medium-pressure 
liquid chromatography (MPLC) system using normal-phase silica flash columns (4, 12, 
24, 40, or 80 g) or reverse-phase C-18 columns (15.5, 50, 80, 120 g). Enantiomeric 
separations were performed on a Teledyne Isco Combiflash purification system with 
CHIRAL PACK IC preparatory columns (DAICEL Corporation). Enantiomeric ratios were 
determined on an Agilent 1100 Series HPLC with an CHIRAL PACK IC analytical columns 
(DAICEL Corporation). Infrared spectra were acquired as films or neat. All nuclear 
magnetic resonance spectra (1H, 13C, and 19F 
) were recorded on instruments with either a Varian with a dual carbon/proton 
probe (400 MHz or 500 MHz), or a Bruker with a dual carbon/proton with a cryoprobe 
(500, 600, 700, or 850 MHz). NMR samples were recorded in deuterated chloroform 




dimethyl sulfoxide (DMSO-d6). Chemical shifts are reported in parts per million (ppm) and 
are referenced to either TMS or the center line of the solvent (for CDCl3, δ 7.26 ppm for 
1H NMR and 77.2 ppm for 13C NMR; for D2O, δ 4.79 ppm for 1H NMR; for MeOD, δ 4.87 
and 3.31 for 1H NMR and 49.0 ppm for 13C NMR; for DMSO-d6, δ 2.50 ppm for 1H NMR 
and 39.5 ppm for 13C NMR). Coupling constants are given in Hertz (Hz). HRMS data were 
collected with a hybrid linear trap quadrupole Fourier Transform (LTQ FT) and an 
electrospray ion source (ESI). Melting points were determined in open capillary tubes 
using an automated melting point apparatus and are uncorrected. Spectroscopic data for 
the known compounds prepared according to the methodology described in the paper 
match with those reported in the literature unless otherwise noted.  
 Biology experiments were conducted in low-binding 1.5 mL Eppendorf tubes using 
calibrated micropipettes for transfer of reagents. Cell growth was monitored using 
disposable plastic cuvettes and a Thermo Scientific NanoDrop OneC.  Samples were 
centrifuged using a Thermo Scientific Sorvall Legend Micro 21R centrifuge set at 10 °C. 
Samples were heated on an aluminum block using a Fisher Scientific Isotemp 125D or 
heated and shaken on a Multi-Therm Benchmark Scientific Shaker H5000-H. An end to 
end rotator was used for continuous mixing of samples at room temperature or 4 °C. 
Concentrations of proteins in the cell lysate were determined using a Biorad Quick Start 
Bradford 1x Dye reagent with Biorad Bovine Serum Albumin standards. Gel 
electrophoresis was conducted with a Biorad Mini-Protean electrophoresis system using 
premade Biorad 4–20% Mini-Protean stain free gels and SDS-PAGE running buffer 
consisting of 50 mM Tris base, 0.39 M glycine and 0.1% SDS. Biorad precision plus all 




transferred using a Biorad Mini-Protean Tetra Cell Transfer Blot system with Towbin 
buffer consisting of 25 mM Tris-Cl pH 8.3, 192 mM glycine, 20% MeOH, and 0.025% 
SDS. Gels and membranes were imaged using a Biorad GoDoc imager using default 
automatic exposure times for ECL detection and stain free imaging. Gels were stained 
using a Pierce Silver Stain kit, or using 0.5% Coomassie blue R-250 in fixing solution 
consisting of 45% water, 45% ethanol, and 10% glacial acetic acid. The Coomassie stain 
was removed with destain solution consisting of 7% ethanol and 5% glacial acetic acid. 
The western blot was performed with Pierce High Sensitivity Streptavidin Horseradish 
peroxidase and visualized using an Amersham ECL Prime kit. 
 




Benzyl (S)-2-amino-3-mercapto-3-methylbutanoate ((+)-2.1). Following a 
modified procedure,81 a 250 mL flask was flame-dried, filled with argon, and charged with 
penicillamine (10.08 g, 67.54 mmol, 1.0 equiv), polyphosphoric acid (26.15 g, 4.0 equiv), 
and benzyl alcohol (125 mL, 0.48 M). The mixture was stirred at 105 °C for 7 h and then 
cooled to room temperature and added to 0.6 N aqueous HCl (1000 mL). The aqueous 


















combined and extracted with 1N HCl (100 mL). The aqueous layers were combined and 
sodium carbonate was added until pH=9 and then the aqueous layer was extracted with 
CH2Cl2 (3 x 250 mL). The CH2Cl2 layers were combined, dried with magnesium sulfate, 
filtered, and concentrated to give a gray liquid, which was further purified by reversed-
phase chromatography. Following MPLC reverse-phase column chromatography  (100% 
Aqueous 0.1% NH3 to 100% MeCN) (+)-2.1 was isolated in 36% yield (5.794 g, 24.21 
mmol) as a pale yellow liquid; Rƒ  = 0.68 (10% MeOH/DCM); [α]25.4589 -41.9 (c 1.22, CHCl3); 
IR (neat) 1732 cm−1; 1H NMR (400 MHz, CDCl3) δ 7.40–7.30 (m, 5H), 5.16 (s, 2H), 3.43 
(s, 1H), 1.40 (s, 3H), 1.38 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 173.3, 135.5, 128.7, 
128.7, 128.6, 66.9, 64.6, 47.8, 29.6, 28.8. HRMS (ESI-TOF) calcd for C12H18NO2S 




Benzyl (R)-2-amino-3-mercapto-3-methylbutanoate ((–)-2.1). Following an 
identical procedure to (+)-2.1 using L-penicillamine (10.08 g, 67.58 mmol, 1.0 equiv), 
polyphosphoric acid (26.49 g, 4.0 equiv), and benzyl alcohol (125 mL, 0.48 M) gave a 
pale yellow liquid in 39% yield (6.252 g, 26.12 mmol); Rƒ  = 0.68 (10% MeOH/DCM); [α]25.4589  
38.5 (c 1.18, CHCl3); IR (neat) 1727 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.40–7.30 (m, 
5H), 5.16 (s, 2H), 3.43 (s, 1H), 1.40 (s, 3H), 1.38 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 















Benzyl (S)-5,5-dimethyl-4,5-dihydrothiazole-4-carboxylate ((+)-2.2). Following 
a modified procedure,112 a 100 mL flask was flame-dried, filled with argon and charged 
with (+)-2.1 (3.99 g, 16.7 mmol, 1.0 equiv), triethylorthoformate (5.6 mL, 33 mmol, 2.0 
equiv), and DCE (50 mL, 0.3 M). The flask was equipped with a Dean–Stark trap filled 
with 4 Å molecular sieves and a reflux condenser. The reaction was heated to reflux and 
the condensing solvent flowed over the molecular sieves for 1 h. The pale yellow solution 
was concentrated under vacuum to an oil and purified by MPLC (EtOAc/hexanes 0–30%). 
The solvents were evaporated to give a white solid in 95% yield (3.94 g, 15.8 mmol) which 
was recrystallized (Et2O) to afford white needles mp 62–66 °C (lit81 63–63 °C); Rƒ  = 0.38 
(30% EtOAc/hexanes); [α] 25589 +3.76 (c 1.09, CHCl3); IR (film): 1741, 1684 cm
-1. 1H NMR 





















4.63 (d, J = 2.7 Hz, 1H), 1.69 (s, 3H), 1.29 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 169.1, 
159.9, 135.4, 128.8, 128.7, 128.7, 85.2, 67.2, 60.1, 28.7, 25.9. HRMS (ESI-TOF) calcd 




Benzyl (R)-5,5-dimethyl-4,5-dihydrothiazole-4-carboxylate ((–)-2.2). Following 
an identical procedure to (+)-2.2 using ((–)-2.1) (2.13 g, 8.91 mmol, 1.0 equiv), 
triethylorthoformate (3.0 mL, 18 mmol, 2.0 equiv), and DCE (27 mL, 0.3 M) gave a white 
solid in 95% yield (2.11 g, 8.48 mmol), which was recrystallized (Et2O) to afford white 
needles mp 63–66 °C; Rƒ  = 0.45 (30% EtOAc/hexanes); [α] 25589 -4.21 (c 1.04, CHCl3); IR 
(film): 1739, 1682 cm-1. 1H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 2.5 Hz, 1H), 7.42–7.32 
(m, 5H), 5.25 (d, J = 2.5 Hz, 2H), 4.63 (d, J = 2.6 Hz, 1H), 1.69 (s, 3H), 1.29 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 169.1, 159.9, 135.4, 128.8, 128.7, 128.7, 85.2, 67.2, 60.1, 28.7, 
25.9. HRMS (ESI-TOF) calcd for C13H16NO2S [M+H]+: 250.0896, found: 250.0894. This 












2-((4-Methoxybenzyl)oxy)acetic acid. Following a modified protocol,119 a flame-
dried and argon purged 500 mL round-bottom flask was charged with 2-bromoacetic acid 
(13.3 g, 95.8 mmol), (4-methoxyphenyl)methanol (13.8 g, 99.9 mmol), and anhydrous 
THF (180 mL, 0.53 M). The mixture was stirred to give a clear solution and then cooled 
in an ice bath for 10 min. A 60% dispersion of sodium hydride (9.6 g, 240 mmol) was 
added in portions over 5 min. A gas evolved and the gray suspension was stirred and 
heated to reflux. After 1 h, the suspension became too thick to stir, and the reflux was 
allowed to continued unstirred. After 14 h, the solvents were evaporated under reduced 
pressure to give a hard white solid, and then the solid was redissolved and partitioned 
between diethyl ether (80 mL) and water (80 mL). The ether layer was extracted with 
water (2 x 40 mL) and then the combined aqueous extracts were acidified to pH ≈ 4 with 
2 M HCl. The solution became cloudy as the solution became acidic, and then the 
aqueous layer was extracted with DCM (3 x 150 mL). The combined organic layers were 
dried over sodium sulfate, filtered, and then concentrated to an oil. The oil was 
precipitated in cold ether to give an off-white semi-solid (8.58 g, 43.7 mmol, 46%); Rƒ  = 
0.53 (10% MeOH/DCM); IR (film): 1728 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.32–7.25 (m, 
2H), 6.92–6.85 (m, 2H), 4.58 (s, 2H), 4.10 (s, 2H), 3.81 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 174.6, 159.8, 130.0, 128.7, 114.1, 73.2, 66.4, 55.4. HRMS (ESI-TOF) calcd for 





















azabicyclo[3.2.0]heptane-2-carboxylate ((+)-2.3). A 250 mL round-bottom flask was 
equipped with a stir bar and flame-dried. The flask was placed under an Ar balloon. To 
the flask was added 2-((4-methoxybenzyl)oxy)acetic acid (2.89 g, 14.7 mmol) followed by 
DCM (35 mL, 0.23 M) and 5 drops of anhydrous DMF. The resulting clear solution was 
stirred and cooled in an ice bath for 10 min. Then, oxalyl chloride (4.5 mL, 51 mmol) was 
added slowly. A gas evolved and the solution became yellow. The flask was removed 
from the ice bath and equipped with a reflux condenser. The solution was refluxed for 1 
h. Then, the reflux condenser was replaced with a short path distillation apparatus. The 



























oil. The oil was reconstituted in DCM (80 mL) to give a yellow solution, which was cooled 
in a dry ice/acetone bath. Separately, (+)-2.2 (3.36 g, 13.5 mmol) and TEA (2.3 mL, 16.8 
mmol) were each dissolved in DCM (20 mL). The TEA solution (20 mL) was added 
dropwise to the flask while stirring at –78 °C over 10 min. The solution turned orange. 
Then, the (+)-2.2 solution (20 mL) was added to the flask dropwise over 10 min. The 
solution was left stirring for 24 h at -78 °C to room temperature. The solution was 
transferred to a separatory funnel and washed with 5% sodium bicarbonate (50 mL). The 
DCM layer was dried with sodium sulfate, filtered, and then evaporated to a red-brown 
liquid. The crude liquid was purified by MPLC (100% H2O to 100% MeCN), concentrated 
to a yellow liquid, and then repurified by MPLC (EtOAc/Hexanes 0 to 40%) to give a clear 
oil (1.12 g, 2.62 mmol, 19%); Rƒ  = 0.70 (40% EtOAc/hexanes); [α] 25589 +136 (c 1.01, 
CHCl3); IR (neat): 1776, 1743 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.41–7.32 (m, 5H), 7.28 
(d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 5.17 (AB q, ΔνAB = 10.6 Hz, JAB = 12.0 Hz, 
2H), 5.12 (d, J = 1.4 Hz, 1H), 4.72 (d, J = 11.3 Hz, 1H), 4.64 (d, J = 1.4 Hz, 1H), 4.56 (d, 
J = 11.3 Hz, 1H), 3.81 (s, 3H), 1.51 (s, 3H), 1.36 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
169.6, 167.4, 159.9, 134.9, 130.3, 128.8, 128.8, 128.7, 128.5, 114.2, 90.8, 72.9, 69.5, 
69.1, 67.5, 64.2, 55.4, 34.0, 25.7. HRMS (ESI-TOF) calcd for C23H25NNaO5S [M+Na]+: 






azabicyclo[3.2.0]heptane-2-carboxylate ((–)-2.3). Following an identical procedure to 
(+)-2.3 using 2-((4-methoxybenzyl)oxy)acetic acid (2.30 g, 11.7 mmol), oxalyl chloride 
(3.1 mL, 35 mmol), DMF (5 drops) and DCM (45 mL), followed by (–)-2.2 (2.60 g, 10.4 
mmol), TEA (1.8 mL, 13.1 mmol) and DCM (65 mL) gave a clear oil (0.980 g, 2.3 mmol, 
22%); Rƒ  = 0.70 (40% EtOAc/hexanes); [α] 25589 +137 (c 0.98, CHCl3); IR (neat): 1773, 1741 
cm-1. 1H NMR (500 MHz, CDCl3) δ 7.40–7.32 (m, 5H), 7.28 (d, J = 8.7 Hz, 2H), 6.89 (d, J 
= 8.6 Hz, 2H), 5.17 (AB q, ΔνAB = 13.1 Hz, JAB = 12.2 Hz, 2H), 5.12 (d, J = 1.4 Hz, 1H), 
4.72 (d, J = 11.3 Hz, 1H), 4.64 (d, J = 1.4 Hz, 1H), 4.56 (d, J = 11.3 Hz, 1H), 4.49 (s, 1H), 
3.81 (s, 3H), 1.51 (s, 3H), 1.35 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 169.7, 167.4, 159.9, 
134.9, 130.3, 128.8, 128.8, 128.7, 128.5, 114.2, 90.8, 72.9, 69.5, 69.1, 67.5, 64.2, 55.4, 

















azabicyclo[3.2.0]heptane-2-carboxylate ((+)-2.4). To a 50 mL round-bottom flask 
equipped with a stir bar was added (+)-2.3 (450 mg, 1.05 mmol), DCM (10.2 mL, 158 
mmol), and water (0.51 mL, 28 mmol). The contents were stirred to give a clear colorless 
biphasic solution. The flask was chilled in an ice bath for 10 min. Then, DDQ (406 mg, 
1.79 mmol) was added in portions. The mixture turned dark and was stirred for 30 min, 
and then the flask was removed from the ice bath and stirring was continued at room 
temperature for 24 h. The mixture became bright red. The solvents were evaporated and 
then the crude mixture was purified by reverse-phase MPLC (100% H2O to 100% ACN). 
The solvents were evaporated and off-white needles formed (246 mg, 0.800 mmol, 76%), 
which were recrystallized from DCM/pentane to give white needles mp 158–162 °C (lit.83 
mp 162–163); Rƒ  = 0.55 (40% EtOAc/hexanes); [α]25.1589  +202 (c 1.04, MeOH), lit [α]
20
589 +191 






























5H), 5.27 (d, J = 1.4 Hz, 1H), 5.19 (s, 2H), 4.82 (d, J = 1.4 Hz, 1H), 4.50 (s, 1H), 1.53 (s, 
3H), 1.38 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 171.3, 167.7, 163.6, 134.8, 128.9, 128.9, 
128.8, 85.3, 71.2, 69.0, 67.7, 64.3, 33.5, 25.8. HRMS (ESI-TOF) calcd for C15H17NNaO4S 




azabicyclo[3.2.0]heptane-2-carboxylate ((–)-2.4). Following an identical procedure to 
(+)-2.4 using (–)-2.3 (300. mg, 0.702 mmol), DDQ (264 mg, 1.16 mmol), water (0.34 mL, 
19 mmol), and DCM (6.7 mL) gave white needles (180 mg, 0.587 mmol, 84%), mp 164–
166 °C; Rƒ  = 0.55 (40% EtOAc/hexanes); [α]25.1589  -198 (c 1.05, MeOH); IR (neat): 3345, 
1729 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.42–7.32 (m, 5H), 5.27 (d, J = 1.2 Hz, 1H), 5.19 
(s, 2H), 4.82 (d, J = 0.6 Hz, 1H), 4.49 (s, 1H), 1.53 (s, 3H), 1.38 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 171.4, 167.7, 134.8, 128.9, 128.8, 128.8, 85.2, 71.2, 69.0, 67.7, 64.3, 
33.5, 25.8. HRMS (ESI-TOF) calcd for C15H17NNaO4S [M+Na]+: 330.0770, found: 















thia-1-azabicyclo[3.2.0]heptane-2-carboxylate ((+)-2.5). A 25 mL round-bottom flask 
was equipped with a stir bar, flame-dried, and filled with Ar. To the flask was added (+)-
2.4 (176 mg, 0.572 mmol) followed by DCM (9.0 mL, 0.062 M). The mixture was stirred 
until the solids dissolved, and then the flask was cooled in a dry ice/acetone bath. After 
cooling for 10 min, triethylamine (95 µL, 0.69 mmol) was added slowly by syringe. The 
solution turned bright yellow. Then, trifluoromethanesulfonic anhydride (125 µL, 0.743 
mmol) was added dropwise by syringe. The solution turned pale gray. After stirring for 20 
min at -78 °C, the solution was transferred to a small column packed with 3 mL of silica 
gel and filtered through the silica gel by gravity. The filtrate was concentrated to give a 
clear oil (205 mg, 0.571 mmol, 82%); Rƒ  = 0.69 (30% EtOAc/hexanes); [α] 25589 +96 (c 0.86 
CHCl3); IR (film): 1793, 1744 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.42–7.34 (m, 5H), 5.51 
(apparent br d, J = 1.7 Hz, 2H), 5.21 (AB q, ΔνAB = 8.9 Hz, JAB =  12.1 Hz, 2H), 4.58 (s, 





































128.9, 128.9 118.5 (q, J = 320.3 Hz), 89.0, 69.5, 69.1, 67.9, 64.8, 34.2, 25.4. HRMS (ESI-
TOF) calcd for C16H16F3NNaO6S2 [M+Na]+: 462.0263, found: 462.0258. These data are 




thia-1-azabicyclo[3.2.0]heptane-2-carboxylate ((–)-2.5). Following an identical 
procedure to (+)-2.5 using (–)-2.4 (121 mg, 0.392 mmol), triethylamine (65 µL, 0.47 
mmol), trifluoromethanesulfonic anhydride (86 µL, 0.51 mmol), and DCM (6.0 mL, 0.064 
M) gave a clear oil (120 mg, 0.274 mmol, 70%); Rƒ  = 0.68 (30% EtOAc/hexanes); [α] 25589 -
94 (c 0.89, CHCl3); IR (film): 1793, 1744 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.43–7.34 (m, 
5H), 5.51 (app s, 2H), 5.21 (AB q, ΔνAB = 9.5 Hz, JAB = 12.0 Hz, 2H), 4.58 (s, 1H), 1.56 
(s, 3H), 1.40 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.5, 162.3, 134.6, 129.1, 128.9, 
128.9, 118.5 (q, J = 320.1 Hz), 89.0, 69.6, 69.2, 68.0, 64.8, 34.2,  25.4. HRMS (ESI-TOF) 
calcd for C16H16F3NNaO6S2 [M+Na]+: 462.0263, found: 462.0294. This enantiomer has 

















azabicyclo[3.2.0]heptane-2-carboxylate ((+)-2.6). A 2-dram vial was equipped with a 
stir bar, flame-dried, and filled with Ar. To the vial was added (+)-2.5 (186 mg, 0.422 
mmol) dissolved in DMF (3.0 mL, 0.14 M). The stirring solution was cooled in an ice bath 
for ten min, and then 15-crown-5 ether (42 µL, 0.21 mmol) was added followed by sodium 
azide (52.3 mg, 0.804 mmol). The reaction was stirred at 0 °C for 20 min, and then room 
temperature for 2.5 h. The solution turned dark green. The crude mixture was filtered and 
then purified by reverse phase MPLC (100% H2O to 100% MeCN). The fractions were 
concentrated to give a light brown oil (105 mg, 0.315 mmol, 75%); Rƒ  = 0.61 (30% 
EtOAc/hexanes); [α]25.4589  +109 (c 1.28, CHCl3); IR (film): 2111, 1783, 1742 cm
-1. 1H NMR 
(400 MHz, CDCl3) δ 7.42–7.32 (m, 5H), 5.48 (d, J = 4.1 Hz, 1H), 5.19 (AB q, ΔνAB = 0 Hz, 
JAB = 12.4 Hz, 2H), 4.92 (d, J = 4.0 Hz, 1H), 4.51 (s, 1H), 1.65 (s, 3H), 1.42 (s, 3H). 13C 































64.8, 31.9, 26.8. HRMS (ESI-TOF) calcd for C15H16N4NaO3S [M+Na]+: 355.0835, found: 




azabicyclo[3.2.0]heptane-2-carboxylate ((–)-2.6). Following and identical procedure to 
(+)-2.6 using (–)-2.5 (313.2 mg, 0.713 mmol), 15-crown-5 ether (71 µL, 0.356 mmol), 
sodium azide (92.7 mg, 1.43 mmol) and DMF (5.1 mL, 0.14 M) gave a light brown oil 
(122.2 mg, 0.368 mmol, 52%); Rƒ  = 0.61 (30% EtOAc/hexanes); [α]24.9589  -112 (c 1.20, 
CHCl3); IR (film): 2109, 1781, 1741 cm-1. 1H NMR (500 MHz, CDCl3) δ 7.42–7.33 (m, 5H), 
5.48 (d, J = 4.1 Hz, 1H), 5.19 (AB q, ΔνAB = 0 Hz, JAB = 10.3 Hz, 2H), 4.91 (d, J = 4.0 Hz, 
1H), 4.51 (s, 1H), 1.65 (s, 3H), 1.41 (s, 3H).13C NMR (126 MHz, CDCl3) 13C NMR (126 
MHz, CDCl3) δ 170.0, 167.5, 134.8, 128.9, 128.8, 128.8, 70.4, 68.0, 67.7, 66.8, 64.8, 
31.9, 26.7. HRMS (ESI-TOF) calcd for C15H16N4NaO3S [M+Na]+: 355.0835, found: 






























azabicyclo[3.2.0]heptane-2-carboxylate ((+)-2.7). A 2-dram vial was equipped with a 
stir bar. Then, (+)-2.6 (113 mg, 0.340 mmol) was dissolved in THF (2.8 mL, 0.11 M) and 
transferred to the vial followed by triphenylphosphine (98.0 mg, 0.374 mmol) and water 
(0.32 mL, 18 mmol). The reaction was heated to 40 °C and stirred for 2 h. A gas evolved. 
The solution was concentrated to a yellow residue and then purified by MPLC 
(EtOAc/hexanes 70–100%). The fairly polar eluent system allowed the product to be 
separated from the triphenylphosphine biproduct. The solvents were evaporated to give 
the product as a clear oil (86.5 mg, 0.282 mmol, 83%); Rƒ  = 0.39 (75% EtOAc/hexanes); 
[α] 25589 168 (c 1.32, CHCl3); IR (film) 3328, 1778, 1738 cm
−1. 1H NMR (400 MHz, CDCl3) δ 
7.41–7.32 (m, 5H), 5.51 (d, J = 4.3 Hz, 1H), 5.18 (AB q, ΔνAB = 4.4 Hz, JAB = 12.2 Hz, 
2H), 4.56 (d, J = 4.4 Hz, 1H), 4.43 (s, 1H), 1.62 (s, 3H), 1.43 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 177.9, 168.1, 134.9, 128.8, 128.8, 110.1, 70.1, 70.1, 67.5, 64.1, 62.9, 31.9, 27.1. 
HRMS (ESI-TOF) calcd for C15H19N2O3S [M+H]+: 307.1111, found 307.1109. These data 




















(+)-2.7 using (–)-2.6 (95.7 mg, 0.288 mmol), THF (2.4 mL), triphenylphosphine, (85.8 mg, 
0.327 mmol), and water (0.27 mL, 15 mmol) gave (–)-2.6 as a clear oil 82% (72.6 mg, 
0.237 mmol); Rƒ  = 0.39 (75% EtOAc/hexanes); [α] 25589 -164 (c 1.30, CHCl3); IR (film) 1772, 
1661 cm−1. 1H NMR (400 MHz, CDCl3) δ 7.41–7.32 (m, 5H), 5.51 (d, J = 4.3 Hz, 1H), 5.19 
(AB q, ΔνAB = 5.1 Hz, JAB = 12.0 Hz, 2H), 4.56 (bs, 1H), 4.43 (s, 1H), 1.62 (s, 3H), 1.42 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 177.9, 168.1, 134.9, 128.8, 128.8, 110.1, 70.1, 
70.1, 67.5, 64.1, 62.9, 31.9, 27.1. HRMS (ESI-TOF) calcd for C15H19N2O3S [M+H]+: 





azabicyclo[3.2.0]heptane-2-carboxylate ((+)-2.8a).  To a flame-dried 1-dram vial was 
added (+)-2.7 (18.3 mg, 0.0597 mmol) and CH2Cl2 (0.35 mL). The pale yellow solution 
was stirred and cooled in an ice bath for 10 min. Then, a solution of pyridine (5.8 µL, 
0.072 mmol) in CH2Cl2 (50 µL) was added dropwise via syringe. Immediately afterwards, 
a solution of 2-phenylacetyl chloride (9.5 µL, 0.072 mmol) in CH2Cl2 (100 µL) was added 






























2 min. Benzene (2 mL) was added, causing a precipitate to form. The mixture was washed 
with phosphate buffer pH = 2 (1 mL) followed by water (1 mL). The organic layer was 
concentrated to an oily residue and purified by MPLC (EtOAc/hexanes 0–30%). The 
solvents were evaporated to give a white residue in 55% yield (13.9 mg, 0.0327 mmol); 
Rƒ  = 0.76 (75% EtOAc/hexanes); IR (film) 1780, 1742, 1661 cm−1. 1H NMR (400 MHz, 
CDCl3) δ 7.41–7.27 (m, 10H), 6.07 (d, J = 9.1 Hz, 1H), 5.64 (dd, J = 9.1, 4.2 Hz, 1H), 5.50 
(d, J = 4.2 Hz, 1H), 5.17 (s, 2H), 4.40 (s, 1H), 3.63 (s, 2H), 1.40 (s, 3H), 1.36 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 173.4, 170.3, 167.4, 134.6, 133.8, 129.6, 129.1, 128.8, 128.7, 





azabicyclo[3.2.0]heptane-2-carboxylate ((–)-2.8a).  Following an identical procedure to 
(+)-2.8a using (–)-2.7 (13.1 mg, 0.0428 mmol), CH2Cl2 (0.35 mL), pyridine (4.1 µL, 0.051 
mmol), and 2-phenylacetyl chloride (6.8 µL, 0.051 mmol) gave a white residue in 62% 
yield (11.2 mg, 0.0264 mmol); Rƒ  = 0.76 (75% EtOAc/hexanes); IR (film) 1781, 1743, 
1661 cm−1. 1H NMR (400 MHz, CDCl3) δ 7.41–7.26 (m, 10H), 6.08 (d, J = 9.0 Hz, 1H), 
5.63 (dd, J = 9.1, 4.2 Hz, 1H), 5.49 (d, J = 4.2 Hz, 1H), 5.17 (s, 2H), 4.40 (s, 1H), 3.63 (s, 
2H), 1.40 (s, 3H), 1.35 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 173.5, 170.5, 167.5, 134.8, 












26.8. HRMS (ESI-TOF) calcd for C23H25N2O4S [M+H]+: 425.1530, found 425.1560. This 





azabicyclo[3.2.0]heptane-2-carboxylate ((+)-2.8b). Following an identical procedure to 
(+)-2.8a using (+)-2.7 (52.3 mg, 0.171 mmol), phenoxyacetyl chloride (28.3 µL, 0.205 
mmol), pyridine (16.5 µL, 0.205 mmol), and DCM (1.0 mL, 0.16 M) gave a clear oil (63.5 
mg, 0.0844 mmol, 84%); Rƒ  = 0.71 (75% EtOAc/hexanes); [α]25.0589 +111 (c 0.90, CHCl3); 
IR (film) 3369, 2966, 1782, 1743, 1691 cm−1. 1H NMR (500 MHz, CDCl3) δ 7.41–7.29 (m, 
8H), 7.04 (d, J = 7.4 Hz, 1H), 6.92 (d, J = 8.8 Hz, 2H), 5.74 (dd, J = 9.2, 4.3 Hz, 1H), 5.58 
(d, J = 4.3 Hz, 1H), 5.20 (AB q, ΔνAB = 0 Hz, JAB = 13.1 Hz, 2H), 4.55 (AB q, ΔνAB = 16.7 
Hz, JAB = 15.2 Hz, 2H), 4.49 (s, 1H), 1.57 (s, 3), 1.42 (s, 3H). 13C NMR (126 MHz, CDCl3) 































67.7, 67.3, 65.0, 58.2, 32.1, 26.9. HRMS (ESI-TOF) calcd for C23H25N2O4S [M+H]+: 




azabicyclo[3.2.0]heptane-2-carboxylate ((–)-2.8b). Following an identical procedure to 
(+)-2.8a using (–)-2.7 (40.1 mg, 0.131 mmol), phenoxyacetyl chloride (21.7 µL, 0.157 
mmol), pyridine (12.7 µL, 0.157 mmol), and CH2Cl2 (0.80 mL, 0.16 M) gave a clear oil 
(44.4 mg, 0.101 mmol, 77%); Rƒ  = 0.71 (75% EtOAc/hexanes); [α]25.0589 -110. (c 0.87 
CHCl3); IR (film) 3369, 2966, 1782, 1742, 1690 cm−1. 1H NMR (400 MHz, CDCl3) δ 7.43–
7.27 (m, 8H), 7.03 (t, J = 7.2 Hz, 1H), 6.92 (d, J = 7.8, 2H), 5.73 (dd, J = 9.2, 4.2 Hz, 1H), 
5.58 (d, J = 4.2 Hz, 1H), 5.19 (AB q, ΔνAB = 0 Hz, JAB = 12.6 Hz, 2H), 4.55 (AB q, ΔνAB = 
11.3 Hz, JAB = 15.1 Hz, 2H), 4.49 (s, 1H), 1.57 (s, 3H), 1.41 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 173.1, 167.9, 167.5, 157.1, 134.8, 129.9, 128.9, 128.9, 128.8, 122.5, 114.9, 
70.5, 67.9, 67.7, 67.3, 65.0, 58.2, 32.1, 26.9. HRMS (ESI-TOF) calcd for C23H25N2O4S 

















azabicyclo[3.2.0]heptane-2-carboxylate ((+)-2.9). A 2 mL conical microwave vial was 
equipped with a stir bar and sealed with a rubber cork. The vessel was flushed with 
nitrogen and then 10% palladium on carbon (19 mg, 0.018 mmol) was added followed by 
a 1:1 solution of THF/water (3.6 mL). The mixture was stirred and sparged with a 
hydrogen balloon for 2 min. Then, (+)-2.8b (20 mg, 0.045 mmol) was dissolved in THF 
(0.2 mL) and added dropwise to the stirring solution. A 5.0% solution of sodium 
bicarbonate was prepared and used to add 1 equiv of sodium bicarbonate (75 µl) to the 
reaction. The reaction was stirred at room temperature for 20 min while hydrogen was 
continuously bubbled through the mixture. Additional THF was added in increments of 0.1 
mL to replace the evaporated solvent. After 20 min the reaction mixture was sparged with 
nitrogen for 2 min and then filtered through a syringe filter and then a plug of Celite. The 
filtrate was concentrated under vacuum to remove the THF, frozen, and then lyophilized 
to give a white powder gave a white powder (10.1 mg, 0.0271 mmol, 60%); [α]25.0589  +227 

































δ 7.41 (t, J = 7.9 Hz, 2H), 7.11 (t, J = 7.3 Hz, 1H), 7.04 (d, J = 8.6 Hz, 2H), 5.58 (d, J = 
4.0 Hz, 1H), 5.54 (d, J = 4.0 Hz, 1H), 4.77 (AB q, ΔνAB = 8.5 Hz, JAB = 12.7 Hz, 2H), 4.24 
(s, 1H), 1.53 (s, 3H), 1.50 (s, 3H).13C NMR (126 MHz, D2O) δ 175.0, 174.8, 172.0, 157.5, 
130.5, 122.9, 115.3, 73.6, 67.0, 66.9, 64.9, 58.1, 31.1, 26.8. HRMS (ESI-TOF) calcd for 




azabicyclo[3.2.0]heptane-2-carboxylate ((–)-2.9). Following an identical procedure to 
(+)-2.9 using 10% palladium on carbon (19 mg, 0.018 mmol), 1:1 THF/water (3.6 mL), 
and (–)-2.8b (20 mg, 0.045 mmol) gave a white powder (11.2 mg, 0.0301 mmol, 66%); 
[α]25.0589  -225 (c 0.153, water); IR (film) 3354, 2968, 1764, 1676, 1598 cm
−1. 1H NMR (500 
MHz, D2O) δ 7.41 (t, J = 8.0 Hz, 2H), 7.11 (t, J = 7.4 Hz, 1H), 7.04 (d, J = 8.5 Hz, 2H), 
5.58 (d, J = 4.0 Hz, 1H), 5.54 (d, J = 3.9 Hz, 1H), 4.77 (AB q, ΔνAB = 8.5 Hz, JAB = 12.7 
Hz, 2H), 4.25 (s, 1H), 1.53 (s, 3H), 1.50 (s, 3H).13C NMR (126 MHz, D2O) δ 174.9, 174.8, 
172.0, 157.5, 130.5, 122.9, 115.3, 73.6, 67.0, 66.9, 64.9, 58.1, 31.1, 26.8. HRMS (ESI-
















d]imidazol-4-yl)pentanoate (2.10). To a flame-dried round-bottom flask was added D-
biotin (3.00 g, 12.3 mmol), NHS (1.44 g, 12.5 mmol), and DMF (80. mL, 0.15M). The flask 
was swirled and heated with a heat gun until the solids went into solution. Then, DCC 
(3.30 g, 16.0 mmol) was added in portions and the reaction was stirred at room 
temperature overnight. A precipitate formed and was removed by filtration. The filtrate 
was evaporated to a white solid. The solid was redissolved in DMSO and purified by 
MPLC (0–100% ACN/H2O). Fractions containing 2.10 were evaporated to give a white 
powder (2.13 g, 12.3 mmol, 51%) mp 180–190 °C; Rƒ  = 0.31 (10% MeOH/DCM); [α]25.3589 
+54.6 (c 1.07, MeOH); IR (film) 1818, 1788, 1745, 1727, 1697 cm−1. 1H NMR (500 MHz, 
DMSO-d6) δ 6.42 (t, J = 1.8 Hz, 1H), 6.36 (s, 1H), 4.31 (dd, J = 7.7, 5.1 Hz, 1H), 4.17–
4.12 (m, 1H), 3.13–3.07 (m, 1H), 2.85–2.82 (m, 1H), 2.81 (s, 3H), 2.70–2.63 (m, 2H), 
2.61–2.54 (m, 1H), 1.70–1.34 (m, 6H). 13C NMR (126 MHz, DMSO-d6) δ 170.3, 169.0, 
162.7, 61.0, 59.2, 55.3, 30.0, 27.8, 27.6, 25.5, 24.3. Previous report reports an additional 
peak under DMSO peak.127 HRMS (ESI-TOF) calcd for C14H20N3O5S [M+H]+: 342.1118, 
found 342.1115. The IR, NMR, and HRMS data are consistent with a previous report, 





























yl)pentanamido)hexanoic acid (2.11). To a round-bottom flask was added 2.10 (1.03 g, 
3.02 mmol) and DMF (20. mL). The mixture was swirled and heated with a heat gun until 
the solids dissolved to give a clear solution. Separately, 6-aminohexanoic acid was 
dissolved in 0.1 M NaHCO3 (20.8 mL) and then added to the flask. The solution was 
stirred at room temperature and the pH was monitored by pH paper. The pH was 
increased to pH = 8 by adding NaHCO3. The reaction was stirred at room temperature 
overnight. Initially, a precipitate formed but it went back into solution after 2 h. After 18 h, 
the solution was acidified to pH = 3 with 6N HCl and a white precipitate formed. The 
precipitate was collected by filtration and washed with cold 0.5 N HCl, followed by ether. 
After drying, a white chalky solid remained (921 mg, 2.58 mmol, 85%) mp 222-224 °C, 
lit128 221-222 °C; [α]25.2589  +47.5 (c 0.51, 1 N NaOH), lit [α]D +23.8 (c 0.5, 1N NaOH);
128 IR 
(film) 1702, 1632, 1540 cm−1. 1H NMR (500 MHz, DMSO-d6) δ 12.01 (s, 1H), 7.74 (t, J = 
5.6 Hz, 1H), 6.44 (s, 1H), 6.37 (s, 1H), 4.35–4.27 (m, 1H), 4.12 (dd, J = 7.8, 4.4 Hz, 1H), 
3.13–3.05 (m, 1H), 3.05–2.94 (m, 2H), 2.81 (dd, J = 12.3, 5.1 Hz, 1H), 2.57 (d, J = 12.3 
Hz, 1H), 2.18 (t, J = 7.1 Hz, 2H), 2.03 (t, J = 7.3 Hz, 2H), 1.68–1.18 (m, 12H). 13C NMR 






























28.1, 26.0, 25.4, 24.3. (One carbon signal was not observed. This is consistent with a 
previous report).129 HRMS (ESI-TOF) calcd for C16H28N3O4S [M+H]+: 358.1795, found 
358.1792. The NMR and HRMS data are consistent with a previous report129, the 




d]imidazol-4-yl)pentanamido)hexanoate (2.12). To a flame-dried round-bottom flask 
was added 2.11 (500. mg, 1.40 mmol), NHS (193 mg, 1.68 mmol), EDC (326 mg, 1.70 
mmol), and DMF (12. mL, 0.12 M). The mixture was stirred at 50 °C overnight. After 18 
h, additional NHS (95. mg, 0.83 mmol) and EDC (160 mg, 0.84 mmol) was added to the 
reaction and the reaction was stirred for 8 h at 50 °C. The solution was evaporated to give 
a white solid. The solid was reconstituted in DMSO and purified by MPLC (ACN/H2O 0%–
100%) to give a white powder (371 mg, 0.816 mmol, 58%) mp 160–166 °C; Rƒ  = 0.28 
(10% MeOH/DCM); [α]25.4589  +46.2 (c 0.56, 10% MeOH/DCM); IR (film) 1823, 1787, 1729, 
1682, 1648, 1621 cm−1. 1H NMR (500 MHz, DMSO-d6) δ 7.74 (t, J = 5.7 Hz, 1H), 6.41 (s, 
1H), 6.35 (s, 1H), 4.30 (dd, J = 7.7, 5.0 Hz, 1H), 4.15–4.10 (m, 1H), 3.12–3.06 (m, 1H), 
3.01 (apparent q, J = 6.5 Hz, 2H), 2.83 (d, J = 5.3 Hz, 1H), 2.81 (s, 4H), 2.65 (t, J = 7.3 




































(126 MHz, DMSO) δ 171.9, 170.3, 169.0, 162.7, 61.1, 59.2, 55.5, 38.1, 35.2, 30.2, 28.7, 
28.3, 28.1, 25.5, 25.3, 24.0. (Two carbon signals were not observed. This is consistent 
with a previous report).130 HRMS (ESI-TOF) calcd for C20H31N4O6S [M+H]+: 455.1959, 
found 455.1958. The NMR and HRMS data are consistent with a previous report130, the 






azabicyclo[3.2.0]heptane-2-carboxylate ((+)-2.13). To a flame-dried vial was added 
(+)-2.7 (37.0 mg, 0.120 mmol) followed by DMF (0.80 mL, 0.15 M). The mixture was 
stirred and resulted in a pale yellow solution. Then, 2.12 (93.3 mg, 0.205 mmol) was 

















































a reverse-phase column and separated (0%–100% ACN/H2O). Fractions containing (+)-
2.13 were evaporated to give a white solid (28.0 mg, 0.0434 mmol, 36%); Rƒ  = 0.32 (10% 
MeOH/DCM); [α]25.2589 +124 (c 0.29, CDCl3); IR (film) 1779, 1744, 1701, 1640 cm
−1. 1H NMR 
(500 MHz, CDCl3) δ 7.42–7.34 (m, 5H), 7.12 (d, J = 8.6 Hz, 1H), 6.59 (s, 1H), 6.50 (t, J = 
5.7 Hz, 1H), 5.79 (s, 1H), 5.68 (dd, J = 8.6, 4.1 Hz, 1H), 5.54 (d, J = 4.2 Hz, 1H), 5.20 (s, 
2H), 4.53–4.49 (m, 1H), 4.44 (s, 1H), 4.34–4.30 (m, 1H), 3.25–3.19 (m, 2H), 3.17–3.12 
(m, 1H), 2.91 (dd, J = 12.9, 4.8 Hz, 1H), 2.73 (d, J = 12.8 Hz, 1H), 2.27 (t, J = 7.4 Hz, 2H), 
2.23–2.18 (m, 2H), 1.78–1.28 (m, 12H), 1.63 (s, 3H), 1.41 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 174.6, 173.4, 173.2, 167.7, 164.2, 134.7, 128.9, 128.9, 128.9, 70.5, 68.2, 67.7, 
65.0, 61.8, 60.2, 58.7, 55.8, 40.8, 39.2, 35.8, (additional peak likely buried under 35.8), 
31.6, 29.0, 28.0, 27.9, 27.1, 26.4, 25.6, 25.0. HRMS (ESI-TOF) calcd for C31H44N5O6S2 























azabicyclo[3.2.0]heptane-2-carboxylate ((–)-2.13b). Following an identical procedure 
to (+)-2.13 using (–)-2.7 (37.0 mg, 0.120 mmol), 2.12 (141 mg, 0.311 mmol), and DMF 
(0.80 mL, 0.15 M) gave (–)-2.13b as a white solid (37.0 mg, 0.57 mmol, 47%); Rƒ  = 0.32 
(10% MeOH/DCM); [α]25.2589  -92.1 (c 0.29, CDCl3); IR (film) 1778, 1744, 1700, 1646, 1535 
cm−1. 1H NMR (500 MHz, CDCl3) δ 7.42–7.33 (m, 5H), 7.24 (d, J = 8.4 Hz, 1H), 6.47 (s, 
1H), 6.41 (t, J = 5.6 Hz, 1H), 5.83 (s, 1H), 5.69 (dd, J = 8.7, 4.2 Hz, 1H), 5.54 (d, J = 4.2 
Hz, 1H), 5.20 (s, 2H), 4.53–4.48 (m, 1H), 4.45 (s, 1H), 4.34–4.29 (m, 1H), 3.30–3.24 (m, 
1H), 3.21–3.11 (m, 1H), 2.90 (dd, J = 12.9, 4.8 Hz, 1H), 2.73 (d, J = 12.7 Hz, 1H), 2.33–
2.18 (m, 4H), 1.79–1.28 (m, 12H), 1.63 (s, 3H), 1.41 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 174.7, 173.3, 173.2, 167.7, 164.1, 134.8, 128.9, 128.9, 128.8, 70.6, 68.3, 67.7, 65.0, 
62.0, 60.2, 58.8, 55.9, 40.9, 39.3, 35.9, 35.8, 31.7, 29.1, 28.0, 28.0, 27.2, 26.5, 25.6, 25.1. 






































azabicyclo[3.2.0]heptane-2-carboxylate ((+)-2.14). Following an identical procedure to 
(+)-2.9 using (+)-2.13 (24.0 mg, 0.0372 mmol), 10% palladium on carbon (19.7 mg, 
0.0186 mmol), NaHCO3 (56.9 mg, 0.0353 mmol), and 1:1 THF/water (1.8 mL, 0.022 M) 
gave (+)-2.14 as a white powder (11.1 mg, 0.0200 mmol, 54%); [α]25.2589  +166 (c 0.23, H2O); 
IR (neat) 1763, 1689, 1640, 1603, 1541 cm−1. 1H NMR (500 MHz, D2O) δ 5.56 (d, J = 3.9 
Hz, 1H), 5.46 (d, J = 3.9 Hz, 1H), 4.62 (dd, J = 8.0, 4.9 Hz, 1H), 4.43 (dd, J = 8.0, 4.5 Hz, 
1H), 4.24 (s, 1H), 3.37–3.31 (m, 1H), 3.24–3.16 (m, 2H), 3.01 (dd, J = 13.0, 5.0 Hz, 1H), 
2.80 (d, J = 13.1 Hz, 1H), 2.43–2.30 (m, 2H), 2.26 (t, J = 7.2 Hz, 2H), 1.78–1.30 (m, 12H), 
1.65 (s, 3H), 1.53 (s, 3H). 13C NMR (126 MHz, D2O) δ 177.0, 176.6, 174.8, 174.5, 73.2, 
66.6, 64.4, 62.1, 60.2, 57.8, 55.4, 39.7, 39.1, 37.6, 35.5, 35.0, 30.1, 27.9, 27.8, 27.6, 26.5, 
25.5, 25.2, 24.9. HRMS (ESI-TOF) calcd for C24H38N5O6S2 [M+H]+: 556.2258, found 






















azabicyclo[3.2.0]heptane-2-carboxylate ((–)-2.14b). Following an identical procedure 
to (+)-2.9 using (–)-2.13b (16.0 mg, 0.0247 mmol), 10% palladium on carbon (10.5 mg, 
0.00910 mmol), NaHCO3 (40.7 mg, 0.0247 mmol), and 1:1 THF/water (2.0 mL, 0.011 M) 
gave (–)-2.14b as a white powder (10.2 mg, 0.0184 mmol, 74%); [α]25.2589  -109 (c 0.25, 
H2O); IR (neat) 1763, 1691, 1636, 1541 cm−1. 1H NMR (500 MHz, Deuterium Oxide) δ 
5.55 (d, J = 3.9 Hz, 1H), 5.45 (d, J = 3.9 Hz, 1H), 4.63–4.59 (m, 1H), 4.42 (dd, J = 7.9, 
4.5 Hz, 1H), 3.36–3.31 (m, 1H), 3.23–3.14 (m, 2H), 3.00 (dd, J = 13.1, 5.0 Hz, 1H), 2.79 
(d, J = 13.0 Hz, 1H), 2.38–2.30 (m, 2H), 2.25 (t, J = 7.1 Hz, 2H), 1.77–1.27 (m, 12H), 
1.64 (s, 3H), 1.52 (s, 3H). 13C NMR (126 MHz, D2O) δ 177.0, 176.6, 174.8, 174.5, 
165.3, 73.2, 66.6, 64.4, 62.1, 60.2, 57.8, 55.4, 39.7, 39.1, 35.5, 35.0, 30.1, 27.9, 27.8, 
27.6, 26.5, 25.5, 25.1, 24.9. HRMS (ESI-TOF) calcd for C24H38N5O6S2 [M+H]+: 




















2.4.2 Antibacterial activity testing 
To determine the antibacterial activity of the compounds, minimum inhibitory 
concentration (MIC) assays were performed using the broth microdilution method as 
previously reported.131 Briefly, ca. 5 x 105 colony forming units (CFU) of Staphylococcus 
aureus strain HG003 in Mueller-Hinton broth (MHB) were incubated with various 
concentrations of each compound for 24 h at 37 °C. After 24 h, the MIC of each 
compound was determined by identifying the first well in which no visible bacterial 
growth was observed. 
 
2.4.3 E. coli cell lysate labeling western blot assay 
 E. coli BL21(D3) was grown in 2xTY rich media (100 mL) until OD600 = 0.4. The 
cells were pelleted by centrifugation (5000 rpm for 5 min) and washed with PBS pH = 7.0. 
The cells were resuspended in PBS pH = 7.0 (100 mL) and then aliquoted (3 mL) into 
Eppendorf tubes. The cells were re-pelleted (7000 rpm for 3 min) and then resuspended 
in PBS pH = 7.0 (200 µL). Either (+)-2.14 or (–)-2.14b was added to the tube and the 
tubes were shaken at 600 rpm for 1 h. Then, the cells were re-pelleted (7000 rpm for 3 
min) and supernatant was poured off. Lysis buffer 1: 200 µg of lysozyme per ml, 50 mM 
Tris-HCI (pH = 7.5), was added to the tube (30 µL) and the cells were resuspended by 
pipetting up and down. The tube was heated to 50 °C and shaken at 600 rpm for 5 min. 
Then, Lysis buffer 2: 110 mM Tris-HCI (pH 8.9), 1.5 mM MgCl2, 80 mM KCl, 500 µg of 
bovine serum albumin (BSA) per mL, 0.1% sodium cholate, 0.1% Triton X-100, 0.45% 
Tween 20, and 0.45% Nonidet P-40, was added (15 µL) and the mixture was heated to 




was combined with 2X Laemmli buffer (15 µL): 4% SDS, 10% beta-mercaptoethanol, 20% 
glycerol, 0.125 M Tris pH 6.8, and 0.005% of bromophenol blue. The sample was boiled 
for 3 min and then allowed to cool to room temperature. An aliquot (15 µL) of the cooled 
sample was loaded onto a Biorad 4–20% precast gel and electrophoresis was conducted 
at 200V until the loading dye reached the end of the gel (25–30 min). Then, the gel was 
transferred to a nitrocellulose membrane (350 mA for 1 h). The membrane was rinsed 
with TBST, and then blocked with 5% milk in TBST for 1 h with gentle rocking. Next, the 
membrane was rinsed with TBST twice and then incubated with streptavidin-HRP (1:2000 
dilution in 3% BSA) for 40 min. Afterwards, the membrane was rinsed with TBST (6 x 5 
min) followed by TBS (3 x 5 min). The membrane was then incubated with ECL detection 
substrates for 20 seconds before imaging. 
 
2.4.4 Streptavidin pull-down experiments 
E. coli cells were treated and lysed as above and then the lysate was diluted with 
TBST to 500 µL. Streptavidin beads (30 µL of packed beads) were washed 3 x 500 µL 
and then the lysate was incubated with the beads for 2 h at room temperature or overnight 
at 4 °C. The flow-through was removed from the beads and then the beads were washed 
with TBST (3 x 500 µL). The beads were combined with 2X Laemmli buffer (30 µL): 4% 
SDS, 10% beta-mercaeptoethanol, 20% glycerol, 0.125 M Tris pH 6.8, and 0.005% of 
bromophenol blue, and then boiled for 5 min. After cooling to room temperature, the eluent 
was loaded onto a Biorad 4–20% precast gel and electrophoresis was conducted at 200 
V until the loading dye reached the end of the gel (25–30 min). The gel was visualized by 




2.4.5 HEK293t western blot and pull-down experiments 
HEK293 cells were cultured at 37° C with 5% CO2. high-glucose DMEM 
(Corning,10-013-CV) media were supplement with 10% FBS serum (Atlanta biological, 
S10250), 10 mM HEPES (Corning, 25-060-C1), NEAA (Gibco 1140-050), and 55 µM 2-
mercaptoethanol (Gibco, 21,985,023). Media was switched each day in order to ensure 
no contamination. HEK293 cells (ca. 10 million)  were lysed with 1 mL of M-PER 
mammalian protein extraction reagent (Thermo Scientific, 78501) supplemented with 
Benzonase (Milipore Sigma, E1014) protease inhibitor. The lysate was centrifuged 
(14,000 rpm for 30 seconds) and then the supernatant was used according t othe 

















CHAPTER 3. SYNTHESIS AND ANTIBACTERIAL EVALUATION OF 
BENZAZETIDINES DESIGNED TO BE CEPHALOSPORIN ISOSTERES 
 
3.1 Introduction  
 Previously mentioned in the introduction chapter (Section 1.4), cephalosporins like 
3.1 with nontraditional C2 substituents including esters and oxadiazoles, are able to inhibit 
the growth of Mtb under non-replicating conditions and so far, the target and mechanism 
of action remains unknown.24, 25 Normally the acylating potential of the b-lactam is 
essential for antibiotic activity because it allows the cephalosporin to covalently inhibit 
PBPs that are essential for cell wall formation (Section 1.2). Thus, previously reported 
isosteres of cephalosporins were inherently designed with electrophilic functional groups 
in order to mimic the ability of b-lactams to react with nucleophiles (Figure 3.1b).132-135 For 
example, penicillin analogs that replace the b-lactam with a cyclobutanone have been 
used to study penicillin biosynthesis and the cyclobutanone has been shown to react with 
key serine residues in b-lactamases to form a hemi-ketal enzyme-inhibitor complex, 
providing broad-spectrum inhibition of b-lactamases.135, 136 However, if the 
cephalosporins are targeting a non-classical enzyme in Mtb (something other than PBPs), 
then perhaps a new non-covalent mechanism could rely on the shape and electrostatic 
surface of the cephalosporin rather than the acylating activity. Here, we attempted to 
design non-reactive isosteres that mimic the shape of cephalosporins but lack the 





Figure 3.1. (a) Cephalosporin 3.1 was identified to be selectively active against Mtb under 
non-replicating conditions, (b) previous examples of b-lactam isosteres,133, 135 (c) and the 
elements of cephalosporins that were incorporated into our benzazetidine library in order 
to obtain maximum overlap. 
 
The benzazetidine scaffold was chosen to replace the cepham core since it 
contains a [4.2.0] bicyclic skeleton with a strained, 4-member, nitrogen-containing ring 
that resembles the shape of cephams. While 2-azetidinones and azetidines are 







































































nature and much less studied than the 2-azetidinone. Simple monocyclic azetidines have 
been constructed through a variety of strategies that often involve the cyclization of linear 
amines by nucleophilic displacement, diazo insertion, palladium catalyzed cyclization, or 
alternatively through reduction of azetidinones.137 Benzazetidines, in which the azetidine 
is appended to an aryl group, have historically had limited options for their synthesis 
(Figure 3.2).138, 139 One strategy to make benzazetidines relies on the use of thermolysis, 
pyrolysis, or photolysis to induce a ring contraction through the loss of nitrogen, sulfur 
dioxide, carbon monoxide, or other groups from the appropriate precursor.140-142 Others 
have found limited success in using strong base to access the benzazetidine from an 
intramolecular SN2 reaction at the nitrogen of a benzyl alkoxyamine, where the incoming 
nucleophile is an aryl lithium generated ortho to the alkoxyamine and the leaving group 
is methoxide.143 Similarly, the [2+2] cycloaddition of benzyne with diaryl azomethines 
provided a small set of benzazetidines with aryl groups bound to the nitrogen and 
neighboring methylene carbon.144 Styrene derivatives with ortho amide substituents have 
also been converted into benzazetidines by activating the benzylic olefin with molecular 
iodine or dimethyl(methylthio)sulfonium triflate.145, 146 For each strategy, the scope was 
limited by either the harsh conditions or the highly specialized substrates that are needed 
for the transformation. With limited synthetic routes available, the benzazetidine scaffold 
has remained underexplored and its potential for development into biologically active 






Figure 3.2. Examples of synthetic methods for producing benzazetidines. 
 
Fortunately, the synthesis of benzazetidines was made much more feasible by 
recent chemistry discovered by Chen and coworkers.147 The method allows for the 
transformation of a benzylamine to a benzazetidine with the C–N bond being formed 
through a palladium-catalyzed C–H amination. Key components to the reaction are the 
use of a picolinic acid directing group that is appended to the benzylamine and a 
phenyliodonium dimethylmalonate (PhI(DMM)) oxidant, which provides a bidentate 
dimethylmalonate ligand to the activate the palladium complex. Together, these ligands 
force the reactive palladium complex into a transition state that kinetically favors the C–
















































Figure 3.3. Proposed mechanism of the palladium catalyzed C–H amination reaction for 
the synthesis of benzazetidines.147 
 
This methodology was chosen for the synthesis of our library because it allows 
diversification at positions on the benzazetidine that translate onto the C2 carboxylic acid 
and the C7 amide side chain of the cephalosporins. Our collaborator, Dr. Tigran 
Abramyan used the OPLS3 force field148 to identify the lowest energy conformations of 
our proposed compounds and then superimposed the lowest energy structure onto 3.1 
(Figure 3.5). The superimposed structures showed that the benzazetidine ortho position 
overlapped with the C2 position on the cephalosporin (Figure 3.1c, highlighted in red). 




























































replacing it with a phenoxyacetyl side chain (Figure 3.1c, highlighted in blue).  The 
azetidine overlapped with the b-lactam; and in terms of reactivity, it has been shown that 
benzazetidines can react with nucleophiles either directly or via isomerization to an aza-
ortho-xyxylene (Figure 3.4),149 however this reactivity has not been explored under 
biological conditions. Thus, we designed and synthesized a library of benzazetidines 
decorated with a variety of common b-lactam side chains and various “C2” functional 
groups and examined their activity against Mtb and ESKAPE pathogens (see Section 1.3 
for more on the ESKAPE pathogens). 
 
 















3.2 Results and discussion 
3.2.1 Synthesis of benzazetidines  
A focused library of 35 compounds including 22 benzazetidines, 3 indole or 
indolines, and 10 flexible N-benzyl amide analogs was designed for maximum overlap 
with cephalosporins. Each proposed compound was modeled in its lowest energy 
conformation using OPLS3 force field148 and then superimposed over a model 
cephalosporin 3.1, which was previously24 found to have activity against Mtb under non-
replicating assay conditions (Figure 3.5).  The alignment indicated that the C2 carboxylic 
acid and side chain of the cephalosporin would translate onto readily functionalizable 
positions on the benzazetidine, specifically at the benzazetidine ortho position and amino 
position (Figure 3.1c, highlighted in red and blue respectively). Overall our strategy was 
to explore a range of functional groups at the ortho position by starting from different 
benzylamine precursors. Then, we removed the picolinic acid directing group and 





Figure 3.5. Low-energy conformations of proposed compounds (magenta) overlaid onto 
cephalosporin 3.1 (green). 
 
 
In order to transform the benzylamine precursors into benzazetidines, we used an 
intramolecular C–H amination reaction that first required the installation of a picolinamide 
directing group. Benzylamines were purchased or synthesized from the nitrile by catalytic 
hydrogenation. Picolinic acid was coupled to benzylamines using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and hydroxybenzotriazole (HOBt) to give 
picolinamides 3.3a–3.3h. The polymeric PhI(DMM) oxidant was prepared according to 
He, et al.147 and reacted with palladium acetate and the picolinamides to form the desired 
benzazetidines 3.4a–3.4h. The yield for the reaction varied based on the ortho substituent 




failed. Fortunately, the ortho methyl ester benzazetidine gave the highest-yielding 
reaction and 3.4a was used as a common intermediate for the cephalosporin-like series 
(3.9a–3.9e and 3.11a–3.11e). A carboxylic acid at the ortho position for compounds 3.5 
and 3.6 was obtained by saponifying the methyl ester. 
 
Scheme 3.1. Transformation of benzylamines 3.2a–3.2h into benzazetidines 3.4a–3.4h. 
 
 
Table 3.1. Yields for picolinamides 3.3a–3.3h and benzazetidines 3.4a–3.4h 
entry series R1 R2 3.3 3.4 
1 a H CO2Me 34 72[a] 
2 b H CO2-n-Pr 79 65 
3 c Me CO2Me 55 30 
4 d H OMe 94 21 
5 e H Cl 41 19 
6 f H Br 49 38 
7 g H F 86 7 





























Scheme 3.2. Saponification of 3.3a and 3.4a. 
 
 
Next, a series of cephalosporin isosteres 3.8a–3.8c were prepared by hydrolyzing 
the picolinic amide bond and then reacylating the benzazetidine with cephalosporin side 
chains (Scheme 3.3). Compounds 3.4d, 3.4f, and 3.4h were readily hydrolyzed with 
sodium hydroxide. The low molecular weight benzazetidine fragments were noticeably 
volatile when the solvents were attempted to be removed, so it was helpful to form the 









































For the series of carboxylic acids 3.9a–3.9e, 3.4a was reacted with excess sodium 
hydroxide to give the mixture of benzazetidine and the picolinate fragments (Scheme 3.4). 
Since both the benzazetidine and picolinate can exist as a zwitterion, extraction under 
acidic or basic conditions resulted in both fragments being ionized and pulled into the 
aqueous layer. Similarly, attempts to separate the benzazetidine from the picolinate by 
reversed phase chromatography resulted in the fragments coeluting. Instead, we 
employed a strategy that would selectively acylate the most nucleophilic amine in the 











3.4d, R = OMe
3.4f, R = Br
3.4h, R = CF3
3.7a, R = OMe, 74%
3.7b, R = Br, 77%









3.8a, R1 = OMe, 47%
3.8b, R1 = Br, 21%





bicarbonate solvent system conveniently removed one of the ionizable groups from the 
benzazetidine. Thus, acidifying to pH = 2 allowed us to extract the carboxylic acids 3.9a–
3.9e using EtOAc, while the picolinate stayed in the aqueous layer.  
 











































37% 66% 62% 74% 65%







We envisioned intermediate 3.10 to be an ideal intermediate for generating a 
series of benzazetidines that mimic the C2 ester on cephalosporins active against Mtb.24 
However, obtaining 3.10 presented a challenge in that esters are more rapidly hydrolyzed 
than amides. As expected, when 3.4a was reacted with one equivalent of sodium 
hydroxide, none of 3.10 was detected and instead only ester hydrolyzed products were 
detected. In order to increase the reactivity of the amide, we attempted to react 3.4a with 
triethyloxonium tetrafluoroborate (Meerwein’s salt). Meerwein’s salts are known to react 
preferentially with amides over esters, so we were hoping to chemoselectively generate 
an imidate, which would be more susceptible to hydrolysis than the ester. Alkylation was 
detected by LCMS, but unfortunately the amide was still not hydrolyzed when subjected 
to basic conditions. Next, we turned our attention to the ability of the picolinamide to act 
as a bidentate ligand, which we hoped would allow us to selectively activate the amide 

























After screening a variety of sodium, magnesium, and zinc salts, we found that 
ZnCl2 enhanced the formation of the desired intermediate 3.10 under basic aqueous 
conditions. We also switched the base and solvent to NaOMe in methanol to reduce the 
potential for unwanted transesterification. Together, these conditions allowed us to 
produce 3.10 in good yield, which was coupled to a set of five acid chlorides to give the 
series of cephalosporin isosteres that mimic the C2 ester on the cephalosporins active 
against Mtb. 
Indole and indoline derivatives were also incorporated into the library to explore a 
ring-expanded scaffold, which would have less strain and be slightly more flexible than 
the benzazetidines. The indole 3.13 was purchased and reduced with triethylsilane to 
give the indoline 3.15. Both the indole and indoline were acylated with a phenoxyacetyl 
chloride to afford 3.14 and 3.16 respectively, each containing an amide that resembles a 






















Scheme 3.5. Synthesis of unconstrained and [4.3.0] analogs. 
 
 
3.2.2 Biological screening against Mtb and ESKAPE pathogens. 
 The benazetidines and related analogs were screened for antibiotic activity against 
Mtb and ESKAPE pathogens using growth inhibition assays. For Mtb, two assays were 
used. In the first assay, cultures of the mycobacteria grew unhindered under normal 
conditions that allow the mycobacteria to replicate.150 The other assay challenged the 













































replicating state.151 Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter 
cloacae were each cultured in rich media and then plated with fresh media in  the 
presence of each compound and incubated for 6 h. Compounds were considered to be a 
hit if they resulted in >90% growth inhibition compared to a DMSO control. These 
compounds did not show activity against Mtb or the ESKAPE pathogens. 
3.3 Conclusions and Future Directions 
 A palladium-catalyzed C–H amination reaction was used to design a library of 
benzazetidines that mimic the three-dimensional shape of cephalosporin antibiotics. The 
compounds did not show antibiotic activity in the assays against Mtb or the ESKAPE 
pathogens. Nonetheless, the benzazetidine scaffold is underexplored in biological 
settings and these data do not rule out the possibility for the heterocycle to engage other 
biological systems. Further biochemical studies could examine whether or not 
benzazetidines can react with biological nucleophiles such as proteinogenic serines or 
cysteines under physiological conditions, either directly or via isomerization to an aza-
ortho-xyxylene. Having the ability to react with nucleophilic species could be 
advantageous to the development of future benzazetidine based drugs. We were able to 
rapidly functionalize the benzazetidine core at the amine and ortho position, which 








Reactions were performed under an argon atmosphere in flame-dried glass 20 mL 
microwave sealed vials or round bottom flasks sealed with a rubber sleeve type septa 
and argon balloon. All chemicals were used as received from a commercial source 
without further purification, unless otherwise noted. Thin-layer chromatography (TLC) 
was preformed using commercial silica gel 60 F254 coated aluminum-backed sheets. 
Visualization was accomplished with UV light (254 nm) and iodine vapor chamber or p-
anisaldehyde stain by heating. Purification was carried out on an automated flash 
chromatography/medium-pressure liquid chromatography (MPLC) system using normal-
phase silica flash columns (4, 12, 24 or 40 g) or reverse-phase C-18 columns (15, 50, 
150 g). Infrared spectra were acquired as films or solids. All nuclear magnetic resonance 
spectra (1H, 13C, and 19F) were recorded on either a 400 MHz or 500 MHz with a dual 
carbon/proton probe or 600 MHz with a dual carbon/proton cryoprobe instrument. NMR 
samples were recorded in deuterated chloroform (CDCl3), deuterated deuterium (D2O), 
deuterated methanol (MeOD), or deuterated dimethyl sulfoxide (DMSO-d6). Chemical 
shifts are reported in parts per million (ppm) and are referenced to the center line of the 
solvent (for CDCl3, δ 7.26 ppm for 1H NMR and 77.2 ppm for 13C NMR; for D2O, δ 4.79 
ppm for 1H NMR; for MeOD, δ 4.87 and 3.31 for 1H NMR and 49.0 ppm for 13C NMR; for 
DMSO-d6, δ 2.50 ppm for 1H NMR and 39.5 ppm for 13C NMR). Coupling constants are 
given in Hertz (Hz). HRMS data were collected with time-of-flight mass spectrometer 
(TOF) or with a hybrid linear trap quadrupole Fourier Transform (LTQ FT) and an 




using an automated melting point apparatus and are uncorrected. Spectroscopic data for 
the known compounds prepared according to the methodology described in the paper 
match with those reported in the literature. 
 
 
3.4.1 General procedure (A) for the synthesis of picolinamides 
In a flame-dried and argon-purged round-bottom flask was added picolinic acid 
(1.0 equiv) followed by anhydrous DCM (0.1 M picolinic acid). The mixture was cooled 
using an ice bath. To the solution was then added EDCI (1.2 equiv), hydroxybenzotriazole 
hydrate (HOBt) (1.2 equiv), and then DIPEA (1.2 equiv). The solution was stirred for 10 
min and then the benzylamine (1.0 equiv) was added slowly. After stirring for an additional 
10 min, the mixture was warmed to rt and stirred overnight at rt. Throughout, the reaction 
was monitored by TLC (30:70 EtOAc/hexanes and UPLC) for product formation. After 
completion, the mixture was transferred to separatory funnel and the organic layer was 
washed with water (2 x 50 mL) and brine (1 x 50 mL). The organic layers were combined, 
dried over Na2SO4 and concentrated to give a crude product that was purified by normal-

















3.4.2 General procedure (B) for the palladium-catalyzed intramolecular C–H 
amination  
A known method was used.147 To a 20 mL flame-dried microwave vial fitted with a 
septum and purged with Ar was added in order picolinamide (1.0 equiv), chlorobenzene 
(0.05 M picolinamide), Pd(OAc)2 (0.10 equiv), and PhI(DMM) oligomer (2.0 equiv). The 
reaction mixture was purged with argon for 30 min. The vial was and heated to 110 °C 
overnight and monitored by TLC (30:70 EtOAc/hexanes and UPLC) for product formation. 
After starting material was consumed, the mixture was cooled to rt, concentrated, and the 
crude mixture purified by normal-phase MPLC (EtOAc/hexanes). 
 
3.4.3 General procedure (C) for benzazetidine amide hydrolysis147  
Benzazetidines 3.4d, 3.4f, or 3.4h (1 equiv) and a 2 N aq solution of NaOH (2.0 
equiv) were reacted in 1:1:3 H2O/MeOH/THF (0.2 M benzazetidine) at rt for 5 h. The 
reaction mixture was then purified by reverse-phase MPLC (100% H2O to 100% MeCN). 




























desired product to a pH = 2 (indicated by universal pH paper) using 2 N aq HCl, and then 
removing the solvents by rotary evaporation. 
 
 
3.4.4 General procedure (D) for acylation toward amides 3.8a–3.8c 
In a 25 mL flask, 3.7a–3.7c were combined with NaH (2 equiv) in anhydrous DMF 
(0.5 M 3.7a–3.7c) at 0 °C and allowed to warm to rt. After stirring for 18 h, 2-phenoxyacetyl 
chloride (3.0 equiv) was added dropwise to the solution. The solution was stirred for an 
additional 2 h and then concentrated to an oil, which was purified by reverse-phase MPLC 



















3.4.5 General procedure (E) for amide hydrolysis and acylation toward amido 
carboxylic acids 3.9a–3.9e 
Using a modification of general procedure C, 3.4a (1.0 equiv) and a 2 N aq solution 
of NaOH (3.7 equiv) were reacted in a solution of 1:1:3 H2O/MeOH/THF (0.1 M 3.4a) at 
rt for 18 h. The resulting orange coloured solution was concentrated to afford a crude 
solid, which was used without characterization or purification. 
To a round-bottom flask was added the above solid followed by water (3.5 mL/100 
mg crude solid) and sodium bicarbonate (110 mg NaHCO3/100 mg crude solid), and to it 
was slowly added a solution of acid chloride (0.65 mmol/100 mg crude solid) in acetone 
(0.17 mL/100 mg crude solid). Upon addition of the acid chloride, gas evolved and a 
precipitate formed. The mixture was stirred for 2 h. After the starting material was 
consumed (UPLC), the mixture was washed with EtOAc (3 x 12 mL). The aqueous layer 
was acidified to pH = 2 with 2N HCl, at which time a precipitate formed. The reaction 
mixture was extracted with EtOAc (3 x 12 mL). The EtOAc layers were combined and 
dried over Na2SO4, filtered, and concentrated to provide a crude solid, which crude 
















3.4.6 Synthesis and characterization of compounds 
 
Preparation of PhI(DMM). Prepared following a literature procedure, but here 
characterized in CDCl3 instead of methanol as previously reported.147 In a 250-mL flame-
dried three-neck round bottom flask purged with argon was added dimethyl malonate (2.0 
g, 15.5 mmol, 1.0 equiv), PhI(OAc)2 (5.0 g, 15.5 mmol, 1.0 equiv), and then CHCl3 (63 
mL). The reaction flask was fitted with a thermometer inlet adapter, the mixture was 
heated to 45 °C and maintained at this temperature for 10 min. After 10 min, the CHCl3 
was removed by rotary evaporation and to the crude colorless oil was then added fresh 
CHCl3 (63 mL). The above process was repeated four more times yielding 6.59 g of a 
white amorphous powder that was used without further purification. 1H NMR (600 MHz, 
CDCl3) d 8.09 (d, J = 7.8 Hz, 1H), 8.06 (d, J = 7.9 Hz, 1H), 8.02–7.96 (m, 3H), 7.93 (t, J 
= 7.9 Hz, 1H), 7.89–7.84 (m, 2H), 7.84–7.81 (m, 2H), 7.80–7.76 (m, 2H), 7.63–7.53 (m, 
5H), 7.54–7.38 (m, 15H), 2.10 (s, 7H), 2.06–2.00 (m, 8H), 1.42–1.35 (m, 13H), 1.32–1.22 
(m, 28H). 13C NMR (151 MHz, CDCl3) d 177.8, 176.6, 174.9, 135.1, 134.9, 134.7, 134.2, 
























Propyl 2-cyanobenzoate.152 In a 100-mL flame-dried round bottom flask 2-
cyanobenzoic acid (1.03 g, 6.98 mmol, 1.0 equiv) and anhydrous DMF (33.0 mL) were 
combined under Ar. While stirring, K2CO3 (1.16 g, 8.38 mmol, 1.2 equiv) was added in 
one portion and the reaction mixture was cooled using an ice bath. After 15 min, 1-
iodopropane (0.82 mL, 8.38 mmol, 1.2 equiv) was added dropwise. The reaction was 
allowed to warm to rt and stirred overnight. After starting material was consumed (TLC 
(30:70 EtOAc/hexanes)) the reaction mixture was filtered through Celite, washed with 
EtOAc (150 mL), and concentrated to give a crude pale yellow solid. The solid was 
dissolved in EtOAc (50 mL), washed with water (2 x 50 mL), brine (1 x 50 mL), dried over 
Na2SO4, filtered, and evaporated to give crude product as a pale yellow oil. Following 
MPLC chromatography (100% hexanes to 50:50 EtOAc/hexanes) propyl 2-
cyanobenzoate was isolated in 91% yield (1.21 g, 6.98 mmol) as a colorless oil; Rƒ = 0.64 
(10% EtOAc/hexanes); IR (film) 2227, 1713 cm−1; 1H NMR (400 MHz, CDCl3) d 8.18–
8.10 (m, 1H), 7.83–7.78 (m, 1H), 7.71–7.61 (m, 2H), 4.37 (t, J = 6.7 Hz, 2H), 1.85 (q, J = 
7.1 Hz, 2H), 1.06 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) d 164.3, 134.9, 132.67, 
132.6, 131.3, 123.3, 117.7, 113.0, 68.0, 22.0, 10.7. HRMS (LTQ FT) calcd for C11H12NO2 













Propyl 2-(aminomethyl)benzoate hydrochloride salt (3.2b). In a 100-mL flame-
dried round bottom flask 10% Pd/C (1.60 g, 1.48 mmol, 0.40 equiv) was added followed 
by anhydrous toluene (10 mL) under Ar. The slurry was stirred and then anhydrous MeOH 
(23 mL) was added followed by propyl 2-cyanobenzoate (700 mg, 3.70 mmol, 1.0 equiv) 
as a solution in 2 mL of anhydrous MeOH. The walls of the flask were rinsed with 
anhydrous MeOH (5 mL) and 4 M HCl in dioxane (2.0 mL, 6.5 mmol, 1.75 equiv) was 
added. The reaction flask was flushed with H2 using a balloon and stirred overnight at rt. 
After the starting material was consumed (UPLC), the flask was flushed with Ar to remove 
all H2 gas. The reaction mixture was carefully filtered through Celite using a fritted glass 
funnel (medium pore) and washed with MeOH. The filtrate was concentrated to give crude 
product as an HCl salt (used without purification) in 98% yield (840 mg, 3.70 mmol) as an 
pale yellow fluffy powder; IR (neat) 2965, 1702 cm−1; 1H NMR (400 MHz, DMSO-d6) d 
8.37 (s, 3H), 8.04–7.99 (m, 1H), 7.73–7.67 (m, 1H), 7.65–7.52 (m, 2H), 4.32 (s, 1H), 4.25 
(t, J = 6.6 Hz, 2H), 1.76 (q, J = 7.0 Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, 
DMSO-d6) d 166.0, 134.9, 132.8, 131.6, 130.6, 129.3, 129.1, 66.6, 40.9, 21.5, 10.4. 















Methyl 2-(aminomethyl)-6-methylbenzoate (3.2c). In a 100-mL flame-dried 
round-bottom flask 10% Pd/C (1.5 g, 1.4 mmol, 0.4 equiv) was added followed by 
anhydrous toluene (9.2 mL) under Ar. The slurry was stirred and then anhydrous MeOH 
(19 mL) was added followed by methyl 2-cyano-6-methylbenzoate (600 mg, 3.42 mmol, 
1.0 equiv) as a solid powder in one portion. The walls of the flask were rinsed with 
anhydrous MeOH (2 mL) and 4 M HCl in dioxane (1.0 mL, 6.0 mmol, 1.75 equiv) was 
added. The reaction flask was flushed with H2 using a balloon and stirred overnight at rt. 
After the starting material was consumed (UPLC), the flask was flushed with Ar to remove 
H2 gas. The reaction mixture was carefully filtered through Celite using a fritted glass 
funnel (medium pore) and washed with MeOH. The filtrate was concentrated to give crude 
product as an HCl salt (used without purification) in 52% yield (391 mg, 3.42 mmol) as a 
yellow fluffy powder; Rƒ = 0.50 (20% EtOAc/hexanes); An analytical sample was purified 
by MPLC reversed phase column chromatography (100% H2O to 100% MeCN): IR (film) 
2957, 1723 cm−1; 1H NMR (600 MHz, DMSO-d6) d 8.52 (s, 3H), 7.53–7.43 (m, 2H), 7.34 
(d, J = 7.2 Hz, 1H), 3.96 (s, 2H), 3.90 (s, 3H), 2.32 (s, 3H). 13C NMR (151 MHz, DMSO-
d6) d 168.4, 135.8, 132.6, 131.7, 130.6, 130.2, 126.9, 52.4, 19.8. HRMS (LTQ FT) calcd 
















Methyl 2-(picolinamidomethyl)benzoate (3.3a).147 From 3.2a using general 
procedure A with 2.0 equiv DIPEA: 34% yield (190 mg, 2.04 mmol). White crystalline 
solid, mp 91–93 °C; Rƒ = 0.85 (20% EtOAc/hexanes); IR (neat) 3416, 1717 cm−1. 1H NMR 
(600 MHz, CDCl3) d 8.93 (s, 1H), 8.56 (d, J = 7.6 Hz, 1H), 8.19 (d, J = 7.8 Hz, 1H), 7.98 
(dd, J = 7.8, 1.4 Hz, 1H), 7.81 (t, J = 7.7 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.50 (t, J = 7.5 
Hz, 1H), 7.42–7.31 (m, 2H), 4.90 (d, J = 6.7 Hz, 2H), 3.97 (s, 3H). 13C NMR (151 MHz, 
CDCl3) d 168.0, 164.3, 150.3, 148.4, 140.0, 137.3, 133.0, 131.4, 131.1, 129.2, 127.8, 
126.1, 122.4, 52.5, 42.5. HRMS (ESI-TOF) calcd for C15H15N2O3 [M+H]+ : 271.1077, 
found 271.1058. These data are consistent with those previously reported.147 Purity 




Propyl 2-(picolinamidomethyl)benzoate (3.3b). From 3.2b using general 
procedure A with 2.0 equiv of DIPEA: 79% yield (420 mg, 1.77 mmol). Colorless oil; Rƒ = 
0.60 (30% EtOAc/hexanes); IR (neat) 3397, 1671 cm−1. 1H NMR (400 MHz, CDCl3) d 8.93 
(s, 1H), 8.57–8.52 (m, 1H), 8.18 (dt, J = 7.8, 1.0 Hz, 1H), 7.99 (dd, J = 7.8, 1.4 Hz, 1H), 
7.85–7.75 (m, 1H), 7.64–7.58 (m, 1H), 7.49 (td, J = 7.5, 1.5 Hz, 1H), 7.41–7.31 (m, 2H), 




















3H). 13C NMR (151 MHz, CDCl3) d 167.6, 164.3, 150.3, 148.3, 139.9, 137.3, 132.8, 131.4, 
131.0, 129.7, 127.7, 126.1, 122.4, 67.0, 42.5, 22.2, 10.7. HRMS (ESI-TOF) calcd for 
C17H19N2O3 [M+H]+: 299.1390, found 299.1402. Purity (UPLC): 98%. 
 
 
Methyl 2-methyl-6-(picolinamidomethyl)benzoate (3.3c). From 3.2c using 
general procedure A with 2.0 equiv of DIPEA: 55% yield (147 mg, 0.927 mmol). Pale 
yellow sticky oil; Rƒ = 0.76 (30% EtOAc/hexanes); IR (neat) 1721 cm−1. 1H NMR (600 
MHz, CDCl3) d 8.60–8.42 (m, 2H), 8.25–8.13 (m, 1H), 7.83 (t, J = 1.7 Hz, 1H), 7.43–7.37 
(m, 1H), 7.35–7.27 (m, 2H), 7.17–7.13 (m, 1H), 4.64 (d, J = 6.2 Hz, 2H), 3.93 (s, 3H), 2.36 
(s, 3H). 13C NMR (151 MHz, CDCl3) d 170.1, 164.0, 150.0, 148.3, 137.4, 136.3, 136.2, 
133.0, 130.3, 130.0, 127.4, 126.2, 122.4, 52.4, 42.1, 20.2. HRMS (ESI-TOF) calcd for 
C16H17N2O3 [M+H]+: 285.1234, found 285.1217. Purity (UPLC): >99%. 
 
 
N-(2-Methoxybenzyl)picolinamide (3.3d).153 From 3.2d using general procedure 
A: 94% yield (500 mg, 2.19 mmol). White crystalline solid, mp 96–98 °C; Rƒ = 0.74 (30% 
EtOAc/hexanes); IR (neat) 1660 cm−1. 1H NMR (600 MHz, CDCl3) d 8.55–8.51 (m, 1H), 
8.45 (s, 1H), 8.21 (dd, J = 7.8, 1.1 Hz, 1H), 7.83 (td, J = 7.7, 1.7 Hz, 1H), 7.43–7.37 (m, 




















6.2 Hz, 2H), 3.89 (s, 3H). 13C NMR (151 MHz, CDCl3) d 164.2, 157.8, 150.3, 148.2, 137.4, 
129.7, 128.9, 126.4, 126.1, 122.4, 120.8, 110.5, 55.5, 39.2. HRMS (ESI-TOF) calcd for 
C14H15N2O2 [M+H]+: 243.1128, found 243.1133. These data are consistent with those 
previously reported.153 Purity (UPLC): >99%. 
 
 
N-(2-Chlorobenzyl)picolinamide (3.3e).154 From 3.2e using general procedure 
A: 41% yield (356 mg, 1.40 mmol). Yellow solid, mp 67–72 °C; Rƒ = 0.32 (30% 
EtOAc/hexanes); IR (neat) 3282, 1668 cm-1. 1H NMR (600 MHz, CDCl3) d 8.55 (d, J = 4.4 
Hz, 1H), 8.49 (s, 1H), 8.22 (d, J = 7.8 Hz, 1H), 7.85 (td, J = 7.7, 1.5 Hz, 1H), 7.48–7.44 
(m, 1H), 7.43 (ddd, J = 7.3, 4.7, 0.9 Hz, 1H), 7.40–7.35 (m, 1H), 7.26–7.21 (m, 2H), 4.77 
(d, J = 6.3 Hz, 2H). 13C NMR (151 MHz, CDCl3) d 164.3, 149.7, 148.2, 137.4, 135.7, 
133.7, 130.0, 129.6, 128.9, 127.1, 126.3, 122.4, 41.4. HRMS (ESI-TOF) calcd for 
C13H12ClN2O [M+H]+: 247.0639, found 247.0642. Purity (UPLC): >99%. These data are 
consistent with those previously reported.154 
 
 
N-(2-Bromobenzyl)picolinamide (3.3f).155 From 3.2f using general procedure A: 
49% yield (328 mg, 1.13 mmol). White solid, mp 91–95 °C; Rƒ = 0.22 (20% 




















Hz, 1H), 8.52 (s, 1H), 8.22 (d, J = 7.8 Hz, 1H), 7.85 (td, J = 7.7, 1.6 Hz, 1H), 7.57 (d, J = 
7.9 Hz, 1H), 7.46 (dd, J = 7.7, 1.1 Hz, 1H), 7.43 (ddd, J = 7.4, 4.8, 1.0 Hz, 1H), 7.29 (t, J 
= 7.5 Hz, 1H), 7.15 (td, J = 7.8, 1.4 Hz, 1H), 4.75 (d, J = 6.3 Hz, 2H). 13C NMR (151 MHz, 
CDCl3) d 164.3, 149.7, 148.2, 137.4, 137.3, 132.8, 130.1, 129.1, 127.7, 126.3, 123.8, 
122.4, 43.8. HRMS (ESI-TOF) calcd for C13H12BrN2O [M+H]+: 291.0134, found 291.0140. 
Purity (UPLC): >99%. These data are consistent with those previously reported.155 
 
 
N-(2-Fluorobenzyl)picolinamide (3.3g).156 From 3.2g using general procedure 
A: 86% yield (478 mg, 2.40 mmol). White crystalline solid, mp 76–78 °C (lit.156 73–74 °C); 
Rƒ = 0.68 (30% EtOAc/hexanes); IR (neat) 1662 cm−1. 1H NMR (400 MHz, CDCl3) d 8.56–
8.52 (m, 1H), 8.40 (s, 1H), 8.25–8.19 (m, 1H), 7.85 (td, J = 7.7, 1.7, Hz, 1H), 7.47–7.37 
(m, 2H), 7.30–7.23 (m, 1H), 7.16–7.00 (m, 2H), 4.73 (d, J = 6.2 Hz, 2H). 13C NMR (151 
MHz, CDCl3) d 164.5, 162.0 (d, J = 246.0 Hz), 149.9, 148.3, 137.5, 130.3 (d, J = 4.3 Hz), 
129.4 (d, J = 4.3 Hz), 126.4, 125.4 (d, J = 15.2 Hz), 124.4 (d, J = 4.3 Hz), 122.5, 115.6 
(d, J = 21.4 Hz), 37.5. HRMS (ESI-TOF) calcd for C13H12FN2O [M+H]+: 231.0938, found 
















N-(2-Trifluoromethylbenzyl)picolinamide (3.3h).153 From 3.2h using general 
procedure A: 69% yield (555 mg, 2.00 mmol). White powder; Rƒ = 0.17 (20% 
EtOAc/hexanes); IR (neat) 3291, 1659 cm-1. 1H NMR (400 MHz, CDCl3) d 8.55 (ddd, J = 
4.7, 1.6, 0.8 Hz, 1H), 8.44 (s, 1H), 8.23 (dt, J = 7.8, 1.1 Hz, 1H), 7.86 (td, J = 7.7, 1.7 Hz, 
1H), 7.67 (d, J = 7.9 Hz, 1H), 7.64 (d, J = 7.7 Hz, 1H), 7.52 (t, J = 7.4 Hz, 1H), 7.43 (ddd, 
J = 7.6, 4.8, 1.2 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 4.86 (d, J = 6.4 Hz, 2H). 13C NMR (151 
MHz, CDCl3) d 164.5, 149.8, 148.3, 137.5, 136.8, 132.5, 130.6, 128.4 (q, J = 30.3 Hz), 
127.7, 126.5, 126.1 (q, J = 5.6 Hz), 124.6 (q, J = 272.6 Hz), 122.5, 40.1. HRMS (ESI-
TOF) calcd for C14H12F3N2O [M+H]+: 281.0903, found 281.0879. Purity (UPLC): >99%. 
These data are consistent with those previously reported.153 
 
 
Methyl 7-benzoyl-7-azabicyclo[4.2.0]octa-1,3,5-triene-2-carboxylate (3.4a).147 
From 3.3a using general procedure B: 39% yield (133 mg, 0.50 mmol). White solid; Rf = 
0.24 (30% EtOAc/hexanes); IR (film) 1717, 1652 cm−1. 1H NMR (600 MHz, CDCl3 , ratio 
of rotamers: 5.4:1) major rotamer: δ 8.67 (d, J = 4.1 Hz, 1H), 8.25 (d, J = 7.8 Hz, 1H), 
7.87 (td, J = 7.7, 1.6 Hz, 1H), 7.65 (d, J = 8.2 Hz, 1H), 7.58 (d, J = 7.5 Hz, 1H), 7.45 (ddd, 




















(diagnostic peaks only): δ 8.79 (d, J = 4.3 Hz, 1H), 8.19 (d, J = 7.8 Hz, 1H), 7.91 (td, J = 
7.8, 1.4 Hz, 1H), 7.56 – 7.50 (m, 2H), 7.32 (t, J = 8.0 Hz, 1H), 5.32 (s, 1H). 13C NMR (151 
MHz, CDCl3) major rotamer: δ 165.4, 161.5, 151.1, 149.6, 148.5, 137.0, 134.9, 129.0, 
126.1, 124.4, 124.1, 115.5, 66.5, 52.2; minor rotamer: δ 163.9, 150.7, 150.2, 148.4, 137.3, 
132.5, 128.8, 126.5, 124.5, 117.5, 59.1. HRMS (ESI-TOF) calcd for C15H13N2O3 [ M+H]+: 





(3.4b). From 3.3b using general procedure B: 65% yield (131 mg, 0.442 mmol). Off-white 
powder; Rƒ  = 0.47 (30% EtOAc/hexanes); IR (neat) 1639, 1339 cm−1. 1H NMR (400 MHz, 
CDCl3, ratio of rotamers 4.3:1) major rotamer: δ 8.71–8.64 (m, 1H), 8.24 (d, J = 7.8, 1.1 
Hz, 1H), 7.87 (td, J = 7.7, 1.8 Hz, 1H), 7.66 (d, J = 7.7 Hz, 1H), 7.58 (d, J = 7.5 Hz, 
1H),7.46–7.43 (m, 1H), 7.43–7.38 (m, 1H), 5.86 (s, 2H), 4.29 (t, J = 6.7 Hz, 2H), 1.86–
1.74 (m, 2H), 1.04 (t, J = 7.4 Hz, 3H); minor rotamer (diagnostic peaks only): δ 8.81–8.77 
(m, 1H), 8.20 (d, J = 7.9 Hz, 1H), 7.92 (d, J = 1.7 Hz, 1H), 7.55–7.50 (m, 1H), 7.38–7.29 
(m, 1 H), 5.32 (s, 2H), 4.34 (t, J = 6.7 Hz, 2H), 1.37 (d, J = 7.0 Hz, 3H).13C NMR (151 
MHz, CDCl3) major rotamer: δ 165.2, 161.7, 151.3, 149.8, 148.7, 137.2, 135.0, 129.1, 













150.8, 150.3, 150.2, 148.3, 137.4, 132.7, 132.6, 131.6, 128.9, 128.6, 128.4, 127.1, 126.6, 
126.0, 125.1, 124.9, 124.7, 122.4, 117.6, 67.5, 22.2, 19.0. HRMS (ESI-TOF) calcd for 




carboxylate (3.4c). From 3.3c using general procedure B: 30% yield (21.0 mg, 0.25 
mmol). Off-white solid residue; Rƒ  = 0.68 (30% EtOAc/hexanes); IR (neat) 1721, 1638 
cm−1. 1H NMR (600 MHz, CDCl3, ratio of rotamers 4.5:1) major rotamer: δ 8.67 (d, J = 
4.6, 1H), 8.24 (d, J = 7.9, 1H 1H), 7.87 (td, J = 7.7, 1.8 Hz, 1H), 7.47–7.41 (m, 2H), 7.20 
(d, J = 7.7 Hz, 1H), 5.79 (s, 2H), 3.90 (s, 3H), 2.65 (s, 3H); minor rotamer: δ 8.78 (d, J = 
4.5 Hz, 1H), 8.30 (d, J = 7.9 Hz, 1H), 7.94–7.89 (m, 1H), 7.54–7.47 (m, 2H), 7.11 (d, J = 
7.9 Hz, 1H), 5.25 (s, 2H), 3.95 (s, 3H), 2.63 (s, 3H). 13C NMR (151 MHz, CDCl3) major 
rotamer: δ 165.9, 161.4, 151.4, 148.6, 147.1, 137.1, 136.3, 136.0, 131.8, 126.1, 124.2, 
115.4, 66.6, 51.9, 21.8; minor rotamer: δ 163.8, 162.8, 150.9, 148.5, 148.3, 147.8, 137.8, 
137.3, 131.6, 126.5, 124.6, 123.0, 117.4, 60.8, 52.5, 21.6. HRMS (ESI-TOF) calcd for 
















yl)methanone (3.4d).147 From 3.3d using general procedure B: 21% yield (45.2 mg, 0.19 
mmol). Off-white residue; Rƒ  = 0.53 (30% EtOAc/hexanes); IR (neat) 1646 cm−1. 1H NMR 
(600 MHz, CDCl3, ratio of rotamers 5.5:1) major rotamer: δ 8.64 (d, J = 4.7 Hz, 1H), 8.24 
(d, J = 7.8 Hz, 1H), 7.86 (td, J = 7.8 Hz, 1.8 Hz, 1H), 7.43 (dd, J = 7.6, 4.7 Hz, 1H), 7.22 
(t, J = 8.0 Hz, 1H), 7.08 (d, J = 7.4 Hz, 1H), 6.61 (d, J = 8.6 Hz, 1H), 5.84 (s, 2H), 3.87 (s, 
3H); minor rotamer: δ 8.77 (d, J = 4.7 Hz, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.50 (dd, J = 7.1 
Hz, 4.9 Hz, 1H), 7.12 (t, J = 8.2 Hz, 1H), 6.90 (d, J = 7.7 Hz, 1H), 6.60–6.57 (m, 1H), 5.28 
(s, 2H), 3.88 (s, 3H).13C NMR (151 MHz, CDCl3) major rotamer: δ 13C NMR (151 MHz, 
CDCl3) δ 161.3, 153.2, 151.5, 151.0, 148.5, 137.2, 130.2, 126.1, 124.3, 114.4, 111.9, 
105.1, 64.7, 56.6; minor rotamer: δ 164.3, 153.5, 151.4, 151.2, 148.6, 137.3, 129.9, 126.4, 
124.5, 112.9, 111.6, 106.5, 57.5, 56.5. HRMS (ESI-TOF) calcd for C14H13N2O2 [M+H]+: 
241.0972, found 241.0945. These data are consistent with data previously reported.147 


















(3.4e).  From 3.3e using general procedure B: 12% yield (11.0 mg, 0.05 mmol), White 
solid; Rƒ  = 0.43 (30% EtOAc/hexanes); IR (neat) 1651 cm−1. 1H NMR (600 MHz, CDCl3, 
ratio of rotamers 5.0:1) major rotamer: δ 8.65 (d, J = 4.3 Hz, 1H), 8.24 (d, J = 7.8 Hz, 1H), 
7.87 (td, J = 7.7, 1.8 Hz, 1H), 7.44 (ddd, J = 7.2, 4.6, 0.9 Hz, 1H), 7.34 (d, J = 7.5 Hz, 1H), 
7.29–7.23 (m, 1H), 7.02 (d, J = 8.3 Hz, 1H), 5.72 (s, 2H); minor rotamer (diagnostic peaks 
only): δ 8.78 (d, J = 4.3 Hz, 1H), 8.17 (d, J = 7.9 Hz, 1H), 7.91 (dd, J = 7.8, 1.4 Hz, 1H), 
7.52 (t, J = 7.2, 5.0 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 5.15 (s, 2H). 13C NMR (151 MHz, 
CDCl3) major rotamer: δ 161.5, 151.0, 150.4, 148.5, 137.1, 130.2, 129.9, 126.1, 124.2, 
124.1, 110.2, 64.5; minor rotamer: δ 150.8, 150.6, 148.4, 137.2, 126.5, 124.5, 124.1, 
112.1, 57.1. HRMS (ESI-TOF) calcd for C13H10ClN2O [M+H]+: 245.0483, found 245.0472. 




(3.4f). From 3.3f using general procedure B: 38% yield (38.0 mg, 0.13 mmol). White solid; 






















rotamers 5.3:1) major rotamer: δ 8.65 (d, J = 3.4 Hz, 1H), 8.23 (d, J = 7.7 Hz, 1H), 7.87 
(dd, J = 7.7, 1.2 Hz, 1H), 7.46–7.42 (m, 1H), 7.37 (d, J = 7.3 Hz, 1H), 7.20 (t, J = 7.8 Hz, 
1H), 7.16 (d, J = 8.3 Hz, 1H), 5.67 (s, 2H); minor rotamer: δ 8.77 (d, J = 3.4 Hz, 1H), 8.17 
(d, J = 7.7 Hz, 1H), 7.91 (t, J = 8.0 Hz, 1H), 7.52 (t, J = 6.3 Hz, 1H), 7.33 (d, J = 7.2 Hz, 
1H), 5.09 (s, 2H).  13C NMR (151 MHz, CDCl3) major rotamer: δ 161.4, 151.0, 150.2, 
148.5, 137.0, 130.4, 126.8, 126.2, 124.1, 113.2, 110.6, 65.3; minor rotamer: δ 164.0, 
150.7, 150.5, 148.4, 137.2, 130.1, 126.6, 124.5, 113.7, 112.5, 57.9. HRMS (ESI-TOF) 




(3.4g). From 3.3g using general procedure B: 7% yield (15.0 mg, 0.07 mmol). Off-white 
solid residue; Rƒ  = 0.53 (30% EtOAc/hexanes); IR (neat) 1658 cm−1. 1H NMR (600 MHz, 
CDCl3, ratio of rotamers 5.5:1) major rotamer: 8.68–8.62 (m, 1H), 8.24 (d, J = 7.8 Hz, 1H), 
7.87 (td, J = 7.7, 1.8 Hz, 1H), 7.47–7.41 (m, 1H), 7.33–7.28 (m, 2H), 6.78 (t, J = 8.2 Hz, 
1H), 5.74 (s, 2H); minor rotamer: δ  8.63–8.61 (m, 1H), 8.16 (d, J = 7.8 Hz, 1H), 7.95–
7.90 (m, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.54–7.48 (m, 1H), 7.24–7.16 (m, 2H), 5.18 (d, J = 
1.9 Hz, 2H). 13C NMR (151 MHz, CDCl3) major rotamer: δ 161.5, 155.6 (d, J = 252 Hz), 
151.2, 148.6, 137.2, 130.9 (d, J = 6.9 Hz), 126.3, 124.2, 116.4 (d, J = 19.9 Hz ), 111.8 (d, 
J = 21.0 Hz ), 108.6 (d, J = 4.4 Hz), 63.5; minor rotamer (diagnostic peaks only): δ 164.2, 













56.1. HRMS (ESI-TOF) calcd for C13H10FN2O [M+H]+: 229.0772, found 229.0752. Purity 




yl)methanone (3.4h).147 From 3.3h using general procedure B: 37% yield (129 mg, 0.47 
mmol). Yellow solid; Rƒ  = 0.31 (20% EtOAc/hexanes); IR (neat) 1647 cm−1. 1H NMR (600 
MHz, CDCl3, ratio of rotamers 6.2:1) major rotamer: δ 8.69 (d, J = 4.4 Hz, 1H), 8.27 (d, J 
= 7.9 Hz, 1H), 7.91 (td, J = 7.7, 1.8 Hz, 2H), 7.60 (d, J = 7.6 Hz, 2H), 7.50–7.45 (m, 2H), 
7.30–7.28 (m, 1H), 5.87 (s, 2H); minor rotamer: δ 8.82 (d, J = 4.7 Hz, 1H), 8.22 (d, J = 
7.9 Hz, 1H), 7.95 (td, J = 7.7, 1.7 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 5.29 (s, 2H).  13C NMR 
(151 MHz, CDCl3) major rotamer: δ 161.5, 150.8, 149.7, 148.6, 137.1, 130.3 (q, J = 3.8 
Hz), 129.4, 126.2, 124.6 (q, J = 35.3 Hz), 124.1, 123.1 (q, J = 271.6 Hz), 119.8 (q, J = 3.8 
Hz), 114.5, 65.1. HRMS (ESI-TOF) calcd for C14H10F3N2O [M+H]+: 279.0740, found: 

















2-(Picolinamidomethyl)benzoic acid (3.5).157 In a 20 mL reaction vial, 3.3a (97.4 
mg, 0.366 mmol, 1.0 equiv) was combined with LiOH (12.9 mg, 0.540 mmol, 1.5 equiv) 
and 2.0 mL of 1:1:4 mixture of H2O:MeOH:THF. The cloudy and pale yellow solution 
became dark yellow and clear after stirring for 5 min and was further stirred for ca. 14 h. 
The mixture was then diluted with ca. 6 mL of water, washed with EtOAc (3 x 25 mL), and 
the layers separated. The aqueous layer was acidified with 2 N HCl to pH 4 and extracted 
with EtOAc (3 x 25 mL). The combined organic layers were dried over Na2SO4, filtered, 
and concentrated to give a crude white solid, which was purified by reverse-phase 
chromatography. Compound 5 was isolated by MPLC reverse-phase column 
chromatography (100% H2O to 100% MeCN) in 55% yield (51 mg, 0.36 mmol) as white 
powder; Rƒ  = 0.60 (10% MeOH/DCM); IR (neat) 2976, 1700 cm−1; 1H NMR (600 MHz, 
DMSO-d6) δ 13.20 (s, 1H), 9.24 (t, J = 6.5 Hz, 1H), 8.67–8.64 (m, 1H), 8.08–7.97 (m, 2H), 
7.91 (dd, J = 7.7, 1.4 Hz, 1H), 7.64–7.59 (m, 1H), 7.52 (td, J = 7.5, 1.4 Hz, 1H), 7.45–7.32 
(m, 2H), 4.81 (d, J = 6.5 Hz, 2H).13C NMR (151 MHz, DMSO-d6) δ 168.5, 163.7, 149.8, 
148.5, 140.1, 137.9, 132.1, 130.5, 128.6, 127.0, 126.6, 121.9, 41.4. HRMS (LTQ FT) 




















7-Picolinoyl-7-azabicyclo[4.2.0]octa-1(6),2,4-triene-2-carboxylic acid (3.6). In 
a 20 mL reaction vial, 3.4a (107 mg, 0.399 mmol, 1.0 equiv) was combined with LiOH 
(14.3 mg, 0.598 mmol, 1.5 equiv) and 2.0 mL of a 1:1:4 mixture of H2O:MeOH:THF. The 
cloudy and pale yellow solution became dark yellow and clear after stirring for 5 min and 
was further stirred for ca. 14 h. The mixture was then diluted with ca. 6 mL of water, 
washed with EtOAc (3 x 25 mL), and the layers separated. The aqueous layer was 
acidified with 2 N HCl to pH 4 and extracted with EtOAc (3 x 25 mL). The combined 
organic layers were dried over Na2SO4, filtered, and concentrated to give a crude white 
solid, which was purified by reverse-phase chromatography. Compound 3.6 was isolated 
by MPLC reverse-phase column chromatography (100% H2O to 100% MeCN) in 41% 
yield (41.7 mg, 0.40 mmol) as a white powder. Rƒ  = 0.73 (10% MeOH/DCM); IR (neat) 
1677 cm−1. 1H NMR (400 MHz, DMSO-d6, 3.4:1 ratio of rotamers); major rotamer: δ 13.19 
(s, 1H), 8.74 (d, J = 4.7 Hz, 1H), 8.15–7.99 (m, 2H), 7.69–7.59 (m, 1H), 7.56–7.41 (m, 
3H), 5.83 (s, 2H); minor rotamer: δ 8.87 (d, J = 4.8 Hz, 1H), 8.23–8.15 (m, 0.15H), 8.01–
7.97 (m, 0.15H), 7.75–7.68 (m, 0.42H), 7.41–7.34 (m, 0.42H), 5.27 (s, 0.45H). 13C NMR 
(151 MHz, DMSO-d6) major rotamer: δ 165.7, 161.0, 150.4, 149.2, 148.9, 137.7, 134.9, 
129.0, 126.7, 123.6, 114.4, 66.2; minor rotamer: δ 165.7, 161.0, 150.4, 149.2, 148.9, 
137.7, 134.9, 129.0, 126.7, 123.6, 114.4, 66.2. HRMS (LTQ FT) calcd for C14H11N2O3 














2-Methoxy-7-azabicyclo[4.2.0]octa-1,3,5-trien-7-ium chloride (3.7a). From 
3.4d using general procedure C: 74% yield (24 mg, 0.14 mmol). White solid; Rf = 0.50 
(10% MeOH/DCM); IR (film) 1595, 1474 cm−1; 1H NMR (500 MHz, MeOD) δ 7.43 (t, J = 
8.2 Hz, 1H), 7.01 (d, J = 3.7 Hz, 1H), 7.00 (d, J = 2.5 Hz, 1H), 5.48–5.45 (m, 2H), 3.91 (s, 
3H). 13C NMR (126 MHz, MeOD) δ 155.7, 143.5, 132.4, 120.8, 117.7, 111.4, 58.8, 57.4. 
HRMS (LTQ FT) calcd for C8H10NO [M+H]+: 136.0757, found: 136.0789.  
 
 
2-Bromo-7-azabicyclo[4.2.0]octa-1,3,5-trien-7-ium chloride (3.7b). From 3.4f 
using general procedure C: 77% yield (25 mg, 0.11 mmol). White solid; Rf = 0.68 (10% 
MeOH/DCM); IR (neat) 1594, 1495 cm−1. 1H NMR (400 MHz, MeOD) δ 7.69 (dd, J = 7.2, 
1.7 Hz, 1H), 7.53 – 7.42 (m, 2H), 5.32 (s, 2H). 13C NMR (151 MHz, MeOD) δ 143.6, 137.9, 
134.6, 133.0, 118.7, 115.9, 59.4 HRMS (LTQ FT) calcd for C7H7BrN [M+H]+: 183.9757, 




















2-(Trifluoromethyl)-7-azabicyclo[4.2.0]octa-1,3,5-trien-7-ium chloride (3.7c). 
From 3.4h using general procedure C: 74% yield (33 mg, 0.16 mmol). White solid; Rf = 
0.69 (10% MeOH/DCM); IR (film) 1585, 1441 cm−1. 1H NMR (500 MHz, MeOD) δ 7.84 (d, 
J = 8.1 Hz, 1H), 7.78 (t, J = 8.0 Hz, 1H), 7.73 (d, J = 7.9 Hz, 1H), 5.51 (s, 2H). 13C NMR 
(151 MHz, MeOD) δ 143.5, 135.2 (q, J = 3.4 Hz), 132.5, 128.1 (q, J = 3.7 Hz), 127.2 (q, 
J = 36.3 Hz), 123.8 (q, J = 270.9 Hz), 123.7, 59.3. HRMS (LTQ FT) calcd for C8H7F3N 
[M+H]+: 174.0525, found: 174.0565.  
 
 
7-pivaloyl-7-azabicyclo[4.2.0]octa-1,3,5-triene-2-carboxylic acid (3.8a). Using 
general procedure E and pivaloyl chloride: 46% (201 mg, 0.863 mmol). Tan powder; Rf = 
0.16 (5% MeOH/DCM); IR (film) 1688, 1632, cm−1. 1H NMR (600 MHz, DMSO-d6) δ 7.45 
(d, J = 8.1 Hz, 1H), 7.38 (t, J = 7.8 Hz, 1H), 7.32 (d, J = 7.5 Hz, 1H), 5.61 (s, 2H), 1.25 (s, 
9H). 13C NMR (151 MHz, DMSO-d6) δ 174.4, 165.7, 149.9, 132.9, 128.9, 125.0, 122.8, 
114.3, 64.5, 38.4, 27.1. HRMS (LTQ FT) calcd for C13H16NO3 [M+H]+: 234.1125, found: 























acid (3.8b). Using general procedure E and 2-(thiophen-2-yl)acetyl chloride: 46% (62 mg, 
0.23 mmol). Yellow solid; Rf = 0.21 (5% MeOH/DCM); IR (neat) 1701, 1618, cm−1. 1H 
NMR (500 MHz, DMSO-d6, ratio of rotamers 2.1:1) major rotamer: δ 13.21 (s, 1H), 7.49 
(d, J = 8.2 Hz, 1H), 7.45–7.35 (m, 2H), 7.28 (d, J = 7.5 Hz, 1H), 7.04 (dd, J = 2.4, 1.1 Hz, 
1H), 7.01–6.95 (m, 1H), 5.44 (s, 2H), 4.02 (s, 2H); minor rotamer (diagnostic peaks only): 
δ 5.10 (s, 2H), 4.17 (s, 2H). 13C NMR (126 MHz, DMSO-d6) major rotamer: δ 166.1, 165.6, 
148.7, 135.9, 131.9, 129.1, 126.9, 126.7, 125.6, 125.4, 123.3, 113.7, 61.7, 33.4; minor 
rotamer: δ 166.3, 165.6, 148.3, 135.5, 131.6, 129.0, 126.9, 126.6, 125.6, 123.0, 113.3, 
58.7, 35.1. HRMS (LTQ FT) calcd for C14H12NO3S [M+H]+: 274.0533, found: 274.0593. 





























mmol), White solid; Rf = 0.12 (5% MeOH/DCM); IR (film) 1702, 1619 cm−1. 1H NMR (500 
MHz, DMSO-d6, ratio of rotamers: 2.0:1) major rotamer: δ 13.19 (s, 1H), 7.48 (d, J = 8.1 
Hz, 1H), 7.44–7.29 (m, 6H), 7.26 (d, J = 7.7 Hz, 1H), 5.42 (s, 2H), 3.75 (s, 2H); minor 
rotamer (diagnostic peaks only): δ 5.09 (s, 2H), 3.93 (s, 2H). 13C NMR (126 MHz, DMSO-
d6) δ 167.3, 165.7, 148.8, 134.9, 131.9, 129.5, 129.1, 128.4, 126.7, 125.7, 123.2, 113.6, 
61.7, 40.5; minor rotamer (diagnostic peaks only): δ 167.4, 165.6, 148.5, 134.5, 131.7, 
129.4, 128.3, 126.0, 122.9, 113.1, 58.6. HRMS (LTQ FT) calcd for C16H14NO3 [M+H]+: 




(3.8d). Using general procedure E and 2-phenoxyacetyl chloride: 36% yield (87 mg, 0.31 
mmol). Pale yellow solid; Rf =  0.15 (5% MeOH/DCM); IR (film), 1723, 1587 cm−1; 1H NMR 
(400 MHz, DMSO-d6; ratio of rotamers 2.3:1) major rotamer: δ 13.19 (s, 1H), 7.50 (d, J = 
8.1 Hz, 1H), 7.41 (t, J = 7.8 Hz, 1H), 7.35–7.26 (m, 3H), 7.05–6.95 (m, 3H), 5.51 (s, 2H), 
4.90 (s, 2H); minor rotamer (diagnostic peaks only): δ 5.15 (s, 2H), 5.01 (s, 2H). 13C NMR 
(151 MHz, DMSO-d6) major rotamer: δ 165.5, 164.8, 157.6, 148.61, 133.0, 129.6, 129.1, 
125.6, 123.5, 121.2, 114.4, 114.0, 65.7, 62.1; minor rotamer (diagnostic peaks only): δ 
165.1, 148.1, 131.7, 125.8, 123.1, 114.6, 114.3, 66.2, 58.8. HRMS (LTQ FT) calcd for 


















acid (3.8e). Using general procedure E and 3-phenoxypropanoyl chloride: 33% (53 mg, 
0.18 mmol). White solid; Rf = 0.25 (5% MeOH/DCM); IR (neat) 1734, 1630 cm−1. 1H NMR 
(400 MHz, DMSO-d6, ratio of rotamers 2.1:1) major rotamer: δ 13.19 (s, 1H), 7.51 – 7.46 
(m, 1H), 7.44 – 7.36 (m, 1H), 7.32 – 7.23 (m, 3H), 6.97 – 6.88 (m, 3H), 5.44 (s, 2H), 4.33 
– 4.24 (m, 2H), 2.88 (t, J = 6.1 Hz, 2H); minor rotamer: (diagnostic peaks only): δ 5.10 (s, 
2H), 3.05 (t, J = 5.9 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) major rotamer: δ 166.9, 
165.6, 158.3, 148.6, 131.9, 129.5, 125.6, 123.2, 120.7, 114.4, 133.6, 63.1, 61.3, 58.5, 
32.2; minor rotamer (diagnostic peaks only): δ 167.0, 165.6, 158.3, 148.5, 131.7, 129.0, 
125.8, 122.9, 113.1, 62.9, 34.0. HRMS (LTQ FT) calcd for C17H16NO4 [M+H]+: 298.1074, 



























(3.9a).  From 3.7a and 2-phenoxyacetyl chloride using general procedure D: 47% yield 
(33 mg, 0.12 mmol). Yellow oil; Rf = 0.26 (30% EtOAc/hexanes); IR (film) 1657 cm−1. 1H 
NMR (400 MHz, CDCl3, ratio of rotamers 1.6:1) major rotamer: δ 7.34 (d, J = 8.9 Hz, 1H), 
7.30 (d, J = 9.5 Hz, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.05–6.94 (m, 3H), 6.58 (d, J = 8.7 Hz, 
2H), 5.40 (s, 2H), 4.77 (s, 2H), 3.80 (s, 3H); minor rotamer (diagnostic peaks only): δ 7.15 
(d, J = 8.3 Hz, 0.49H), 5.14 (s, 2H), 4.81 (s, 2H), 3.84 (s, 3H). 13C NMR (151 MHz, CDCl3) 
major rotamer: δ 164.7, 157.7, 153.3, 150.3, 130.4, 130.0, 122.1, 114.4, 113.2, 111.6, 
104.9, 68.2, 61.6, 56.4; minor rotamer: δ 165.5, 157.8, 153.9, 149.6, 130.4, 129.8, 122.0, 
114.8, 111.6, 111.5, 103.8, 67.5, 57.5, 56.5. HRMS (LTQ FT) calcd for C16H16NO3 [M+H 




(3.9b). From 3.7b and 2-phenoxyacetyl chloride using general procedure D: 21% (6.0 mg, 
0.02 mmol). White solid; Rf = 0.46 (30% EtOAc/hexanes); IR (film) 1654 cm−1. 1H NMR 
(600 MHz, CDCl3, ratio of rotamers 2.3:1) major rotamer: δ 7.37–7.29 (m, 2H), 7.27 (d, J 
= 8.0 Hz, 1H), 7.19–7.12 (m, 2H), 7.04 (t, J = 7.3 Hz, 1H), 6.98 (d, J = 8.2 Hz, 2H), 5.27 
(s, 2H), 4.79 (s, 2H); minor rotamer (diagnostic peaks only): δ 4.97 (s, 2H), 4.81 (s, 2H). 












127.2, 122.3, 114.4, 113.6, 110.6, 68.1, 62.4; minor rotamer (diagnostic peaks only): δ 
165.7, 130.6, 130.0, 126.8, 114.7, 110.0, 67.8, 58.1.  HRMS (LTQ FT) calcd for 




yl)ethan-1-one (3.9c). From 3.7c and 2-phenoxyacetyl chloride using general procedure 
D: 56% (48 mg, 0.16 mmol). Pale yellow solid; Rf = 0.46 (30% EtOAc/hexanes); IR (neat) 
1656 cm−1. 1H NMR (400 MHz, CDCl3, ratio of rotamers 2.8:1) major rotamer: δ 7.49–7.30 
(m, 4H), 7.24 (d, J = 5.5 Hz, 1H), 7.05 (t, J = 7.3 Hz, 1H), 6.99 (d, J = 7.8 Hz, 2H), 5.45 
(s, 2H), 4.80 (s, 2H); minor rotamer (diagnostic peaks only): δ 7.18 (d, J = 7.8 Hz, 1H), 
5.14 (s, 2H), 4.83 (s, 2H). 13C NMR (151 MHz, CDCl3) major rotamer: δ 165.2, 157.5, 
149.2, 130.1, 129.8, 128.8 (q, J = 3.6 Hz), 125.0 (q, J = 35.4 Hz), 123.0 (q, J = 272.3 Hz), 
122.3, 120.2 (q, J = 3.6 Hz), 114.6, 114.4, 68.1, 62.3; minor rotamer (diagnostic peaks 
only): δ 165.8, 148.7, 129.9, 129.9, 127.5 (q, J = 3.8 Hz), 119.9 (q, J = 4.0 Hz), 114.2, 
67.9, 58.0. HRMS (LTQ FT) calcd for C16H13F3NO2 [M+H]+: 308.0893, found: 308.0891. 















(3.10).  3.4a (202 mg, 0.752 mmol, 1 equiv), zinc chloride (209 mg, 1.53 mmol, 2 equiv), 
25% sodium methoxide in MeOH (0.34 mL, 1.51 mmol, 2 equiv), and anhydrous MeOH 
(6.0 mL) were combined in a flame dried glass vial under Ar. The solution was heated to 
45°C and stirred for 18 h. The volume was reduced to 2 mL under a stream of nitrogen. 
The crude solution was purified by reverse phase MPLC (100% H2O to 100% MeCN) and 
fractions containing 3.10 were acidified to pH = 2 using 2 N aq HCl and concentrated 
under vacuum to give a white powder in 88% yield (124 mg, 0.62 mmol); Rf = 0.23 (30% 
EtOAc/hexanes); IR (neat) 3329, 1716 cm−1; 1H NMR (400 MHz, MeOD) δ 8.09 – 8.03 
(m, 1H), 7.72 – 7.66 (m, 2H), 5.51 (s, 2H), 3.94 (s, 3H). 13C NMR (101 MHz, MeOD) δ 
165.2, 143.1, 139.1, 131.8, 131.8, 127.6, 124.0, 60.6, 53.1. HRMS (LTQ FT) calcd for 
C9H10NO2 [M+H]+: 164.0706 found: 164.0703. 
 
 
Methyl 7-pivaloyl-7-azabicyclo[4.2.0]octa-1,3,5-triene-2-carboxylate (3.11a). 






















solid, mp 84-87 °C; Rƒ = 0.48 (30% EtOAc/hexanes); IR (neat) 1721, 1650 cm−1. 1H NMR 
(500 MHz, DMSO-d6) δ 7.49 (d, J = 8.1 Hz, 1H), 7.41 (t, J = 7.8 Hz, 1H), 7.36 (d, J = 7.5 
Hz, 1H), 5.62 (s, 2H), 3.84 (s, 3H), 1.26 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 174.4, 
164.6, 149.9, 132.7, 129.1, 123.6, 122.5, 114.6, 64.4, 52.2, 38.4, 27.1. HRMS (LTQ FT) 




carboxylate (3.11b). From 3.10 using general procedure D: 66% yield (47.9 mg, 0.167 
mmol). White crystalline solid, m.p 107-109 °C; Rƒ = 0.32 (30% EtOAc/hexanes); IR 
(neat) 1721, 1667 cm−1. 1H NMR (500 MHz, DMSO-d6, ratio of rotamers 2.1:1) major 
rotamer: δ 7.52 (d, J = 8.2 Hz, 1H), 7.49–7.38 (m, 2H), 7.32 (d, J = 7.5 Hz, 1H), 7.06–
7.02 (m, 1H), 7.01–6.96 (m, 1H), 5.46 (s, 2H), 4.03 (s, 2H), 3.85 (s, 3H); minor rotamer 
(diagnostic peaks only): δ 5.11 (s, 2H), 4.18 (s, 2H). 13C NMR (126 MHz, DMSO-d6) major 
rotamer: δ 166.2, 164.5, 148.7, 135.8, 131.8, 129.3, 127.0, 126.7, 125.4, 124.2, 123.0, 
114.1, 61.6, 52.3, 33.3; minor rotamer (diagnostic peaks only): δ 166.3, 148.4, 135.5, 
131.5, 129.2, 126.9, 126.6, 124.4, 122.7, 113.8, 58.6, 35.0. HRMS (LTQ FT) calcd for 

















(3.11c). From 3.10 using general procedure D: 62% yield (43.1 mg, 0.153 mmol). White 
crystalline solid, m.p 99-101 °C; Rƒ = 0.34 (30% EtOAc/hexanes); IR (neat) 1729, 1657 
cm−1. 1H NMR (500 MHz, DMSO-d6, ratio of rotamers 2.1:1) major rotamer: δ 7.51 (d, J 
= 8.2 Hz, 1H), 7.47–7.37 (m, 1H), 7.36–7.22 (m, 6H), 5.44 (s, 2H), 3.84 (s, 3H), 3.75 (s, 
2H); minor rotamer: (diagnostic peaks only): 5.09 (s, 2H), 3.94 (s, 2H). 13C NMR (126 
MHz, DMSO-d6) major rotamer: δ 167.4, 164.6, 148.8, 134.9, 131.8, 129.5, 129.3, 128.4, 
126.8, 124.2, 123.0, 114.3, 61.6, 52.3, 40.50; minor rotamer (diagnostic peaks only): δ 
167.5, 148.5, 134.5, 131.6, 129.5, 128.4, 124.5, 122.6, 113.6, 58.6. HRMS (LTQ FT) 




carboxylate (3.11d). From 3.10 using general procedure D: 74% yield (77.1 mg, 0.259 
























(neat) 1719, 1680 cm−1. 1H NMR (500 MHz, DMSO-d6, ratio of rotamers 2.7:1) major 
rotamer: δ 7.54 (d, J = 8.1 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 7.38–7.29 (m, 3H), 7.06–6.96 
(m, 3H), 5.53 (s, 2H), 4.91 (s, 2H), 3.84 (s, 3H); minor rotamer (diagnostic peaks only): 
5.15 (s, 2H), 5.01 (s, 2H). 13C NMR (126 MHz, DMSO-d6) major rotamer: δ 164.9, 164.5, 
157.6, 148.6, 132.8, 129.6, 129.3, 124.2, 123.2, 121.3, 114.5, 114.4, 65.7, 62.0, 52.3; 
minor rotamer (diagnostic peaks only): δ 165.2, 148.1, 131.6, 124.4, 122.8, 114.7, 114.6, 
66.2, 58.7. HRMS (LTQ FT) calcd for C17H16NO4 [M+H]+: 298.1074, found: 298.1070. 






carboxylate (3.11e). From 3.10 using general procedure D: 65% yield (88.2 mg, 0.283 
mmol). White crystalline solid, mp 100–102 °C; Rƒ = 0.08 (30% EtOAc/hexanes); IR (neat) 
1735, 1630 cm−1. 1H NMR (600 MHz, DMSO-d6, ratio of rotamers 2.2:1) major rotamer: δ 
7.52 (t, J = 8.2 Hz, 1H), 7.43 (t, J = 7.8 Hz, 1H), 7.33 (d, J = 7.4 Hz, 1H), 7.31–7.25 (m, 
2H), 6.97–6.90 (m, 3H), 5.45 (s, 2H), 4.27 (t, J = 6.1 Hz, 2H), 3.85 (s, 3H), 2.88 (t, J = 6.1 














(t, J = 5.9 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) major rotamer: δ 167.0, 164.6, 158.3, 
148.7, 131.8, 129.5, 124.2, 122.9, 120.7, 114.4, 114.1, 63.1, 61.2, 58.5, 52.2, 32.2; minor 
rotamer (diagnostic peaks only): 167.1, 164.5, 158.3, 148.5, 131.6, 129.3, 124.5, 122.6, 
114.4, 113.6, 62.9, 54.9, 34.0.  HRMS (LTQ FT) calcd for C18H18NO4 [M+H]+: 312.1231, 





Methyl 2-((2-phenoxyacetamido)methyl)benzoate (3.12). Methyl 2-
(aminomethyl)benzoate hydrochloride and 2-phenoxyacetic acid were reacted using 
general procedure A: 59% yield (181 mg, 0.60 mmol). White solid; Rf = 0.17 (30% 
EtOAc/hexanes); IR (film) 1717, 1659 cm−1. 1H NMR (400 MHz, CDCl3) δ 7.97 (dd, J = 
7.8, 1.4 Hz, 1H), 7.75 (s, 1H), 7.55 (ddd, J = 7.7, 1.6, 0.5 Hz, 1H), 7.50 (td, J = 7.1, 1.3 
Hz, 1H), 7.36 (td, J = 7.4, 1.7 Hz, 1H), 7.29–7.23 (m, 2H), 6.98 (tt, J = 7.6, 1.0 Hz, 1H), 
6.90–6.84 (m, 2H), 4.73 (d, J = 6.6 Hz, 2H), 4.47 (s, 2H), 3.88 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 168.1, 167.8, 157.4, 139.7, 133.1, 131.6, 131.2, 129.8, 128.9, 127.9, 
122.0, 114.8, 67.5, 52.4, 42.2.  HRMS (LTQ FT) calcd for C17H18NO4 [M+H]+: 300.1231, 


















Methyl 1-(2-phenoxyacetyl)-1H-indole-4-carboxylate (3.14). Methyl 1H-indole-
4-carboxylate 3.13 and 2-phenoxyacetyl chloride were reacted using general procedure 
D: 29% yield (102 mg, 0.33 mmol). White solid; Rf = 0.47 (30% EtOAc/hexanes); IR (neat) 
1700 cm-1.1H NMR (600 MHz, CDCl3) δ 8.71 (d, J = 8.2 Hz, 1H), 8.03 (d, J = 7.6 Hz, 1H), 
7.71 (d, J = 3.8 Hz, 1H), 7.44–7.40 (m, 2H), 7.32 (dd, J = 8.7, 7.3 Hz, 2H), 7.06–6.97 (m, 
3H), 5.19 (s, 2H), 3.98 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 167.2, 166.7, 157.6, 136.5, 
130.4, 130.0, 127.0, 125.9, 125.1, 122.5, 122.2, 121.3, 114.9, 110.9, 68.2, 52.2. HRMS 
(LTQ FT) calcd for C18H16NO4 [M+H]+: 310.1074, found: 310.1065. Purity (UPLC): >99%.  
 
 
Methyl indoline-4-carboxylate (3.15).158 Using a modified procedure from Ansari 
et. al,159 3.13 (202 mg, 1.15 mmol, 1 equiv), triethyl silane (0.50 mL, 3.13 mmol, 2.7 
equiv), and excess TFA (1.87 mL, 24.23 mmol, 21.1 equiv) were reacted in anhydrous 
DCM (10 mL) at rt for 18 h. The resulting champagne colored solution was washed with 
water (2 x 10 mL), brine (1 x 10 mL), dried over Na2SO4, filtered, and then concentrated 
to an oil. 3.15 was isolated by MPLC reverse-phase column chromatography (100% H2O 






















EtOAc/hexanes); IR (film) 3365, 2852, 1694 cm−1. 1H NMR (400 MHz, CDCl3) δ 7.33 (dd, 
J = 7.8, 1.0 Hz, 1H), 7.06 (td, J = 7.8, 0.8 Hz, 1H), 6.77 (dd, J = 7.7, 1.1 Hz, 1H), 3.88 (s, 
3H), 3.59 (td, J = 8.4, 0.9 Hz, 2H), 3.40 (t, J = 8.4 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 
167.6, 152.8, 132.3, 127.4, 126.8, 119.9, 113.0, 51.8, 47.2, 31.1. HRMS (LTQ FT) calcd 
for C10H12NO2 [M+H]+: 178.0863, found: 178.0862. 95% purity. These data are consistent 
with data previously reported. 
 
 
Methyl 1-(2-phenoxyacetyl)indoline-4-carboxylate (3.16). From 3.15 and 2-
phenoxyacetyl chloride using general procedure A: 54% yield (95 mg, 0.31 mmol). Pale 
yellow solid; Rf = 0.28 (30% EtOAc/hexanes); IR (film) 1702, 1676 cm−1. 1H NMR (400 
MHz, CDCl3) δ 8.47 (d, J = 8.0 Hz, 1H), 7.71 (dd, J = 7.9, 1.1 Hz, 1H), 7.34–7.27 (m, 3H), 
7.03–6.97 (m, 3H), 4.78 (s, 2H), 4.21 (t, J = 8.4 Hz, 2H), 3.91 (s, 3H), 3.60 (t, J = 8.5 Hz, 
2H). 13C NMR (101 MHz, CDCl3) δ 166.8, 166.4, 158.0, 144.0, 134.2, 129.8, 128.1, 126.5, 
125.7, 122.0, 121.3, 114.8, 68.4, 52.1, 47.4, 29.7. HRMS (LTQ FT) calcd for C18H18NO4 
[M+H]+: 312.1231, found: 312.1228. Purity (UPLC): 98%.  
 
3.4.7 ESKAPE pathogen screening materials and methods  
For screening against ESKAPE pathogens, strains used included Enterococcus 















ATCC 700603, Acinetobacter baumanii BAA 1606, Pseudomonas aeruginosa ATCC 
27853 and Enterobacter cloacae ATCC 13047. Enterococcus faecium was grown in Brain 
Heart Infusion (BHI) broth, and all other strains were grown in Mueller Hinton (MH) broth. 
Strains were inoculated the night before testing into 7 mL of media and cultured overnight 
at 37 °C. The following morning, bacteria from overnight cultures were diluted in their 
respective media and cultured at 37 °C for several hours until they entered log phase 
(OD600 0.40–0.8). Log phase bacteria were diluted to OD600 0.001 and plated 200 µL/well 
of 96-well plates. 2 µL of 100X compound diluted in DMSO was added, and mixed into 
culture. Plates were incubated at 37 °C until ready to read at 6 h and 24 h. A compound 
was considered active if it showed at least 90% growth inhibition when compared to the 
DMSO control. 
 
3.4.8 Replicating and non-replicating Mtb screening methods 
Compounds were screened against Mtb under replicating conditions and also 
conditions in which Mtb is rendered non-replicating by a combination of host-relevant 
stresses, including an acidic pH, low oxygen, reactive nitrogen species, and a fatty acid 
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